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ABSTRACT 
The need for a prophylactic vaccine against HIV remains a global priority as the pandemic 
continues to expand. An effective HIV vaccine will need to be able to target multiple HIV 
subtypes or recombinant forms, be safe enough to administer to infants and 
immunocompromised people and be affordable to guarantee supply in developing countries. Due 
to its well established safety record, potency and low production cost, Mycobacterium bovis 
Bacille Calmette Guérin (BCG) has been considered as a HIV vaccine vector. BCG expressing 
HIV proteins under the control of strong promoters have been shown to be unstable.   One of the 
ways of controlling expression in bacteria is through the use of a Tet repressor which is able to 
bind tet operator sequences (tetO) only in the presence of the analogue anhydrotetracycline 
(ATc). This system has been widely used for conditional control of gene expression to determine 
gene function. The application of this system in rBCG vaccine design is completely novel, and 
should significantly alleviate the problems associated with instability. The aim of this study is  to 
utilise the tetracycline dependent gene regulation system to down-regulate recombinant antigen 
expression in BCG during the expansion of seed stocks and up-regulate expression prior to or 
post vaccination. 
The design was based on constitutively expressing the DNA binding repressor protein, 
TetRr1.12, such that in the presence of ATc, the TetR-ATc complex binds tet operator sites 
placed within a promoter upstream of the recombinant antigen, causing a shutdown of 
recombinant antigen expression during in vitro growth. A series of the episomal TetRr1.12 
regulatory systems containing different combinations of tet operator sequences (tetO1 and/or 
tetO2 flanking the -10 region of the Psmyc promoter) and the tetRr1.12 repressor gene in different 
orientations were constructed. The systems were initially evaluated for expression and stability 
using GFP as a model antigen and then with HIV Gag and reverse transcriptase (RT) as antigens.  
Two stable recombinant M. bovis BCG expressing HIV-1 RT were selected to evaluate the 
immunogenicity of an rBCG-HIV vaccine using the tetracycline regulated system. The rBCG 
were administered to mice as a single vaccination in a prime-boost combination with a Modified 
Vaccinia virus Ankara (MVA) vaccine boost expressing HIV-1 Gag, RT, Tat, Nef and gp150. The 
frequency of antigen specific cells induced in mice after vaccination were evaluated using an 
IFN-γ ELISPOT assay and a cytokine bead array assay was used to quantify a spectrum of 
cytokines released into the culture supernatant during stimulation with RT specific peptides.  
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The minimum dose of ATc required to achieve repression of GFP expression was determined in 
M. smegmatis and BCG. All the TetRr1.12 systems responded to ATc as GFP expression was 
repressed in the presence of ATc and induced upon its removal. A minimum ATc dose of 100 - 
250 ng/ml achieved a 2.5-fold GFP repression in M. smegmatis and 2 µg/ml achieved a 2-fold 
repression in BCG ΔpanCD. The induction upon ATc removal was poor in M. smegmatis as 
none of the recombinants showed maximal induction, whereas rBCG ΔpanCD showed complete 
induction of GFP.  
 
In the presence of ATc all the recombinant mycobacteria were genetically stable for over  42 
culture generations. However, in the absence of ATc GFP was over-expressed as depicted by 
high fluorescence, a reduction in colony size and genetically unstable recombinants, in M. 
smegmatis after 42 generations, <56% recombinants harbouring the tetRr1.12 gene in the same 
orientation as the gfp gene and <2% recombinants harbouring the tetRr1.12 gene in the opposite 
orientation to the gfp gene were genetically intact. In BCG ΔpanCD after 49 generations, 76 - 
81% recombinants harbouring the tetRr1.12 gene in the same orientation as the gfp gene and 57 - 
74% recombinants harbouring the tetRr1.12 gene in the opposite orientation to the gfp gene 
remained genetically intact.  
The recombinants containing the tetRr1.12 gene in the same orientation as the GFP, pPM3r2.1 
and pPM4r2.1 were the most stable and thus were selected to generate the episomal HIV-
TetRr1.12 plasmids, pPM3RT, pPM3Gag, pPM4RT and pPM4Gag by replacing the gfp gene in 
the plasmids with the HIV-1 subtype C rt and gag genes. Included in the study were the 
episomal multicopy HIV-TetRr1.7 systems, pRC3RT and pRC3Gag that utilise the TetRr1.7 
repressor for regulation. The pRC3RT and pRC3Gag contain the tetRr1.7 gene orientated in the 
same direction as the HIV-1 rt and gag genes, respectively. Stability assessment revealed that 
rBCG ΔpanCD[HIV-TetR] harbouring the gag  gene were unstable as a 1170 bp fragment 
containing p24, p6 and the V3-SV5 epitope tag was deleted. Two of recombinants harbouring 
the rt gene, rBCG ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT] were stable, but the rBCG 
ΔpanCD[pPM4RT] lost a 1452 bp fragment containing the rt gene and the V3-SV5 epitope tag. 
The genetically stable systems were used to generate rBCG HIV-1 subtype C vaccines and the 
immunogenicity assessed in BALB/c mice. 
A prime with the rBCG ΔpanCD vaccines via the intraperitoneal route and a boost with an MVA 
elicited antigen-specific intracellular IFN-  expression in the mice splenocytes in response to 
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stimulation with HIV-1 peptides. Compared to the responses elicited by the control, rBCG 
ΔpanCD[pCONEPI] prime and MVA-C boost, the responses elicited by rBCG ΔpanCD vaccines 
and MVA-C boost were higher, the responses to the V3-CTL CD8 peptide were 4.2-fold higher, 
the responses to the RT-CD8 peptide were 5.6-fold and the responses to the RT-CD4 were 2.4-
fold higher. Removing ATc from the vaccines prior to vaccination did not alter the immune 
response significantly as rBCG vaccines that contained ATc elicited comparable levels of 
immune responses as those without ATc. Additionally, the spectrums of HIV-specific cytokines 
released from the splenocytes were mainly IFN-  and TNF-α.  
A stable rBCG vaccine expressing HIV-1 RT antigen has been developed, where antigen 
expression can be down-regulated in vitro to improve vector stability and up-regulated in vivo to 
induce strong immune responses. These results indicate that we overcame the challenges of low 
antigen expression caused by genetic instability that can lead to the weak immunogenicity 
usually associated with expression of viral antigens in BCG.  
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1.1. MYCOBACTERIUM BOVIS BACILLE CALMETTE GUÉRIN: A TB 
VACCINE 
Tuberculosis (TB), a chronic infectious disease caused by Mycobacterium tuberculosis accounts 
for over 2 million deaths per year 1, 2. The TB vaccine, Bacille Calmette Guérin (BCG), was 
developed by a French bacteriologist, Albert Calmette and his colleague Camille Guérin at the 
Institut de Lille in France in 1908 3, 4. They isolated a virulent strain of the bovine tubercle 
bacillus Mycobacterium bovis from a cow with TB and attenuated it by repeatedly subculturing 
it on glycerinated bile-potato medium through more than 200 serial passages 5, 6. It took over 13 
years for the strain to completely lose virulence 4, 7. The attenuated M. bovis strain was 
evaluated intensively in vitro and in animal models between 1908 and 1921 and there was no 
evidence of reversion to virulence, implying that the attenuation resulted from very stable 
deletions and mutations 6, 8, 9.   
 
1.1.1. THE GLOBAL USE OF BCG AS A TB VACCINE 
The first BCG vaccine was administered by Weil Halle in Paris in 1921 10. It was given orally to 
a newborn whose mother had died soon after giving birth from TB 5, 11. The infant was given 3 
doses of 2 mg (8 x 10
7
 bacillary elements per dose) at 3, 5 and 7 days after birth 10. The child was 
immunized against TB throughout his life span 12. 
 
BCG was officially adopted by the Health Committee of League of Nations as a TB vaccine in 
1928, and introduced into the World Health Organization (WHO) and Expanded Programme on 
Immunization (EPI) in 1974 7, 13-15. Over the years the BCG vaccine has been given to millions of 
infants, and it has been followed by the reports of mortality rate reduction 5. 
 
The practice of intradermal (i.d.) administration was introduced in 1927, the percutaneous route 
was introduced in 1931, and the oral route was discontinued in 1973 5, 14, 16. To date BCG is used 
in TB control programs and it is recommended by the WHO for all infants under the age of 1 
year unless they are infected with HIV 17-20. Every year, about 80% of the world’s infant 
population receive BCG vaccination, principally in developing countries where TB is highly 
endemic (Figure 1.1) 11, 14, 21. In South Africa the BCG vaccine has been administered as routine 
neonatal vaccination since 1974 22. It has displayed a high protective efficacy when given to 
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newborns against life-threatening forms of childhood TB, such as TB meningitis and miliary TB 
23-26. Furthermore, Fine et al., (1999)27 reported that BCG vaccination also protects against 
leprosy. 
 
Figure 1.1: WHO/UNICEF global BCG immunization coverage at 88% in 2009, estimated by 193 
WHO Member States 27 July 2010. Taken from, 
http://www.who.int/immunization_monitoring/diseases/tuberculosis/en/index.html. 
 
1.1.2. CHALLENGES FACING THE USE OF THE BCG AS A TB VACCINE  
Despite the numerous advantages that make BCG an attractive vaccine, there are a few negative 
aspects that indicate that the vaccine could be improved. BCG has variable protective efficacy. 
In addition, cases of disseminated BCG disease have been reported in immunocompromised 
individuals after BCG vaccination 5, 28-31.  Furthermore BCG sensitizes for the tuberculin skin 
test (a test used to determine if an individual or an animal has developed an immune response to 
the bacterium that causes TB) and thus compromises the use of this test in humans and animals, 
which is one of the reasons why BCG is not a routine vaccine in the United States 32. 
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1.1.2.1. Variable efficacy of the BCG vaccine 
BCG vaccine efficacy has been assessed in numerous clinical trials and the most controversial 
element of the vaccine is its variable efficacy in preventing TB, which ranges from 0 - 80% with 
an average protection of 50% 14, 26, 33-36. While BCG vaccine protects against childhood TB, this 
protective efficacy wanes over an estimated period of 10 - 15 years and consequently the vaccine 
often fails to protect adults from pulmonary TB and other mycobacterial diseases 24, 37, 38. The 
lowest BCG vaccine efficacy is found in the tropical regions of the world, such as Sub-Saharan 
Africa and South-East Asia 35, 39, 40.  
 
There are a number of proposed reasons for this discrepancy in protective efficacy of BCG 
against TB, most of which lack strong clinical support 15, 38, 40-42. These reasons include genetic 
variations in BCG strains, different preparation methods and administration routes and doses of 
the vaccine 3, 43-45, occurrence of environmental non-tuberculous mycobacteria (NTM) and other 
mycobacterial infections 23, 38, 46, genetic variation, age and nutrition status and socioeconomic 
conditions of the hosts 24, 34, 47 and the inadequacy of the antigenic repertoire of M. bovis BCG 48. 
Furthermore a few studies have reported that the waning protective immunity against TB could 
be attributed to the waning memory immunity induced by BCG, which is robust during 
childhood after vaccination and then weakens as the individual approaches adulthood 37, 49, 50. 
Aydinlioglu et al., (1993)37 assessed the immunity of 219 healthy newborns from 3 - 12 months 
after BCG vaccination. They observed a decline in the immunity to the tuberculin, as an 87% 
reactivity was observed at 3 months and a 61% at 12 months. 
 
a. Genetic variation of BCG strains  
Pasteur is the original attenuated M. bovis strain 3, 8, 41. This strain has been propagated many 
times in a large number of laboratories since 1921. Consequently deletions, duplications and 
single nucleotide mutations have occurred in the genome of the strain 8, 51. Therefore BCG 
strains are genetically and phenotypically dissimilar. At present the five main M. bovis BCG 
strains that are produced and distributed worldwide, are Tokyo, Connaught, Russian, Danish and 
Moreau 3, 43, 52. These strains vary morphologically, biochemically and in protein expression 
within the hosts, and thus display different immunogenicity 3, 41, 43, 44. 
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b. The possible impact of environmental mycobacterial infections on the efficacy of BCG 
vaccination 
One hypothesis for the differing efficacy of BCG vaccination is based on the different 
prevalence of environmental mycobacteria in different regions. It has been scientifically proven 
in animal studies that environmental NTM interfere with or inhibit the multiplication of BCG 
and thus preclude the induction of protective immunity to TB 23, 34, 53. Thus in geographical areas 
where environmental mycobacteria are abundant, such as tropical regions, the BCG vaccine has 
shown the lowest protective efficacy 11, 23. To confirm this hypothesis Black et al., (2001)39 
assessed blood samples obtained from individuals who had not been vaccinated with BCG living 
in northern Malawi, where the BCG vaccine has a very low efficacy. The blood samples showed 
positive interferon gamma (INF- ) responses to a variety of mycobacterial antigens, which 
indicated that these individuals were greatly exposed to environmental mycobacteria. 
1.1.2.2. Risks associated with BCG vaccines 
Until recently, BCG has been considered to be very safe, now it is contraindicated for 
immunocompromised, malnourished or asymptomatic HIV-positive infants as these individuals 
have an increased risks of regional, extra-regional, localized and disseminated BCG disease 17, 54, 
55. Furthermore, BCG-induced immune reconstitution inflammatory syndrome (IRIS) has been 
identified in children receiving antiretroviral therapy 22, 56. As a result the WHO recommends that 
the BCG vaccine not be given to HIV-infected, asymptomatic HIV-positive or 
immunocompromised infants 20, 22. 
1.1.3. STRATEGIES DESIGNED TO ENHANCE BCG VACCINE EFFICACY AGAINST 
TB 
Despite its variable efficacy and failure to protect against pulmonary disease, BCG is still able to 
confer protection against TB meningitis and leprosy 14, 23, 25. Consequently the vaccine is 
included in most TB vaccine strategies 11, 57, 58. The development of a safe and efficacious BCG 
vaccine against TB has been an ongoing process for years 59, 60. Various strategies have been 
designed and evaluated in a variety of preclinical experiments using different animal models and 
some have completed Phase I clinical trials 18, 55, 61-63. These strategies include BCG-homologous 
prime boost immunization regimens 58, 64, 65, BCG-heterologous prime-boost immunization 
regimes 23, 31, 66-68, reintroduction of the region of deletion-1 (RD1) locus into BCG 6, 69-71, the use 
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of subunit vaccines 72, 73, TB polyprotein vaccines 40, 74, DNA vaccines 75, 76, the use of adjuvants 
62, 77, expression of major antigens of M. tuberculosis in a separate vaccine vector, such as pox-
viruses (including modified vaccinia virus ankara (MVA)) and adenoviruses 58, 68, 78 and the 
development of auxotrophic vaccines 18, 55, 79, which will be reviewed in the following section.  
 
The ability of the BCG vaccine to elicit cell-mediated immunity, particularly INF-  secreting T-
cells, is responsible for protection against TB 39, 45, 80, 81. This immunogenicity of the BCG has 
led to its investigation as a heterologous antigen delivery vehicle (reviewed extensively in the 
following section). Recombinant BCG engineered to express high levels of immunodominant 
antigens of M. tuberculosis have been constructed against TB 18, 63, 82-84. These antigens are 
conserved amongst all mycobacterial species, exported and very immunodominant in both 
animals and humans 18, 58, 63, 78, 85. These proteins belong to the mycolyl-transferase antigen 85 
complex (Ag85A, Ag85B and Ag85C), a group of the major secretory proteins 58, 85, 86.  
 
While prime-boost regimens appear to be very promising strategies for the development of an 
improved TB vaccine given the waning immunity to BCG, various reviews have reported that 
the heterologous prime boosts are superior to homologous prime boosts in term of BCG efficacy 
enhancement 11, 58. The advantage of heterologous prime boost regimens is that two different 
vaccines expressing the same antigen are used, and thus any of the vaccine strategies listed 
above can be and have been used to boost a BCG prime 30, 58, 66, 77, 87, 88. Furthermore since in 
developing countries BCG is administered to all infants, development of an improved BCG 
boost is a focus of the TB vaccine research. The use of rBCG prime with heterologous boost will 
be discussed further in Section 1.2.7.2 d. 
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1.2. THE USE OF BCG AS A HETEROLOGOUS ANTIGEN DELIVERY 
VEHICLE 
Preceding the 1990s there was a lack of information on BCG and its genetic mechanisms as it 
was not commonly studied due to its slow growth rate and complex cell wall 7. The interest in 
BCG grew after the development of molecular tools and methods that facilitate the manipulation 
of the strain and allow simple transfer, expression and secretion of heterologous antigens in this 
strain 89-92. As a result BCG has been researched extensively and its recombinant forms, rBCG 
expressing heterologous antigens have been constructed and evaluated in vitro and in vivo.  
1.2.1. RECOMBINANT BCG 
Recombinant M. bovis BCG (rBCG) has been tested as a monovalent vaccine in numerous 
animal models and human cells to deliver viral, bacterial and parasitic antigens, where it 
expresses antigens for specific diseases 68, 84, 93-96. In several animal studies rBCG has conferred 
protection against diseases. In mice Grode et al., (2002)97 showed anti-listerial protection 
induced by BCG expressing the p60 antigen of Listeria monocytogenes, which protected the 
animals against L. monocytogenes challenge. Govan et al., (2006)98 reported that outbred New 
Zealand White rabbits were protected against cottontail rabbit papillomavirus (CRPV) challenge 
following immunization with rBCG expressing the CRPV major capsid protein, L1. Other 
diseases that have been protected against by rBCG expressing defined antigens include Lyme 
disease 99, pneumococcal infection 100, malaria 101 and Bordetella pertussis 21.  
 
In some studies rBCG has prolifically expressed the recombinant antigens and evoked robust 
immune responses, however only conferred partial or no protective immunity 96. Immunization 
of sheep with rBCG expressing one of the major excreted/secreted Toxoplasma gondii antigens, 
GRA1 lead to the induction of strong GRA1-specifc cell-mediated responses, but only partially 
protected the animals against oocyst challenge infection102. Other antigens that have been 
successfully expressed in BCG are the human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) and simian immunodeficiency virus (SIV) antigens, 
which will be discussed in detail in the next section. Considering the above studies it is evident 
that live recombinant BCG vaccines expressing pathogen-derived antigens present potential 
vaccine candidates for development of future vaccination strategies. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
8 
 
The global use of BCG as a live vaccine vector is due to a number of features. BCG has been 
found to be reasonably safe as it can be administered orally to infants and it shows a very low 
incidence of side effects 102, 103;  it is not affected by maternal antibodies as it can be given at any 
time after birth 104, 105; it is simple and inexpensive to produce 92, 106, 107; it is heat-stable 105; and 
its cell wall components make it a potent adjuvant 102, 108, 109. BCG can be genetically 
manipulated or altered fairly easily to maximise its immunogenicity 105; and it has the ability to 
express large heterologous genes 92, 110-112. BCG is persistent in vivo seeing that it survives in the 
human antigen presenting cells (APC), such as macrophages and dendritic cells for long periods 
of time and consequently a single inoculum of BCG can elicit long-lasting immunity as the 
antigen is continuously produced and presented to the immune system 60, 92, 104, 113, 114. In 
addition, rBCG vaccines can elicit either cellular or humoral, or both of these immune responses 
against heterologous antigens 91, 93, 109, 115, 116.  
 
1.2.2. RECOMBINANT BCG EXPRESSING HIV- 1 ANTIGENS 
HIV, the causative agent of AIDS has been a global pandemic for almost 30 years 117. Millions of 
HIV infections and deaths have occurred, and an effective vaccine still remains elusive 118, 119. 
There have been a number of major scientific challenges in developing a vaccine for this virus, 
for instance its genetic diversity as a result of high mutation rate in viral replication, the lack of 
immune correlates of protection, as well as the genetic and geographical diversity of HIV where 
prototype viruses have not been identified 120-124. Although antiretroviral (ARV) therapy has 
become increasingly available and has proven successful in the suppression of viral load and 
disease, access in Africa remains limited due to cost and uncertainty of supply 125, 126. As a result, 
effective, inexpensive HIV vaccines remain our greatest hope of fighting AIDS.  
 
Researchers are aiming to develop a safe, immunogenic and affordable AIDS vaccine that will 
reduce this pandemic. Several vaccine strategies such as neutralizing antibodies (NAbs); DNA 
vaccines; prime-boost regimens; subunit vaccines; particle-based vaccines and live vectors have 
been developed and tested in an attempt to develop an HIV vaccine 67, 78, 124, 127.  
 
It has been reported that AIDS is the result of cross-species infections of humans by lentiviruses 
of primate origins 128. One example of such infections is SIV. SIV infects different species of 
nonhuman primates and has been reported to be the cause of AIDS in these species. The 
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SIV/macaque model is currently the most appropriate animal model seeing that its infectivity and 
immunogenicity are very similar to those of humans. Consequently rBCG vaccine vectors 
expressing different HIV and SIV immunogens have been studied in small animal models and 
nonhuman primates in order to evaluate their immunogenicity, and the major studies are listed in 
Table 1.1.  
 
One of the first studies performed in an animal model was conducted by Aldovini and Young, 
(1991)104 in BALB/C mice, where they reported induction of both antigen-specific cellular and 
antibody responses after immunization with rBCG expressing a variety of HIV-1 polypeptides. 
In the subsequent years studies have been conducted to show that rBCG can induce both of these 
responses to the major proteins of HIV or SIV in different animal models, such as rhesus 
macaques 129-131, baboons 132, guinea pigs 112, 133 and BALB/c mice 105, 134.   
1.2.2.1. Neutralizing antibody responses to HIV- 1 antigens 
It is hypothesized that virus-neutralization plays a role in controlling virus infection, thus 
neutralizing antibodies (NAb) are still considered as one of the major effector mechanisms 
against HIV infection 135. In some rhesus macaque studies, NAbs have completely blocked 
experimental infections 136-138. These responses have been explored in BCG/HIV vaccine studies 
in an attempt to neutralize different strains in order to reduce initial viral load. Most of these 
studies aim to induce long lasting antibodies against the envelope glycoprotein 135, 139.  
 
In BALB/c mice and guinea pigs Lim et al., (1997)140 demonstrated induction of Env specific 
IgG antibodies (Ab) after an oral immunization with rBCG expressing SIV Env, which 
neutralized growth of virulent SIVmac251 field isolates in vitro. Similarly Hiroi et al., (2001)135 
also induced high titres of Env V3-specific IgG antibodies in the serum of mice vaccinated with 
rBCG-V3J1 via nasal immunization, which were able to neutralize clinical HIV-1 isolates in 
vitro. Additionally, expressing HIV env V3 in BCG Someya et al., (2005)127 demonstrated 
induction of a strong antigen-specific NAb response for 24 weeks in rhesus macaques. Although 
the response did not provide protection against a pathogenic SHIV challenge, it significantly 
reduced viral load after a challenge with a non-pathogenic SHIV.  
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1.2.2.2. Specific T-cell responses to HIV- 1 antigens 
Studies have shown that cell-mediated immunity, cytotoxic T lymphocyte (CTL) and Th1-type 
responses are effective against HIV since these responses prolong disease progression by 
releasing cytokines that reduce viral load 141, 142. It is speculated that CD4
+
 T-cell responses can 
limit HIV-1 transmission and vigorous CD8
+
 T-cell-mediated anti-HIV-1 responses might help 
to maintain low viraemia as seen in long-term non-progressors and acute serocoverters 143-146.  
 
Generally to induce CTLs, researchers generate rBCG vaccines expressing peptides derived from 
the structural and regulatory proteins such as Env, Gag, Pol and Nef 129, 133, 147. Yasutomi et al., 
(1993)129 demonstrated induction of CTLs to Gag in rhesus monkeys immunized intradermally 
with rBCG-SIVmacgag. Using rBCG-Env V3 (Table 1.1) to immunize guinea pigs and mice, 
Honda et al., (1995)133 showed induction of CTLs, which played a role in protection of the 
animals against HIV infection. Winter et al., (1995)148 demonstrated that CTLs are induced to the 
central region of Nef in BALB/c mice vaccinated with rBCG expressing SIVmac251 nef gene. 
Similarly Lagranderie et al., (1997)93 observed strong systemic and mucosal CTLs to Nef in 
BALB/c mice following oral immunization with rBCG SIV nef.   
 
Sequence analysis have suggested that CTL epitopes conserved across different genetic HIV 
subtypes and directed against Gag, Env, Pol and RT sequences exist 149-151. These epitopes are 
expected to reduce the occurrence of escape mutants in HIV infected individuals. Therefore 
another strategy employed to ove come the emergence of escape mutants is the development of 
polyepitope rBCG vaccine. The polyepitope rBCG would be generated by integrating multiple 
sequences encoding HIV T and B cell epitopes into a single vector 139. 
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Table 1.1: A summary of some immunogenicity studies on SIV and HIV immunogens expressed in BCG as vaccine vector (data modified and updated 
from Chapman et al., 2010
152
)  
HIV/SIV GENE/ANTIGENS 
EXPRESSED BY BCG 
 
EXPERIMENTAL DESIGN ANIMAL 
MODEL 
KEY RESULTS REFERENCES 
 
HIV-1 Env gp120 expressed 
under the control of hsp60 
promoter 
 
 
Single inoculation with 2x106 cfu BCG 
containing integrating vector expressing 
HIV-1 Env gp120 or model antigens ( -
galactosidase or fragment C of tetanus 
toxin) 
 
 
BALB/C mice 
 
 
 CTL responses (specific lysis) to HIV-1 Env 
gp120 immunodominant epitope, P18 peptide  
 Induction of humoral responses to model 
antigens ( -gal and tetanus toxoid) 
 Induction of cellular immune responses (IFN-  
production) in animals vaccinated with rBCG-
-gal, and not with rBCG-gp120. 
 
 
Stover et al., 1991
105
 
 
 
HIV-1 gag, pol and env 
expressed separately under 
the control of hsp70 
promoter 
 
Single i.d. or i.v. inoculations with 5x106 
cfu of rBCG-gag or rBCG-env  
 
BALB/C mice  Induction of humoral responses to HIV-1 
proteins in all mice inoculated intravenously  
 Induction of CTL responses (specific lysis) in 
mice inoculated with rBCG-gag; CTL activity 
attributed to CD8+ splenocytes   
 Induction of cellular immune responses (IFN-  
& IL-2 production) in animals vaccinated with 
rBCG-gag.  
 
Aldovini and Young, 
1991
104
 
SIVmac251 gag expressed 
under the control of hsp70 
promoter 
Two i.d. vaccinations with rBCG at 4 sites 
(dose:108 cfu) 19 weeks apart  
mamu-A*01+ 
rhesus macaques 
 Immunization elicited MHC class 1-restricted 
CD8+ SIVgag-specific CTL 
 No anti-SIVmac gag antibody response was 
generated in immunized animals. 
 
Yasutomi et al., 
1993
129
 
SIVmac251 nef gene under 
the control of M. 
paratuberculosis PAN 
promoter 
 
 
Inoculation with 107 cfu rBCG(SIVmac251 
nef) via s.c. 
BALB/C mice  Proliferative  and CTL responses against Nef 
peptides. 
Winter et al., 1991
148
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HIV env V3 (encoding 19 
amino acids of the Japanese 
HIV-1 V3 consensus 
sequence 
NTRKSIHIGPGRAFYATGS  
which has a neutralization 
sequence identical to that of 
HIV-1MN 
Animals were vaccinated once with rBCG 
by s.c. injection at a dose of 5 mg (~108 
cfu; guinea pigs) and 0.1 mg (~3x106; 
mice). 
guinea pigs and 
mice 
 DTH responses to Env V3 and PPD were 
induced in guinea pigs after immunization with 
rBCG-Env V3 and following systemic passive 
transfer of spleen cells obtained from rBCG-
Env V3-vaccinated guinea pigs 
 CTL responses were induced in mice by  
vaccination with rBCG-Env V3 
 guinea pig immune antisera had ability to (i) 
neutralize primary HIV-1 isolates and (ii) block 
HIV infection in SCID mice. 
Honda et al., 1995
133
 
 
SIVmac251 gag expressed 
under the control hsp70 
promoter 
 
Two i.d. vaccinations with rBCG at 4 sites 
(dose:108 cfu) 19 weeks apart, subsequent 
boosting (13 months after) with SIVmac 
Gag peptide p11C (dose: 1 mg; i.m.) 
formulated with a lipid-A-containing 
liposome in aluminium hydroxide, and 
pathogenic SIV challenge 
 
mamu-A*01+ 
rhesus macaques 
 
 Vigorous p11C-specific CTL response 
generated was greater than those generated by a 
single modality immunization with p11C 
peptide-liposome inoculation 
 No protection was afforded by this CTL 
response against SIV challenge 
 Recovered virus after challenge had identical 
SIV gag demonstrating that the CTL response 
did not select for viral variant that might escape 
T-cell immune recognition 
 
 
Yasutomi et al., 
1995
153
 
SIVmac251 nef expressed 
under the control of PAN 
promoter 
Oral immunization with rBCG (109 cfu) 
for 5 consecutive days (total dose of 5x109 
cfu) 
BALB/c mice  rBCG translocated to oropharyngeal mucosa 
and intestinal epithelium 
 Strong systemic and mucosal responses were 
induced 
 Specific anti-Nef CTLs demonstrated in 
intraepithelial CD8+ cells 
 
Lagranderie et al., 
1997
93
 
SIVmac251env gp110 fused 
to β-lactamase gene and 
encoding gene under the 
control of the pBlaF* 
promoter 
inoculation with (dose: 107 cfu) via s.c. 
immunization 
BALB/c mice and 
guinea pigs 
 Strong CTL responses and humoral immune 
responses elicited in both mice and guinea pigs 
immunized by parenteral routes 
 The anti-gp110 IgGs produced were able to 
neutralize in vitro growth of virulent 
SIVmac251 field isolates 
 guinea pigs immunized by the oral route 
produced significant levels of anti-gp110 IgAs 
in the faeces, demonstrating that rBCG is able 
to induce local humoral immunity in the 
intestinal mucosa 
Lim et al., 1997
140
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SIVmac251 Nef protein, and 
large fragments of the Env 
and Gag proteins 
 
Immunization via different mucosal routes 
(oral, aerogenic, nasal, and rectal) 
BALB/c mice  Local, specific IgA, systemic IgG, strong, 
specific cytotoxic responses of splenocytes 
against Nef, Env, and Gag was observed 
whatever the mucosal route of immunization 
 
Lagranderie et al., 
1998 
110
 
SIVmac251 Gag, Pol, 
truncated Env and Nef 
(separately subcloned into 
shuttle vector under 
regulatory control of the 
hsp70  promoter) 
 
Animals inoculated i.v. with 4 rBCG 
constructs containing SIV gag, pol, env, 
and nef combined in a single inoculum 
(dose: 5-7x108 cfu) 
rhesus macaques  Vaccination elicited SIV-specific IgA and IgG 
antibody, and weak cellular immune responses, 
including CTL and helper T cell proliferation to 
Gag, Pol and Env 
Leung et al., 2000
130
 
HIV env V3 (encoding 19 
amino acids of the Japanese 
HIV-1 V3 consensus 
sequence)  
 
 
Animals inoculated with rBCG either by 
nasal (10 g, ~106 cfu), oral (100 g) or 
s.c. (100 g) routes, once a week for 3 
consecutive weeks 
C57BL/6J mice  High titres of Env V3-specific IgG antibodies 
were generated in the serum of nasally-
immunized animal, maintained for >12 months, 
and had ability to neutralize clinical HIV-1 
isolates in vitro 
 Env V3-specific IgG-producing cells were 
detected in mononuclear cells obtained from 
spleen, nasal cavity and salivary gland 
 
Hiroi et al., 2001
135
 
HIV env V3 (encoding 19 
amino acids of the Japanese 
HIV-1 V3 consensus 
sequence)  
 
 
 
rBCG-HIVEnv inoculated via either a 
single (i.d., i.n. and i.r.) or combination 
(i.r./i.d. and i.r./s.c.) routes.  (i.r. = 80 mg 
of vaccine once a week for 2-4 
consecutive weeks; s.c. and i.d. = 1.0 and 
0.1 mg once respectively; i.n. = 10 g 4 
times weekly for 3 weeks) 
guinea pigs  DTH responses to both PPD and Env-V3 
peptide were detected in animals inoculated 
with  a combination of i.r. and i.d. routes 
 Animals inoculated by combined rotes had 
significantly higher titres of HIV-1-specific IgG 
and IgA in serum with enhanced neutralization 
activity  
 Induction of high levels of IFN-  and IL-2 
mRNA in PBMC, splenocytes and 
intraepithelial lymphocytes up to 2 years after 
combination inoculation 
 
 
Kawahara et al., 
2002
154
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HIV env V3 (encoding 19 
amino acids of the Japanese 
HIV-1 V3 consensus 
sequence)  
 
 
rBCG-HIVEnv inoculated via oral route  
(80 mg of freeze-dried vaccine once a 
week for 4 consecutive weeks, providing a 
total dose of 320 mg) 
guinea pigs  Env-V3 peptide-specific DTH responses were 
detected in immunized animals 1.5 years post 
inoculation 
 Env-V3 peptide-specific proliferative responses 
detected in PBMC and intestinal intraepithelial 
lymphocytes indicating induction of functional 
T cells to HIV-1 Env in both systemic and 
mucosal compartments 
 
 
Kawahara et al., 
2002
106
 
SIVmac251 gag, nef and env 
(truncated) expressed 
individually in rBCG  
 
 
 
Single i.d. inoculation (5×108 cfu) into 5 
sites on the back, and rectal or oral 
boosting doses (6 ×1010 cfu) were 
administered intrarectally or 
intragastrically, resoectively every 2 days 
for 6 days, (total dose of 18×1010 cfu). All 
the animals were challenged intrarectally 
with pathogenic SIVmac251  
cynomolgus 
macaques (M. 
fascicularis) 
 After i.d. inoculation, monkeys exhibited CTL 
responses targeted against the three antigens 
and IFN-γ secretion was observed 
 A rectal or oral boosting dose elicited anti-SIV 
IgAs in the rectum of vaccinated monkeys and 
increased IFN-γ secretion by circulating blood 
cells. No antibodies were detected and no CD4+ 
T-cell-mediated anti-SIV responses before 
challenge were observed 
 No protection from SIVmac251 challenge  
 
Mederle et al., 
2003
155
 
HIV env V3 (encoding 19 
amino acids of the Japanese 
HIV-1 V3 consensus) 
sequence  
 
 
 
One s.c. immunization of 10mg rBCG env 
V3  and challenge from week 24  with 
either low-dose SHIV-MN, high-dose 
SHIV-MN, or SHIV-98.6PD at different 
intervals. 
rhesus macaques  Significant levels of NAb for the 24 weeks 
tested that were predominantly HIV-1 type 
specific- neutralized primary HIV-1 isolates in 
vitro  
 Neutralization was not observed against HIV-
1SF33/X4 or primary HIV-1 R5 isolates 
 Viral load in the vaccinated macaques was 
significantly reduced following low-dose 
challenge with SHIV-MN, and early plasma 
viremia was decreased after high-dose SHIV-
MN challenge. Replication of pathogenic 
SHIV-89.6PD was not affected 
  
Someya et al., 
2005
127
 
SIVmac239  full length gag in 
rBCG-Tokyo downstream of 
hsp60 promoter  
Animals were vaccinated with rBCG via 
i.d.  by single inoculation (10 mg) and a 
replication-deficient vaccinia virus strain 
(DIs) expressing SIVmac239 gag-pol  
(rDIs-SIVgag) i.v. (106 pfu) in 
heterologous prime-boost or reverse 
combination. Control groups received 
cynomolgus 
macaques 
(Macaca 
fascicularis) 
 rBCG-SIVgag/rDIs-SIVgag regimen induced 
high levels of SIV-specific IFN-γ spot-forming 
cells which afforded effective protective 
immunity against mucosal challenge with SHIV 
KS661c 
 Other vaccination regimens including the 
opposite combination or the single-modality 
 
Ami et al., 2005 156 
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combinations containing rBCG with 
empty plasmid or DIs encoding -
galactosidase. All animals were challenged 
via intra-rectal inoculation with 
pathogenic 2000 TCID50 of SHIV 
KS661c, a derivative of SHIV89.6  
 
combinations did not effectively protect against 
viral challenge 
HIV-1 clade A  consensus gag  
(HIVA; containing a string of 
CD8+ T-cell epitopes) fused 
to M.tb 19-kDa signal 
sequence and expressed in a 
lysine auxotrophic strain of 
BCG  
rBCG vaccination via i.p. (106 cfu). 
Animals boosted with recombinant rMVA 
expressing HIVA (106 pfu) 
 
BALB/c Mice  rBCG prime-vaccination enhanced HIV-1 
specific CD8+ T-cell responses induced by 
rMVA boost immunization  
 Heterologous rBCG/rMVA regimen enhanced 
the vigour and quality of CD8+ T-cell response 
including that to a subdominant epitope  
 This enhancement was directly related to dose, 
with higher doses effecting greater enhancement 
 A DNA prime-rBCG boost regimen afforded 
protection against a surrogate virus challenge 
 
Im et al., 2007
157
 
 HIV-1 group M consensus 
envelope (CON6) either as a 
surface, intracellular, or 
secreted protein  
 
rBCG vaccination via i.p. (either 108 , 107 
, or 106 cfu). Animals boosted with 
recombinant CON6 gp140 protein 
formulated in RiBi adjuvant  via i.p. (50 
g) 
Mice immunised with rAd5 and rVV in 
prime/boost combination served as 
positive controls 
BALB/c Mice  rBCG-induced T-cell responses to HIV-1 
envelope in spleen were lower than those 
induced by rAd/rVV prime/ boost  
 rBCG induced comparable responses to rAd-
rVV immunization in the female reproductive 
tract and lungs  
 T-cell responses induced by rBCG were 
primarily CD4+, although rBCG alone did not 
induce anti-HIV-1 antibody  
 However, rBCG could prime for a protein boost 
by HIV-1 envelope protein. Thus, rBCG can 
serve as a vector for induction of anti-HIV-1 
consensus Env cellular responses at mucosal 
sites 
 
 
Yu et al., 2007
111
 
Full-length SIV Gag protein 
under the control of hsp60 
promoter (rBCG-SIVGag) 
0.5ng/mg 
rBCG-SIVGag inoculated i.d by single 
inoculation of 0.1 mg or oral route  (80 mg 
once a week for 2 consecutive weeks, 
providing a total dose of 160 mg) 
guinea pigs  IgG2 levels greater than IgG1 
 IFN-γ  mRNA expression detected in PBMC for 
both i.d. and oral vaccine groups 
 i.d. rBCG induced  DTH responses to PPD and 
SIV Gag p27 protein which were maintained for 
up to 50 weeks 
Kawahara et al., 2006 
and 2008 
112, 158
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
16 
 
  Oral rBCG induced a long-lasting DTH 
response to the SIV Gag p27 protein, but not to 
PPD 
 
 
Full-length HIV-1 subtype C 
gag under the control of mtrA 
or katG promoters  and 19-
kDa localisation signal 
sequence  
 
rBCG vaccination via i.d. (108 cfu) four 
times. 
All animals boosted via i.m. with HIV-1 
subtype C Pr55gag virus-like particles (Gag 
VLPs; 11 g) 1 year after last rBCG 
vaccination 
chacma baboons 
(Papio ursinus) 
 Induction of BCG vector-specific T-cell  
immune responses and recall responses after 
subsequent rBCG vaccinations 
 Development of low but detectable T-cell 
responses to HIV-1 Gag after rBCG vaccination 
and which were efficiently boosted by Gag 
VLPs 
 Generation of IFN- -producing CD3+ CD8+ T 
cells after rBCG/Gag VLPs prime/boost 
vaccination 
 PBMCs from immunised baboons targeted 
peptides with documented HIV-1 Gag epitopes 
 
Chege et al., 2009
132
 
Full-length SIVmac239 gag 
and pol and a modified env 
under the control of M.tb 
alpha antigen promoter and 
19-kDa localisation signal 
sequence  
 
rBCG vaccination via i.d. (106 to 109 cfu) 
or i.v. (109, 108, 107, 106 cfu) twice, 23 
weeks apart. All animals boosted via i.m. 
with rAd5 (1010 viral particles) expressing 
SIV Gag/Pol and Env once 20 weeks after 
last rBCG vaccination 
mamu-A*01+ 
rhesus macaques 
 Induction of BCG vector-specific T-cell  
immune responses with second rBCG 
vaccination showing a robust recall response 
 Development of low but detectable T-cell 
responses to SIV Gag and Pol but not Env after 
rBCG vaccination. 
 Generation of p11C tetramer-binding and highly 
polyfunctional CD8+T cells after rBCG/rAd5 
prime/boost vaccination 
 
Cayabyab et al., 2009 
159
       
Whole HIV-1 CRF01_AE 
gag gene 
Mice inoculated a single injection of 0.1 
mg of the rBCG/HIV-1gagE vaccine via 
s.c. and i.d. 
Prime boost: prime with rBCG/HIV-
1gagE 2x106 cells via s.c. and a boost 
rDIs/HIV-1gagE 1x106 pfu via i.v. or i.d. 
BALB/c mice 
 
 One month later higher CTL against various 
positions of the Gag protein by s.c. compared to 
that by i.d. 
 prime boost, increased CTL responses induced as 
noted by specific cell lysis  
 both routes sustained similar CTL levels seven 
months post immunization 
 
 
 
Promkhaykaew et al., 
2009147 
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HIVA , an HIV-1 clade A-
derived immunogen under 
the control of Ag85B 
promoter and linked to the 
19 kDa signal peptide 
 
Animals were primed with BCG.HIVA401 
at 106 cfu i.p. and boosted with 
MVA.HIVA i.m at 106 pfu or 
OAdV.HIVA i.m at 107 infection units 
(IU) after 12 weeks  
 
BALB/c mice 
rhesus macaques 
 BCG.HIVA401 alone induced undetectable and 
weak HIV-1-specific CD8 T-cell response in 
mice and macaques, respectively 
 In a prime boost regimen robust and broad HIV-
1-specific T-cell were induced 
 Multiple antigen-specific T-cell clonotypes were 
recruited into memory 
 Induction of persistent potent T-cell responses 
specific for PPD antigen  
 
Rosario et al., 
2010131 
 
 
HIVA, an HIV-1 clade A-
derived immunogen under 
the control of Ag85B 
promoter and linked to the 
19 kDa signal peptide 
 
 
Animals inoculated with 1x107 cfu 
BCG.HIVA401 via i.d. and boosted with 
two i.m. injections of 5x107 pfu 
MVA.HIVA after 11 and 14 weeks 
 
 
 
 
 
 
neonate Indian 
rhesus macaques 
 
 PPD response peaked at 4 weeks and declined 
thereafter 
 BCG.HIVA401 alone elicited a strong BCG-
specific response 
 In a prime boost regimen, BCG-specific IFN- -
secreting lymphocytes were induced, however 
declined 23 weeks later 
 HIV-specific T-cell responses were detected 1 
week after the first boost, but were very weak 
 
Rosario et al., 
2010160 
 
 
 
 
 
 
 
 
 
 
Trimeric HIV-1 V3 loop 
(mV3) under the control of 
hsp60 promoter 
Mice inoculated via i.p. 1x107 cells/mouse 
and  guinea pigs inoculated via i.p. 1x108 
cells/animal and boosted 4 weeks later 
with the same cells via the same route 
 
BALB/c mice 
guinea pigs
 Induction of V3-specific antibodies, IgG2a was 
prevalent in the V3-specific antiserum  
 IgG1 and IgG3 were very low 
 DTH response was induced in guinea pigs 
 V3-specific T-cells in mice spleens, which were 
retained 5 months post-vaccination. 
 
Kim et al., 2011134 
 
Abbreviations: Cytotoxic T lymphocyte (CTL);  Delayed-type hypersensitivity (DTH); heat shock protein (hsp); intradermal (i.d.); intranasal (i.n.); intrarectal (i.r.); intraveneous (i.v.); purified 
protein derivative (PPD); severe combined immunodeficiency (SCID); simian immunodeficiency virus (SIV)-HIV chimeric simian-human immunodeficiency virus (SHIV); simian-human 
immunodeficiency virus (SHIV-MN);  highly pathogenic SHIV strain (SHIV-89.6PD); subcutaneous (s.c.). 
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1.2.3. FACTORS INFLUENCING THE IMMUNE RESPONSES TO RECOMBINANT 
BCG 
There are a few factors that should be considered in developing rBCG vaccines, such as the 
immunization route, localization of the heterologous antigen and the dosage of BCG as these 
determine the type of rBCG immune response elicited post vaccination 148, 161, 162. These factors 
are described in detail in the following sections. 
1.2.3.1. Immunization route  
Precise comparisons of immune responses elicited by rBCG administered through different 
routes are difficult since doses administered vary. Both antigen-specific humoral and cellular 
immune responses have been induced concurrently by the rBCG vaccines administered via 
combined routes. Kawahara et al., (2002)154 immunized guinea pigs with rBCG expressing HIV 
Env V3 via either a single (Intradermal (i.d.), intranasal (i.n.) and intrarectal (i.r.)) or 
combination (i.r./i.d. and i.r./ subcutaneous (s.c.)) routes. They observed humoral and cellular 
immune responses against both HIV-1 and tuberculin in systemic and mucosal compartments 
with all immunization routes, however, the animals inoculated with combined routes displayed 
significantly higher levels of immune responses compared to the animals inoculated via a single 
route.  
 
Kawahara et al., conducted two studies in 2006 and 2008112, 158, in which they immunized guinea 
pigs with rBCG-SIVgag via i.d. and oral routes (Table 1.1). They observed long-lasting cellular 
and humoral immunity against both viral and bacterial antigens with both vaccination routes, 
which were maintained for up to 50 weeks. However, different kinetics of Gag-specific INF-  
responses were observed between the two immunization groups, 1 year post-immunization 
stronger responses were observed in the i.d. immunization group, whereas 3 years post-
immunization the levels between the two groups became identical. 
 
Studies have reported that mucosal compartments are the major sites of infection entry for 
viruses such as HIV and SIV 115, 163-165. Furthermore it has been demonstrated that the gut-
associated lymphoid tissue (GALT) is an important site for the interaction between the host and 
the pathogen during HIV infection, CD4
+
 T-cell depletion during the acute stage of infection and 
HIV replication during both the acute and the chronic stages of infection 115, 163-166. Consequently 
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generating a vaccine that would be administered via the mucosal route could provide the first 
line of defence against the invasion of infection by inducing antigen-specific immunity at this 
primary route of transmission.  
 
Indeed, studies in different animal models have shown that mucosal vaccination of rBCG is 
effective as it has been able to elicit strong long term antigen-specific humoral and cellular 
immunity 111, 127, 133, 135. For instance, after immunizing mice nasally with rBCG expressing HIV 
env V3, Hiroi et al., (2001)135 observed induction of high titres of Env V3-specific IgG 
antibodies, which were able to neutralize clinical HIV-1 isolates in vitro. Similary in rhesus 
macaques Someya et al., (2005)127 reported that primary HIV-1 isolates were neutralized by high 
titres of HIV-1 type specific NAb that were elicited following immunization with rBCG 
expressing HIV env V3. With the aim to raise both of these immune responses against SIV, 
Lagranderie et al., (1998)110 immunized BALB/c mice via different mucosal routes such as oral, 
aerogenic, nasal and rectal with a cocktail of three different rBCG strains each expressing large 
fragments of SIVmac251 Nef, Env and Gag proteins. Although the vaccines induced local IgA, 
systemic IgG and CTLs against the three SIV antigens with all routes of immunization, they still 
observed some discrepancies in the responses. They concluded that the local and systemic 
immune responses induced with the rectal and oral routes were the most appropriate routes. 
 
Considering the above studies, due to its innate adjuvant properties and the ability to induce 
CTLs and antibodies against HIV/SIV infections, BCG could be an ideal vaccine candidate for 
generating mucosal immunity. 
1.2.3.2. Localization of the heterologous antigen and the impact on immunogenicity  
A number of studies have highlighted the importance of heterologous antigen display in 
influencing the type of protective cell-mediated immunity elicited by BCG 97, 99, 111, 167. Generally 
the mycobacteria-derived antigens are processed and presented by the macrophages. Hess et al., 
(2000)168 reported that antigens delivered into the phagolysosome are usually processed via the 
major histocompatibility complex (MHC) class II pathway and thus induce predominantly CD4
+
 
T cells. Consequently, in BCG-immunized animals the CD8
+ 
T-cell responses induced are weak 
111.  
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Yu et al., (2007)111 hypothesized that the weak induction of CD8+ T-cell responses following 
BCG vaccination could be enhanced by processing the antigens expressed via the MHC class I 
pathway. It has been demonstrated in several studies that rBCG engineered to express 
heterologous antigens as membrane associated lipoproteins or as secreted proteins by fusing 
them to the secretion signal sequences induce better immune responses than the antigens 
localized in the BCG cytoplasm as these antigen display strategies ensure that the antigens are 
processed via the MHC class I pathway 97, 99, 115, 157, 169.  
 
The M. tuberculosis 19 kDa lipoprotein signal is normally used to direct export and link the 
heterologous antigens to the BCG cell membrane 99. This lipoprotein is a cell wall or membrane-
anchored protein and is highly immunogenic in vivo 80. Stover at al., (1993)99 immunized mice 
with an rBCG expressing the Borrelia burgdorferi outer surface protein A (OspA) antigen as a 
membrane associated lipoprotein. Their vaccine induced protective antibody responses that were 
100 - 1000-fold higher than those elicited by rBCG expressing OspA in the cytoplasm or as a 
secreted fusion. Similarly Dennehy et al., (2007)167 showed that linking the heterologous antigen, 
VP6 protein to the 19 kDa lipoprotein signal sequence that transported it to the membrane was 
important for induction of protective immunity against rotavirus in mice. 
 
The alpha (α) antigen from BCG or M. kansasii is usually used to export heterologous antigens 
113. Several studies have shown that this antigen exposure increases immune responses elicited 97, 
111. Honda et al., (1995)133 inoculated guinea pigs and mice with rBCG secreting the HIV-1 V3 
epitope (Table 1.1) via s.c. route. In guinea pigs following immunization and systemic passive 
transfer of the spleen cells they observed delayed-type hypersensitivity (DTH) responses to Env 
V3 and purified protein derivative (PPD) and HIV-specific antibody responses that were able to 
neutralize primary HIV-1 isolates. In mice CTLs were induced. Additionally the guinea pigs 
serum IgG effectively blocked HIV infection in severe combined immunodeficiency (SCID)/Hu 
mice. 
 
Yu et al., (2007)111 immunized BALB/c mice with rBCG HIV-1 Env (Table 1.1). This antigen 
was expressed as an immunogen in different locations in BCG, i.e. either as a surface, 
intracellular or secreted protein. The secreted antigen induced the highest Env-specific T-cell 
IFN-  responses. Using a similar system Grode et al., (2002)97 generated an rBCG expressing the 
immunodominant antigen p60 of Listeria monocytogenes in different bacterial compartments and 
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examined the cellular immunity in BALB/c mice. The anti-listerial protection evoked by the 
membrane-linked p60 lipoprotein and the secreted p60 were nearly equal and protected the mice 
from listeriosis, whereas cytosolic p60 failed to protect mice from listeriosis. In a subsequent 
study Grode et al., (2005)170 constructed an rBCG vaccine that secreted the membrane-
perforating listeriolysin (Hly) of L. Monocytogenes and was deficient in urease C production 
(∆ureChly+rBCG). ∆ureChly+rBCG showed improved protection against aerosol infection with 
M. tuberculosis compared to the parental BCG strain and improved antigen translocation into the 
cytoplasm. 
Based on the above studies it is clear that expressing the antigen as a membrane-anchored 
protein or secreting it in BCG improves immunogenicity.  
1.2.3.3. The dose of BCG 
Most rBCG vaccine immunogenicity studies have implicated the dosage of BCG as a major 
factor influencing the T helper type 1 (Th1)/ T helper type 2 (Th2) nature of immune response 
elicited 161, 169. High doses of BCG deliver large amounts of foreign antigen, which favour higher 
humoral responses and lower cellular responses, and vice versa 59, 162. This is due to the fact that 
higher levels of antigen favour humoral immunity as the maturation of B lymphocytes is 
dependent on the constant presence of the antigen 162.  
 
In a murine model Langermann et al., (1994)169 demonstrated that the antibody response is 
dependent on the dose of BCG administered. Following immunization of the animals with rBCG 
expressing an outer-surface protein of Borrelia burgdorferi, OspA linked to the 19 kDa antigen, 
they observed that the lowest dose of the vaccine did not induce humoral responses, whereas the 
highest dose yielded high antibody titres. Power et al., (1998)161 studied the effects of different 
doses of BCG on the type of immunity elicited in BALB/c mice. They reported that low doses 
elicited a Th1 response, whereas higher doses favoured a mixture of Th1/Th2 responses and a 
Th2-mediated humoral response. Additionally, In BALB/c mice Michelon et al., (2006)162 
showed that rBCG expressing the MSP1a antigen of Anaplasma marginate with an in vivo up-
regulated vaccine vector induced significant serocoversion to MSP1a that was 26x above the pre-
immunization levels and weak MSP1a specific Th1 responses, whereas a vaccine vector that was 
not up-regulated induced humoral immunity to MSP1a that was 6x above the pre-immunization 
levels, and markedly stronger cellular responses. 
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1.2.4. COMPLICATIONS IMPEDING THE EXPRESSION OF HETEROLOGOUS 
ANTIGENS IN RECOMBINANT BCG 
In spite of its frequent use as a heterologous delivery system, there have been reports of 
complications associated with rBCG. In addition to causing disseminated BCG disease in 
immunocompromised individuals (mentioned in Section 1.1.2.2), M. bovis BCG grows 
extremely slowly in vitro, cultures have ~ 22 hr doubling time and colonies take up to ~ 4 weeks 
to develop on solid medium 103, 171. In liquid medium the strain aggregates, which hinders 
quantification of the cultures and minimizes the quality of the vaccine cultures 172. 
 
Low heterologous antigen expression and vector genetic instability are the two major issues 
accountable for reduction of the potency of the rBCG expressing viral antigens and prohibition 
of its commercial production 95, 106, 125, 152. These two issues are circuitously linked and can be 
attributed to a number of factors, which vary from the expression mechanism of the heterologous 
antigen to the codon compatibility between antigens and the host 95, 103, 107, 173. Low antigen 
expression and vector instability often result in induction of weak or no immune responses 
following vaccination.  
1.2.4.1. Low heterologous antigen expression 
Generally in recombinant bacteria, the introduction of foreign antigens require the resources (in 
the form of energy) of the host cells for maintenance and expression. As a result the metabolism 
of the host cells is disturbed 173-176. When the heterologous antigen expression machinery uses up 
the host cell’s resources it places a metabolic load on the host 173-175. As a result the growth rate 
of the host cell is hindered 95, 105.  
 
The factors that influence the metabolic load are the plasmid copy number and over-expression 
of foreign antigens 176, 177. Higher plasmid copy number leads to increased expression levels and 
therefore higher cellular energy utilisation. Over-expression of foreign antigens can lead to the 
formation of inclusion bodies and production of mis-folded proteins. This induces the expression 
of cellular proteases and chaperones in order to degrade these proteins 173, 176, 178. This 
degradation process increases toxicity within the cell and consumes cellular energy. The 
depletion of cellular energy becomes a metabolic burden 103, 176.   
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1.2.4.2. Genetic instability of the rBCG 
Vector instability occurs during in vitro culturing and/or post immunization of mammalian 
subjects as a result of the metabolic load imposed by the heterologous antigen 176. It results in 
either of two processes. The first is structural instability, where there is an alteration or loss of 
the gene encoding the heterologous antigen due to mutation 95, 103. The second is plasmid 
inheritance instability where the entire plasmid is lost by the cells in the culture 60, 106. These 
processes result in a production shift in the culture, where the plasmid-less cells outgrow the 
plasmid-bearing cells 173, 179. This leads to low production of the heterologous antigens, which in 
turn lowers the immunogenicity of the vaccine and ultimately reduces protective efficacy 173. The 
rate at which genetic instability occurs is determined by the fitness level of the recombinants, 
which in turn is determined by the degree of the metabolic load 173. On condition that multiple 
passages are required for the large scale production of rBCG vaccines, vector instability makes 
the commercial production of the vaccine impractical 176.  
1.2.5. STRATEGIES DESIGNED TO IMPROVE BCG AS A RECOMBINANT 
DELIVERY SYSTEM 
1.2.5.1. Development of safer rBCG  
As mentioned earlier, prior to the emergence of HIV/AIDS pandemic, BCG was considered safe, 
however now there are BCG safety concerns that have been raised since the reports of 
disseminated BCG disease in immunocompromised individuals have been published. Recent 
rBCG studies are aimed at developing rBCG vaccines that are safe for immunocompromised 
individuals, while maintaining the protective efficacy. Such vaccines could be used in areas with 
high HIV prevalence, where they could be administered for protection against TB to infants with 
unknown HIV status and individuals who are immune-compromised or HIV-positive.  
 
Moreover due to reports of Mother-to-child transmission (MTCT) of HIV via breast-feeding 157, 
180, these safe vaccines could be given to infants to prevent MTCT, where they would be 
administered at birth. Although studies have shown that maternal ARV therapy regimens and 
infant nevirapine can significantly reduce the risk of MTCT 157, 180, the high cost of these drugs 
prevents the constant supply in developing countries considering the drugs would have to be 
administered during the entire breastfeeding phase. 
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Auxotrophic strains of BCG have been recently constructed, whereby mutations are introduced 
into the strains to prevent them from synthesising essential growth compounds, e.g. a BCG 
mutant in which a gene encoding lysine is inactivated, is a lysine auxotroph. These auxotrophic 
strains are then unable to grow unless the lacked amino acid is added into the culture 79, 157, 181. 
Additionally auxotrophs have been shown to be safer than the parent BCG strains following 
administration to immune-deficient animal models 32, 48, 55, 181. 
 
With the aim to develop an rBCG vaccine with improved safety and efficacy, Tullius et al., 
(2008)55 generated a rBCG ferrin mycobactin auxotroph expressing the highly immunoprotective 
M. tuberculosis 30 kDa major secretory protein rBCG(mtbB)30 and a rBCG pantothenate 
auxotroph expressing the same antigen (rBCG(panCD)30). They compared their vaccines to 
rBCG30 (a wild type rBCG strain expressing the same antigen) in terms of in vitro growth and 
immunogenicity in SCID mice and guinea pigs. The rBCG(mtbB)30 expressed the antigen at 
similar levels to the wild type rBCG30, however it induced better cellular immunity that 
conferred superior protection. The rBCG(panCD)30 on the other hand was comparable to 
rBCG30 in efficacy. Essentially both the auxotrophic vaccines were more attenuated than BCG 
and provided a safer alternative to the wild type BCG.  
 
In attempt to develop a vaccine to protect infants from acquiring HIV-1 via breast-feeding, Im et 
al., (2007)157 generated a lysine auxotrophic of BCG (Table 1.1) and tested it in BALB/c mice. 
Their vaccine was very immunogenic and thus provided protection against aerosol challenge 
with M. tuberculosis. In a prime and heterologous boost regimen it elicited virus-specific 
responses that provided protection against surrogate virus challenge. They concluded that 
administration of this vaccine soon after birth may prime HIV-1 specific immune responses, 
which could be boosted with other vaccines expressing the same immunogen or by natural 
exposure to HIV-1 in the milk during breastfeeding, and thus reduce MTCT via breast milk.  
 
Based on the above studies, it is clear that although auxotrophic strains are more attenuated, they 
still displayed immunogenicity comparable to that displayed by the parent BCG strains. 
Additionally, as mentioned in section 1.1.2 the tendency of BCG to sensitize for the tuberculin 
skin test is one of the limitations that prevent its extensive use. The results from a study 
conducted by Chambers et al., (2000)32 reported that auxotrophs allow for the generation of 
vaccines that will not interfere with the tuberculin skin test. In their study they showed that 
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immunization of guinea pigs with a leucine auxotroph of BCG conferred considerable protection 
from M. bovis infection and against hematogenous spread of M. tuberculosis without developing 
a cutaneous DTH reaction to tuberculin. In a more recent study a safety profile of the auxotrophs 
was demonstrated, where Sampson et al., (2011)48 assessed the leucine and vitamin pantothenate 
auxotroph of M. tuberculosis in SIV-infected rhesus macaques, a good model for HIV-positive 
humans and observed no vaccine-associated adverse effects. 
1.2.5.2. Improvement of rBCG stability and heterologous antigen expression  
Evidently the potency of the rBCG vaccine is determined by the genetic stability of the vector 
and its ability to express sufficient heterologous antigen to induce a good protective immune 
response. Research is focusing on approaches designed to develop a potent rBCG vaccine. These 
include the use of single-copy integrative vectors, codon optimization, heterologous BCG 
primed-boost regimens and the use of inducible expression systems 31, 64, 95.    
a. BCG shuttle vectors for the expression of heterologous antigens 
Most episomal shuttle vectors were developed from a Mycobacterium fortuitum cryptic plasmid, 
pAL5000, in combination with an E. coli cloning vector, pIJ666 and a kanamycin resistance 
gene 60, 110. These vectors replicate at about five copies per mycobacterial cell 90, 105, 182. To 
address the problems of low antigen expression, episomal vectors have been used with 
constitutive promoters so that the heterologous antigens are constitutively expressed and are thus 
presented at levels sufficient to trigger immunity 95, 157.  
In some studies episomal-based vaccines have displayed instability in vitro, this could be a result 
of metabolic load due to high heterologous antigen expression levels 29, 176. Furthermore, in vivo 
the unstable episomal vectors are unable to maintain stability in the absence of selection in cases 
where the antibiotic markers are used as selectable markers 60, 91. This is a disadvantage as the 
vaccinated subjects will have to be given antibiotics in order for the vaccine to remain stable 21, 
183.    
In order to overcome vaccine instability issues, integrative vectors were designed as alternative 
systems for expression of heterologous antigens 95, 105, 184. These vectors are derived from 
temperate mycobacteriophages such as L5 and Ms6 60, 184. They encode the integrase function 
that allows the phage attP to recombine with the bacterial homologous attB sites, which results 
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in the integration of the vectors into the mycobacterial genome 60, 95, 184. These vectors are better 
retained than episomal vectors 167. Additionally, integrative vectors are usually stable even in the 
absence of selection 105. 
 
Since integrative vectors integrate into the mycobacterial genome as a single copy, heterologous 
antigen expression levels are reduced in comparison to episomal vectors 167, 185. However this 
expression reduction is counterbalanced by the in vivo stability of these vectors that allows the 
antigen synthesis to persist for long periods of time 95.  Furthermore, optimum levels of 
heterologous antigen expression can be achieved by the use of integrative vectors in combination 
with strong promoters 104, 105, 167.  
b. Selectable markers used in rBCG 
The E. coli-mycobacterial shuttle vectors used in BCG vaccines for cloning and expression rely 
on the antibiotic resistance genes as selectable markers 60, 89, 186. Due to G-C rich thick and waxy 
cell walls of mycobacteria, it is not easy for many antibiotics to permeate through the walls. 
Thus antibiotics that can remain stable for prolonged incubations are required to facilitate the 
identification of recombinant mycobacteria 60, 89, 186. The problem is that these antibiotic 
resistance genes are unfavourable for in vivo based vaccines, given that to maintain stability 
selection antibiotics would have to be administered to the vaccinees.   
To circumvent the above issue, expression systems that do not carry antibiotic resistance markers 
have been developed. Superinfection immunity to mycobacteriophages 187 and resistance to 
mercury 186 have been used as selectable markers in mycobacterial expression systems. However, 
these systems proved to be unsuitable for use in recombinant vaccine as they lack in vivo 
selective pressure 60, 186, 187.  Consequently, the use of mycobacterial auxotrophs as selection 
markers has been investigated. The failure of auxotrophic strains to grow without the essential 
compounds provides for selection 60. The complementing genes are included on the plasmids in 
these auxotrophic strains to maintain the plasmids, which in turn improves stability. Borsuk et 
al., (2007)60 used unmarked homologous recombination to knock out the leuD gene of the BCG 
strain in order to generate a BCG auxotrophic for the amino acid leucine. Expression of LeuD on 
a plasmid allowed complementation and also acted as a selectable marker. This system 
maintained the selective pressure, and as a result remained stable both in vitro and in vivo.  
Similarly Im et al., (2007)157 developed a rBCG vectored by a lysine auxotroph of BCG that 
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carried a plasmid with a lysA-complementing gene. They reported that complementation 
increased the plasmid stability in vivo and precluded mutation of the heterologous genes.  
c. Codon optimization 
Instability of E. coli-mycobacterium shuttle vectors may be attributed to the rare codons 
contained by the heterologous antigens 188. Expression of proteins with rare codons can also 
cause metabolic load, which leads to low antigen expression 173, 189. Codon optimization is a 
method that is developed as a solution to this issue. This method is applied to ensure that the 
codons of the heterologous antigen are compatible with those of the host expression system 64, 
107. It has been applied to enhance foreign antigen transcription and translation in rBCG vector-
based vaccines as well as immunogenicity in mammalian cells 96, 107. 
 
Kanekiyo et al., (2005)107 observed a 40-fold increase in expression levels of HIV-1 p24 Gag 
gene in BCG after codon optimization. Additionally small doses of the codon optimized vaccine 
were able to induced HIV-1-specific cellular and antibody immune responses in mice. Applying 
this method Varaldo et al., (2006)96 were able to enhance the expression of a Schistosoma 
mansoni antigen, Sm14 by approximately 4-fold. However, immunity conferred by the 
optimized vaccine in an outbred Swiss mouse model against cercarial challenge did not improve, 
instead it was comparable to that conferred by the non-codon optimized vaccine.  
 
As reported in the above studies codon optimization enhances the expression of the heterologous 
antigen, which implies that lower doses of the vaccine maybe sufficient to induce immunity. 
This could help alleviate the problem of low antigen expression that requires administration of 
high vaccine doses. However, there is no guarantee that the immunogenicity of the vaccine will 
be enhanced.  
d. BCG prime with a heterologous boost  
As reported in numerous TB studies (section 1.1.3.1), the heterologous BCG prime-boost 
regimen is more effective than a homologous regimen 58, 78, 111. Thus this regimen has been 
implemented in the development of rBCG vaccines. In some of these studies protective 
immunity against virus challenges has been conferred 31, 156. Ami et al., (2005)156 immunized 
cynomolgus macaques with a rBCG-SIVgag prime and a rDIsSIVgag boost (Table 1.1) and 
elicited protective immunity against mucosal challenge with a pathogenic SHIV virus.  
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In other studies the use of the heterologous BCG primed-boost regimen has led to the induction 
of robust memory responses and production of enhanced antigen-specific CD4
+
 T cells and 
polyfunctional CD8
+ 
T cells 155, 159. Chege et al., (2009)132 reported that rBCG expressing the 
HIV-1 subtype C gag (Table 1.1) efficiently primed a HIV-1 subtype C (Pr55gag) virus-like 
particles (Gag VLPs) boost in Chacma baboons as low T-cell responses to HIV-1 Gag were well 
boosted. Using the same approach in rhesus macaques and BALB/c mice Rosario et al., (2010)131 
demonstrated enhancement of HIV-specific T-cell responses following a prime with rBCG 
expressing an HIV-1 Clade A-derived immunogen (BCG.HIVA) and a boost with MVA-
vectored or ovine adenovirus expressing the same antigen.  
 
Overall, BCG vaccinations display good priming ability to the immune system seeing that robust 
anti-HIV-1 immune responses were generated in the above studies. Thus BCG vaccines 
administered via this regimen could potentially confer some protection against an HIV infection. 
e. The use of inducible promoters  
Another approach designed to solve the issue of constitutive expression that results in over-
expression of heterologous antigens that increases metabolic load and reduces stability is the use 
of inducible systems 173, 190.  Inducible systems are structures that allow for the control of gene 
expression in prokaryotes and eukaryotes, with the aid of inducible promoters. These systems 
will be explained extensively in the following section.  
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CHAPTER 2: A REVIEW ON REGULATION OF GENE EXPRESSION IN 
MYCOBACTERIA 
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2.1. INTRODUCTION 
Bacterial species exist in the environment that is very unstable and sometimes tends to be non-
optimal for these species to grow properly. This instability is a result of nutrient variations and 
surrounding toxicity 191, 192. Bacterial species have to adapt to these variations in order to survive. 
Their adaptation response is activated by regulated gene expression systems that enable them to 
modify their physiologies in order to respond rapidly and appropriately 192-194. The regulation 
systems contain transcriptional regulators that respond to specific cellular and environmental 
signals and then trigger transcription, translation and gene expression mechanisms, which allow 
the modification processes to occur 195, 196.  
2.2. REGULATED GENE EXPRESSION SYSTEMS  
The discovery of regulated gene expression systems was one of the greatest benefits to scientific 
research. These systems provide a way for manipulation and control of gene expression in 
prokaryotes as well as eukaryotes. This facilitates the genetic analysis of species and their 
biological processes, such as regulatory cascades and processes essential for growth 191, 193, 197, 198.  
The regulation systems can be utilised for facilitation of protein expression and purification, and 
identification and analysis of essential genes 199-201. The key factor in these systems is the 
inducible promoters used to drive the expression of the target genes. These are normally strong 
promoters, which can be switched on or/and off under defined conditions 197, 202. 
2.2.1. REGULATED EXPRESSION SYSTEMS USED IN MYCOBACTERIA 
The study of mycobacterial gene expression is complicated by the bacteria’s long generation 
time that leads to low protein production. Due to extremely short generation time, E. coli and 
Streptomyces lividans are often used to host and express mycobacterial proteins 203. However, 
given the high G-C content of mycobacterial DNA and post-translational modification of 
mycobacterial proteins, which tend to be rich in glycine, alanine, proline and arginine, translation 
and protein production are not always efficient in these strains 171, 199, 204, 205. To facilitate protein 
production and purification in this species regulated gene expression systems were developed 201, 
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206. These systems include, the Acetamidase (Ami) 204, Transfer (Tra) 207, Pristinamycin-inducible 
206 and Tetracycline-inducible (Tet) 197, 199 systems.  
2.2.1.1. The Acetamidase system 
The Acetamidase (Ami) system was discovered in M. smegmatis and was the first regulation 
system used in mycobacteria 204, 208. The system uses the regulatory elements to control the 
expression of a highly inducible acetamidase, an enzyme that enables M. smegmatis to grow with 
aliphatic amides as the sole carbon source 190, 204.  
The Ami system consists of five genes that are driven by four promoters situated between them 
(Figure 2.1) 190. The first is the amiE gene, which encodes acetamidase. AmiE is located 
downstream of and forms an operon with three other genes, amiA, amiS and amiD 204, 209. amiC 
and amiD encode positive regulators, AmiC and AmiD, respectively. The expression of amiC is 
driven by the Pc promoter and that of amiD is driven by the P2 promoter 
190. There is only one 
negative regulator, AmiA, which is encoded by amiA 208, 210. Finally, amiS encodes a part of a 
putative ABC transporter system 190.   
The regulation of the Ami system is as complex as its structure 208. In the absence of acetamide, 
AmiA binds to the P2 promoter, which prevents the RNA polymerase from binding thereby 
repressing the expression of amiD, amiS and amiE genes 204. However during the repressed state 
a basal level of transcription does occur from P2 leakage. AmiA may also bind to Pc promoter, 
which causes a reduction in the expression of AmiC. In the presence of acetamide, AmiC 
interacts directly with the acetamide and AmiA, which causes a conformational change that 
prevents AmiA from binding to the P2 promoter in so doing resulting in the expression of AmiD. 
As soon as it is expressed, AmiD activates the P3 promoter, which drives the expression of 
acetamidase 190, 210.  
It has been reported that under induced conditions the acetamidase shows a high induction ratio 
and can account for up to 10% of the total protein production 190, 209, 210. Furthermore, this enzyme 
has been used for overexpression of mycobacterial genes, antisense expression and for 
construction of conditional mutants of both fast and slow growing mycobacteria species 204, 209, 211, 
212. 
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Figure 2.1: The gene organization of the acetamidase operon (modified from Parish et al., 2001210). 
This operon consists of amiE encoding acetamidase; an upstream amiS encoding a component of a 
putative transporter; amiA encoding negative regulator; and amiC and amiD encoding the positive 
regulators. These genes are controlled by the promoters located between them. In the absence of 
acetamide, AmiA binds to the P2 promoter and prevents transcription of the amiD, amiS and amiE genes. 
In the presence of acetamide, AmiA dissociates from the P2 promoter, which causes the transcription of 
downstream genes.  
There are a few reasons that make the Ami system unsuitable for gene regulation studies, despite 
its highly inducible nature 190, 213. These include the large size of its operator that makes it 
difficult to manipulate, its complexity, and low stringency 208, 214. Additionally, the system is 
unsuitable for application to vaccine design seeing that under repressed conditions it allows basal 
expression of the target genes, which implies that genes under its control will always be 
expressed 190, 210.   
2.2.1.2. The Transfer system 
The Transfer (Tra) system was recently identified, it is essential for conjugative transfer of the 
11-kb pSN22 plasmid in Streptomyces nigrifaciens 215. The system consists of a highly active 
inducible Ptra promoter and a repressor gene, traR encoding a temperature-sensitive TraR 
molecule 
215
. It is temperature sensitive and thus controlled by temperature changes. At 
temperatures  28 C, the TraR
 
represses the initiation of transcription at the Ptra promoter. In 
contrast, at temperatures >28 C, the TraR
 
is inactivated, which leads to the induction of the Ptra 
promoter and transcription initiation 
215
.  
The Ptra promoter has been used for high level heterologous expression of a Streptomyces 
griseus protease in Streptomyces lividans. Also, the Tra system has been employed in 
mycobacterial gene regulation. However, it is not ideal for controlling gene expression in 
mycobacteria given that it is activated at 28 C, a sub-optimal temperature for mycobacteria 
growth. Furthermore, the Ptra promoter does not allow very high protein production levels since 
it displays intermediate strength, a 15-fold reduction in activity compared to other mycobacterial 
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promoters, such as hsp60 207. In the context of vaccine efficacy, the intermediate strength of the 
Ptra promoter would result in sub-optimal levels of antigen expression and consequently low 
immune responses. 
2.2.1.3. Pristinamycin inducible gene regulation 
The Pristinamycin (Pip) system was developed for gene expression control in eukaryotes and has 
been successfully used in plants and mammals 216, 217. Although it is not commonly used, the Pip 
system has been successfully adapted for use in both rapidly and slow growing strains of 
mycobacteria 206. 
The system consists of a very sensitive Streptomyces coelicolor Pip repressor that responds to 
the inducer and the Streptomyces pristinaespirlis Pptr promoter that drives the expression of the 
gene of interest 206, 218, 219. The clinically approved antibiotics that belong to the streptogramin 
group (pristinamycin, virginiamycin and Synercid) serve as inducers for the system. In the 
absence of the inducer, the Pip repressor binds to three operators overlapping the promoter 
region upstream of the Pptr promoter 217-219.  This binding results in the inhibition of transcription 
initiation, which is induced upon addition of the inducer as the repressor dissociates from the 
operators 206, 217.  
Forti et al., (2009)206 tested the system in the rapidly growing M. smegmatis and slow growing 
M. tuberculosis using the lazZ gene as a reporter, pristinamycin as an inducer and an integrative 
vector. They demonstrated that under induced conditions, the promoter activity increased up to 
50-fold in M. smegmatis and up to 400-fold in M. tuberculosis. Complete repression of the 
promoter was observed in the absence of the inducer unlike in eukaryotes, where a low baseline 
expression was observed 217. Furthermore, by constructing conditional mutants of M. 
tuberculosis in the fadD32 and pknB genes, Forti et al., (2009)206 demonstrated that the system 
was highly effective as the strains did not grow in the absence of pristinamycin I indicating that 
the genes are essential for growth. 
2.2.1.4. The Nitrile-inducible gene expression 
This system originates from Rhodococcus rhodochrous, a saprophytic organism. This organism 
is used in the industrial production of acrylamide and nicotinamide 205, 220. The regulatory circuit 
of the system consists of the nitA gene encoding the nitrilase enzyme that detoxifies a broad 
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range of these compounds 220.  The expression of this gene is controlled by NitR 221. Seeing that 
NitR is homologous to AraC, a protein that serves as both positive and negative regulator of the 
arabinose operon, it is hypothesized that NitR is similarly regulated 205. Nitrile and nitrile 
containing compounds act as inducers for this system, because in their presence, this organism 
produces large amounts of nitrilase enzyme encoded by the nitA gene. Under induced conditions, 
nitrilase can account for 35% of the total cellular protein 205. 
Since Rhodococcus rhodochrous is closely related to mycobacteria, Pandey et al., (2009)205 
hypothesized that the Nitrile system would be effective in mycobacteria. In their study they 
adapted the Nitrile system for use in mycobacteria to regulate the expression of genes in the fast 
growing M. smegmatis and the slow growing M. tuberculosis. Ehrt et al., (2005)222 reported that 
negatively-regulated promoters often produce basal levels of transcription. In order to avoid this 
low basal transcription Pandey et al., (2009)205 designed a positive feedback system, in which the 
regulatory protein is induced simultaneously with the gene of interest. Their expression cassette 
contained the nitR gene, encoding the NitR under the control of nitA promoter and the gene of 
interest was driven by the second nitA promoter that was located in a separate operon. Their 
system achieved 100-fold induction in both mycobacterial strains using GFP as a reporter. 
Additionally, they also demonstrated that the system was not affected by the phases of growth 
and during growth in macrophages.  
2.2.2. TETRACYCLINE INDUCIBLE (TET) SYSTEM 
As mentioned above, most regulated gene expression systems have features that make them 
unattractive for the development of an inducible/ regulated recombinant vaccine. In this study we 
are using the tetracycline inducible (Tet) system for controlling gene expression in M. smegmatis 
and M. bovis BCG. Tet systems are derived from the Tn10-encoded Tetracyclines (Tc)-
resistance determinant from E. coli 222-225. Tc-resistance is said to be the most sensitive form of 
antibiotic resistance and is widely distributed in gram-negative bacteria 198, 222, 225, 226. To date Tet 
systems are the most widely used systems for conditional gene expression in prokaryotes and 
have been modified for use in eukaryotes 225, 227. These systems use Tetracyclines as inducers 198, 
199, 228, 229.   
Tetracyclines are a few of the most frequently used broad-spectrum of antibiotics, which kill 
cells by diffusing via the cell membrane 230, 231. In prokaryotic cells, these antibiotics inhibit 
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protein synthesis by preventing the attachment of the aminoacyl-tRNA to the ribosomal acceptor 
(A) site, which prevents the action of the 30S ribosome 227, 230, 232. In eukaryotic cells, 
tetracyclines inactivate the mitochondrial 30S ribosomes. 
2.2.2.1. Tetracycline resistance 
Tc-resistance occurs via two mechanisms, the first is ribosomal protection and the second is an 
efflux-based mechanism. In the former, Tet (O) a class of the ribosomal protection proteins 
(RPPs) dislodges Tc from the A site of 70S ribosome to restore polypeptide elongation and thus 
confers Tc-resistance to the bacteria 227, 233. The efflux-based mechanism confers resistance by 
transporting the drug out of the cell 227. The efflux-based system is the most commonly used 
given that it has the most tightly regulated promoters and is used in this current study 198.  
2.2.2.2. Efflux-based tetracycline resistance 
The Tc-resistance determinant encoding active efflux is also referred to as the Tet system. The 
system consists of two genes, the resistance gene (tetA) and regulatory gene (tetR) oriented with 
divergent polarity 226, 234, 235. The two genes are separated by an 81 bp central regulatory region 
that consists of overlapping promoters, PA, PR1 and PR2 from which they are transcribed 
236. Tet 
operators, tetO1 and tetO2 are also found in the regulatory regions (Figure 2.2) 
225.  
tetA encodes a 36-kilodalton (kD) resistant protein, TetA, which is a membrane-spanning 
tetracycline/metal-proton (proton-[tc.Me]
+
) antiporter 237. TetA is responsible for the export of Tc 
from the cell 231, 237. tetR encodes a 46-kD regulatory protein, TetR 192. TetR is a dimeric DNA-
binding repressor with two monomers, each consisting of 10 -helices 238, 239. TetR contains N-
terminal DNA-binding domains each has three helices (α1 to α3) that contain the -helix-turn- -
helix (HTH)-motif, which mediates DNA binding to the operators 226, 240. TetR also contains a 
tetracycline binding region, which is located inside the C-terminal domain 240.  
2.2.2.3. Regulation of the Tet system 
TetR has high affinity for the operators, and this binding to the operators tightly regulates the 
expression of both TetA and TetR 234, 237, 240-242. In the absence of Tc, TetR binds to the two 
operators with its DNA-binding domain, this binding prevents access of RNA polymerase to the 
promoter and thus inhibits transcription initiation resulting in the shutting down of the TetA and 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
36 
 
TetR expression (Figure 2.2, panel A) 222, 225, 231. The TetR-tetO interaction is said to be very 
strong, about Ka~10
11
M
-1
, this is depicted by the complete repression in the absence of the drug 
243. The presence of Tc reduces TetR-tetO interaction by nine orders of magnitude 243, 244.  
Tc crosses the cytoplasmic membrane by passive diffusion in a neutral form 240, 244, 245.  In the 
cytoplasm Tc forms complexes with the bivalent metal ions such as magnesium (Mg
2+
), forming 
an active [tc.Mg]
+ 
complex (Figure 2.2, panel B). The [tc.Mg]
+ 
complex binds to the TetR-
operator complex with high affinity of about Ka~10
9
M
-1
, which is much stronger than that for the 
ribosome of Ka~10
6
M
-1
 222, 234, 246. Binding of two molecules of [tc.Mg]
+ 
to a TetR dimer 
diminishes repressor affinity for tetO by causing a conformational change within the DNA-
binding domain of the TetR, which then dissociates from the operators 222, 234, 247, 248. This TetR 
dissociation from the operators results in the initiation of TetA antiporter expression 222. The 
TetA antiporter exports Tc out of the system by exporting the [tc.Mg]
+ 
complexes. An export of 
each [tc.Mg]
+ 
complex out of the cell imports a proton simultaneously, which results in the 
reduction of Tc concentration within the cell (Figure 2.2, panel B). After all the Tc has been 
exported out of the cell, the remaining TetR binds to the tetO, which then shuts the expression of 
both Tet proteins 225.  
TetR binds to the operator sites with different affinities. The affinity of TetR for tetO2 is 
estimated to be 3 - 5 times higher than that for tetO1 
226. Occupation of tetO1 ensures a complete 
repression of both TetA and TetR 226. In contrast, occupation of tetO2 ensures repression of the 
TetA expression, while allowing the PR driven expression of TetR. This permits low level read-
through of TetR, which provides a tightly regulated security circuit that prevents accidental 
expression of TetA (Figure 2.2) 225, 241, 244. This regulation is important as it prevents long-term 
production of the TetA protein, which is said to be detrimental to the cell in the absence of Tc as 
it tends to be toxic at a high concentration 223, 249. Essentially the expression of the TetA export 
protein is fine-tuned, in order to mediate Tc-resistance and at the same time avoid toxicity 
problems caused by its background expression 225
,250. 
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Figure 2.2: The genetic organization of the Tc-resistance determinant (modified from Hillen and Berens, 1994226).  This system consists of divergently 
oriented tetA and tetR genes separated by a region of three overlapping promoters and two operator sequences. PR1 & PR2 promoters drive tetR expression and tetA 
expression is driven by PA promoter. A. In the absence of Tc, TetR binds to the operators in the regulatory region, and this result in the repression of tetA. B. In 
the presence of Tc, tetA is expressed as the Tc binds to the TetR causing it to dissociate from operators. 
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2.2.2.4. Gene regulation by the Tet system  
The Tet system is the most widely used tool for gene function studies. It has been successfully 
employed in both in vivo and in vitro studies 202, 240. The Tet system has a few advantages that 
make it the most popular tool for gene regulation, (i) The tetracylcines (the inducers of the 
system) are able to penetrate most cell walls and tissues, (ii) the systems is highly sensitive, and 
thus low, nontoxic levels of the inducers are sufficient for regulation, (iii) the system allows the 
regulation and control of gene expression in liquid culture and during animal infections 198, 199, 202, 
226, 251. Furthermore, the system has been adapted for gene regulation in gram-positive bacteria, 
acid-fast bacteria as well as eukaryotic systems such as human mammalian cells, transgenic 
animals and plants 199, 250-253.  
2.2.2.5. Gene regulation by the Tet system in mycobacteria  
Carroll et al., (2005)199 used the Tet system as a tool to determine the function of a trpD gene in 
M. tuberculosis. Firstly they showed that the system worked efficiently in M. smegmatis and M. 
tuberculosis using the GFP as a reporter and demonstrated a controllable on/off switch for 
fluorescence upon addition and removal of the inducer, anhydrotetracycline (ATc), a tetracycline 
derivative. They further generated a conditional auxotroph mutant of M. tuberculosis, where they 
used a Tc-inducible promoter to direct expression of the tryptophan biosynthetic enzyme, TrpD. 
Their results showed tight regulation of the trpD as the strain displayed auxotrophy by 
completely switching off the trpD only in the absence of tetracycline. 
Ehrt et al., (2005)222 demonstrated ATc-dependency of the gene expression by the Tet system in 
M. smegmatis and M. tuberculosis in liquid culture. They further constructed a conditional gene 
knockout for a cell division essential gene, ftsZ in M. smegmatis. ATc concentrations 10- and 20- 
fold below the minimal inhibitory concentration for M. smegmatis and M. tuberculosis, 
respectively gave maximum gene expression. Additionally, they demonstrated gene regulation in 
M. tuberculosis within the macrophage phagosome. 
Boldrin et al., (2010)208 developed a repressible mycobacterial promoter system based on two 
different chromosomally encoded TetR and Pip repressors. They tested their system in M. 
smegmatis and M. tuberculosis, where they created conditional mutants of ftsZ and fadD32, 
respectively. The gene of interest was placed under the control of Pptr, which depends on the 
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pristinamycin I repressor. The Pip structural gene on the other hand was placed under the control 
of a TetR-dependent promoter. ATc was used as an inducer, such that its presence induced 
production of the Pip repressor leading to the repression of the Pptr promoter. Their results 
showed that both strains stopped growing in the presence of the inducer, which confirmed the 
essentiality of the knocked-out genes for growth. This demonstrated tight regulation by the 
system. All in all their system showed high stringency and versatility. 
2.2.2.6. Limitations of the Tet system 
Despite the efficiency of the system, there are some practical drawbacks that have been stated. 
Tetracyclines are nontoxic to cells at minimal levels, however in Tet systems the antibiotics 
serve as transcriptional inducers and thus have to be present continually. Vaccinees given 
vaccines harbouring the Tet systems would have to be given the tetracyclines to activate the 
expression of antigens, which is undesirable in humans and transgenic animals and for gene 
therapy. The continuous presence of the inducers makes the experiments sub-optimal 225, 252. 
Furthermore, according to Berens and Hillen, (2004)250 the constant presence of the tetracyclines 
leads to accumulation of resistance, depot-building in the organism and if present in gestation 
may result in reduction in transgene expression levels. An additional disadvantage is that in 
conditional knock-down systems, tetracyclines have to be removed from the bacterial culture in 
order to initiate gene silencing.  The removal process is very slow and difficult as it requires 
procedures that may affect biological processes under investigation 197, 198, 252.   
To overcome the above problems the reverse Tet mutants that require tetracyclines as co-
repressors were developed 197, 198. A reverse Tet (revTet) system allows the expression of the 
target gene to occur in the absence of tetracyclines and permits gene silencing in its presence 198, 
250.  
2.2.3. REVERSE TETRACYCLINE (REVTETR) SYSTEM 
Scholz et al., (2003)241 demonstrated that mutations can be introduced in the tetR gene to change 
the inducer specificity of the TetR protein. This was done by random mutagenesis where three 
amino acids, E15A, L17G and L25V within the α-1 helix of the DNA-binding domain were 
mutated. These changes reverse the allosteric response of the binding of TetR to Tc, whereas 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
40 
 
binding of Tc to the wtTetR causes the repressor to dissociate from the operators, binding of Tc 
to mutated TetR (revTetR) causes the repressor to bind to the operators 198, 238.  
In 2004 Scholz and colleagues254 introduced different mutations in the tetR gene and generated 
more than 100 revTetR mutants. They tested the allosteric response of the revTetR mutants to 
the inducer. While most contained 2 - 5 amino acid mutations, some contained only 1 mutation 
and still showed a reverse allostery. Several reverse Tet mutants were characterised and analyzed 
by Berens and Hillen, (2004)250 in E. coli and Bacillus subtilis.  One of the mutants, TetRr1.7 
was selected, it contained the E15A, L17G and L25V mutations. The TetRr1.7 mutant showed 
the most efficient regulation in E. coli, switching off target gene expression completely upon the 
addition of ATc 254.   
The newly developed revTetR mutants were tested in gram positive bacteria by Kamionka et al., 
(2005)255, where they wanted to expand the regulatory window of the Tet promoter in B. subtilis. 
Both wtTetR and the revTetR were used. In the presence of 0.4 µM ATc, the highest induction 
obtained with the wild type system was 300-fold, and a 500-fold gene knockout was observed 
with the revTetR system. 
2.2.3.1. Regulation of the RevTetR system 
Once it is in the system Tc binds to the revTetR protein, which results in the formation of a Tc-
revTetR complex. A conformational change occurs to the DNA binding domain of the revTetR 
protein, which enables the Tc-r vTetR complex to bind to the operator region. The occupation of 
the operators leads to the shutting down of TetA expression. Upon removal of Tc, revTetR 
dissociates from the operators, thus allowing TetA expression 222, 238, 255.   
2.2.3.2. Gene regulation by the RevTetR system in mycobacteria 
The revTet system has been used repeatedly in mycobacteria to generate Tc-dependent 
conditional gene knockouts to study gene function.  Gandotra et al., (2007)200 used the TetRr1.7 
mutant to generate a conditional knock-down mutant of the M. tuberculosis growth essential 
gene, prcBA. The gene was silenced in vitro by adding ATc. They were able to determine the 
function of the prcBA encoded core proteasome, as the silencing of the gene uncovered the 
requirement of the proteasome for virulence at a chronic phase of infection in mice. In their 
study Guo et al., (2007)197 used the TetRr1.7 to construct a conditional mycobacterial mutant of 
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an M. smegmatis growth essential gene, secA. The SecA1 protein was efficiently repressed in the 
presence of as low as 10 ng/ml of ATc, which demonstrated the sensitivity of the system. 
Additionally, a 90-fold decrease of the cell envelope associated porin, MspA was observed after 
the silencing of the secA gene. MspA was identified as the substrate of a secretion system. Based 
on their results, it is clear that gene silencing can be used for identification of substrates involved 
in biological processes. 
It was previously reported that repression by the Tet system requires high levels of the revTetR 
protein, which occurs if the TetRr1.7 gene is expressed in a multicopy plasmid and transcribed 
by a strong mycobacterial promoter 198. In order to improve repression by the revTetR systems, 
Klotzsche et al., (2009)198 codon optimised the revTetRs by adapting the codon usage of the tetR 
gene to that of M. tuberculosis. This resulted in the formation of new revTetR mutants, which 
did not require a multicopy plasmid and a strong promoter for efficient expression.  They tested 
the codon optimized mutants in M. smegmatis and M. bovis BCG. Upon the addition of ATc, the 
mutants mediated up to 50-fold repression in both strains. Additionally, complete silencing of the 
M. smegmatis secA gene by chromosomally integrated revTetR mutants was achieved. 
2.2.4. THE USE OF THE TET SYSTEMS IN EUKARYOTES 
2.2.4.1. The rTA (Tet-off) system 
Due to its success in gene function and biological studies in prokaryotes, the Tet system has been 
modified for application in eukaryotes. These systems were introduced to eukaryotes to provide 
a way to regulate gene expression directly by changing experimental conditions 256, 257.  Since 
regulation systems are operated by inducible promoters, they provide a good tool for in vivo gene 
function studies in transgenic animals 256, 258. In these studies, the system is useful for conditional 
inactivation and over-expression of the genes in a tissue-specific and time-dependent manner 258.  
Gossen and Bujard, (1992)259 first described a Tet system that was adapted for use in mammalian 
cells. They converted the TetR into a tetracycline controlled transcriptional activator (tTA) by 
fusing the herpes simplex virus (HSV) - VP16 activation domain and the TetR-tet operator 
mutant from E. coli 252, 253, 260. The tTA stimulates transcription from a minimal inducible human 
cytomegalovirus (PhCMV-1) promoter combined with seven operators (tetO) 
259. Gene expression 
from this promoter is tightly controlled by the presence or absence of tetracycline and its 
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derivatives 259, 261. The original system was based on the presence of two plasmids, a constitutive 
plasmid expressing the tTA and a plasmid containing the target gene under the control of an 
inducible promoter containing the operators upstream of the TATA box 259, 262. The TetR moiety 
provides an inducer-dependent conditional DNA-binding domain that mediates the docking of 
the VP10 to a synthetic promoter 262. The binding of the tTA to the promoter and subsequent 
transcription of target gene is inhibited by the presence of Tc 253, 259.  
Gossen and Bujard, (1992)259 were the first group to test the tTA system. They use the tTA to 
regulate the luciferase gene in mammalian HeLa cell lines. The results showed that the luciferase 
acivity can be regulated up to 10
5
-fold by adding and removing Tc. In their study, a Tc 
derivative, doxycycline (Dox) was used as an inducer.  
Paulus et al., (1996)260 aimed to deliver as well as control the expression of heterologous genes 
in mammalian cells. They developed a retroviral vector that enclosed both response and 
regulatory units of the Tet system. They tested the vector in different mammalian cell types, by 
regulating the luciferase activity using Tc to control the system. Tc-dependent regulation was 
observed in all cell types transduced with the vector. The highest induction was observed in 
infected NIH 3T3 cells, where the levels in the absence of Tc were about 340-fold higher than 
the levels in the presence of the drug. 
2.2.4.2. The rtTA (Tet-on) system 
Four amino acid changes were made in the TetR moiety of the tTA to form the reverse tTA 
(rtTA) system, which changed the tetO binding 252. In the rtTA system the transactivator requires 
the presence of tetracyclines to bind to tetO in order to activate the expression of the target gene.  
The rtTA has been shown to efficiently regulate the expression of exogenous genes in many 
eukaryotic systems, such as, transgenic mice and tissue culture etc. 261, 262. Although both rtTA 
and tTA systems have shown similar extents of transgenic expression, the induction kinetics of 
the tTA are slower given that the tetracyclines have to be removed completely to achieve the 
highest induction, which makes the rtTA a faster protein expresser 258.  
An improved Tc-dependent reverse transativator, rtTA2
S
-S2 was recently developed for 
transgenic animal studies 258, 261. The rtTA2
S
-S2 has the same induction kinetics as the rtTA, but 
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has a 10-fold enhanced regulation, higher sensitivity to tetracyclines and no residual binding 
affinity to the operators in the absence of tetracyclines and thus lower background activity 258, 263.  
In 2003 Gallagher and colleagues258 showed that the rtTA2
S
-S2 system can be tissue-specific. 
They used the system to control protein synthesis in mice kidneys. They used the rTA
LAP
-1 
mouse line, which were transgenic mice that produce the rtTA under the control of the liver 
activator protein (LAP) promoter. They demonstrated the tightly controlled and reversible 
expression in the kidneys and livers by using the reporter lines with luciferase and the LacZ 
genes by adding and removing doxycycline (Dox). Dox was added in the drinking water. In the 
kidneys the transgene expression was observed in cortical proximal tubules. No luciferase and -
galactosidase activity were observed in mice that were not given Dox or after withdrawal of 
Dox. By exposing the rtTA producing mothers to Dox before mating, they showed that sufficient 
amounts of Dox cross the placental barrier during development of the foetus as the kidneys and 
livers of the newborns showed transgene activity.  
2.2.5. SENSITIVITY OF THE TET SYSTEMS TO TETRACYCLINES 
Due to their non-toxicity Tetracyclines have been clinically approved for administration to 
animals as well as humans 208, 216. In the current study ATc is used as a co-repressor. This Tc 
derivative is the most commonly used drug 251. ATc has numerous properties that make it a 
superior compound (Figure 2.3): (i) it has a high functional stability in cell culture, (ii) it a more 
active and efficient inducer than all the Tc derivatives given that the binding constant of the TetR 
for [ATc
-
Mg
+
] is Ka~10
11
M
-1
, which is higher than the one for [Tc
-
Mg
+
] of Ka~10
9
M
-1
, (iii) ATc 
has higher minimum inhibitory concentration (MIC) than Tc and (iv) ATc is the least toxic 
derivative of Tc 208, 225, 243, 251. Therefore ATc levels required to repress the expression of the 
transcription of the target gene are 10-fold below the levels required for protein inhibition 249, 251. 
Moreover, using HeLa cells Gossen and Bujard, (1993)251 showed that concentration at which 
the prolonged ATc presence begins to affect the growth rate of the cells in culture is more than 
1000-fold above the effective concentration.  
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Figure 2.3: Structures of tetracyclines for gene regulation in prokaryotes and eukaryotes
227
. A. 
Tetracycline. B. Doxycycline, a derivative that is commonly used in transgenic animal studies. C. 
Anhydrotetracycline, a derivative that is commonly used in prokaryotic studies. 
 
 
2.2.6. AIMS OF THE THESIS 
Our research group is working on developing M. bovis BCG as a vaccine vector, specifically to 
express HIV-1 antigens. The successful development of a recombinant M. bovis BCG as an HIV 
vaccine (rBCG-HIV) is going to depend largely on overcoming instability associated with the 
expression of viral antigens. The aim of this study is to utilise the tetracycline dependent 
gene regulation system to down-regulate recombinant antigen expression in BCG during 
the expansion of seed stocks and up-regulate expression prior to or post vaccination. 
This project will investigate whether the reverse tetracycline dependent regulatory system could 
be functionally developed for use in BCG using a multicopy episomal plasmid. The design is 
based on constitutively expressing the DNA binding regulatory protein revTetR, such that in the 
presence of the analogue anhydrotetracycline (ATc) in the media, the revTetR-ATc complex 
would bind tet operator sites placed within the M. smegmatis derived Psmyc promoter and result in 
shutdown of antigen expression during in vitro growth. In this way it could be tested if rBCG 
seed stocks can be expa ded in the presence of ATc and if the vaccine remains stable. When 
tetracycline is removed the rBCG should express antigen at a higher level. The system will first 
be optimized using GFP as a model antigen, and then tested using HIV antigens. The most stable 
HIV antigens will be tested for immunogenicity in mice. The application of this system in 
rBCG vaccine design is completely novel, and promises to significantly alleviate the 
problems associated with instability. 
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3.1.  INTRODUCTION 
Ideally the rBCG vaccine should express the heterologous antigen at low levels during in vitro 
culturing in order to avoid over-expression of the antigen within the bacteria that would cause 
vector instability. Subsequently, the expression should be induced after vaccine administration to 
ensure that a sufficient amount of the antigen is produced in order to induce a strong protective 
immune response.  
 
We aim to investigate a candidate rBCG HIV-1 subtype C vaccine that utilises the reverse (rev) 
TetR inducible system, derived from an E.coli Tn10-encoded Tetracycline (Tc)-resistance 
determinant 222 to regulate the expression of the recombinant HIV antigen. Our rBCG vaccine 
will down-regulate the HIV antigen expression during in vitro preparation of seed stocks and up-
regulate it prior to and/or post vaccination. 
 
As reviewed in Chapter 2, Scholz et al., (2004)254 developed 100 reverse TetR repressor mutants 
and determined their efficiency by analysing their ATc-dependent expression using -
galactosidase ( -gal) as a reporter gene. The efficiency of the mutants was measured as an 
induction factor, which was given as the ratio of -gal activity in the presence and absence of 
ATc. The most efficient mutants were the TetRr1.7 and TetRr1.12, which had induction factors 
of 102 and 90, respectively. The TetRr1.7 repressor is encoded by the tetRr1.7 gene, which has 
the following amino acid mutations in the protein sequence, E to A at position 15; L to G at 
position 17; L to V at position 25 (Appendix D1) and the TetRr1.12 repressor is encoded by the 
tetRr1.12 gene with amino acid mutations, V to G at position 20; G to R at position 21; I to N at 
position 22 in the protein sequence (Appendix D2). 
 
In our laboratory the tetRr1.7 and tetRr1.12 mutants were codon optimized for regulation 
purposes in mycobacteria, and placed under the control of the strong M. tuberculosis hsp60 
promoter to generate the TetRr1.7 and TetRr1.12 expression cassettes, respectively (Dr Helen 
Stutz). The TetRr1.7 repressor has been utilised for gene silencing purposes in mycobacteria, 
where it has demonstrated excellent repression proficiency in the presence of the co-repressor, 
ATc 197, 198, 200. In 2009, Mayat264 constructed different shuttle plasmid designs of the episomal 
TetRr1.7 dependant regulatory system by inserting the TetRr1.7 cassette into the pNM3 and 
pNM4 vector backbones (Appendix D3.1) in different orientations as illustrated in Figure 3.1. 
Four designs of the episomal TetRr1.7 plasmids resulted (Appendix D3.2), these constitutively 
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express the TetRr1.7 protein from the hsp60 promoter. The mechanism in which the TetRr1.7 
dependent regulatory system regulates the expression of recombinant antigens is depicted in 
Figure 3.2. She explored the potential of the TetRr1.7 plasmid designs to control the expression 
of a reporter protein, a jellyfish Aequorea Victoria green fluorescent protein (GFP) within the 
model organism M. smegmatis, i.e. the repression of GFP expression in the presence of ATc and 
induction in its absence. In the pilot experiment a concentration of 100 ng/ml of ATc was used. 
The results confirmed the concept of the study by showing that the reporter GFP could be 
repressed by ATc by approximately 3-fold. The maximum repression of the systems occurred 8 
hours after the addition of ATc.  
 
 
 
Figure 3.1: Strategy for the insertion of the TetRr1.7 cassette into selected pNM3 and pNM4 vector 
backbones (Modified from Mayat, (2009)263). The TetRr1.7 cassette, comprising the hsp60 promoter, the 
tetRr1.7 regulatory gene and the hsp60 transcriptional terminator (tt) was cloned into the XbaI site of the 
vectors in either orientation.  
 
Using different concentrations of ATc and monitoring the induction 12 hours after its removal, 
Mayat, (2009)264 demonstrated that the induction of GFP expression occurred in a concentration 
dependent manner. The cultures that contained lower concentrations of ATc achieved the highest 
induction, whereas cultures that contained higher concentrations of ATc did not produce as 
higher levels of GFP. rM. smegmatis[pNM3] and rM. smegmatis[pNM4] showed no evidence of 
GFP repression in the presence of ATc or induction after its removal, which was expected since 
these plasmids do not contain the TetRr1.7 cassette to allow regulation.  
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Figure 3.2: Diagram illustrating the design of the TetR dependant regulatory system (modified from poster presented by Dr Helen Stutz). In the presence of 
ATc, TetR-ATc forms and binds to the tetO operator sequences of the Psmyc promoter, which blocks the promoter activity, and thus the expression of the gene of 
interest is repressed. In the absence of ATc, the TetR regulator protein cannot bind to the tetO operator sequences, thus the expression of the gene of interest is 
induced. 
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3.1.1. STUDY OBJECTIVES 
There is no published data on the TetRr1.12 mutant, thus it was selected for regulation of 
recombinant antigen expression in this study. The objective was to develop, evaluate and 
optimize the regulatory system using the TetRr1.12 repressor in the model organism M. 
smegmatis. Next would be to introduce and evaluate the system in the pantothenate auxotrophic 
strain M. bovis BCG mc2 6000 (M. bovis BCG ΔpanCD). In 2009, Mayat264 performed a 12 hour 
assay to monitor the induction of GFP expression after ATc removal and did not achieve 
complete induction, therefore in this study we aim to increase the assay period and monitor both 
GFP expression and genetic stability. The experimental plan is depicted graphically in Figure 
3.3. 
 
Figure 3.3: A schematic illustration of the project plan for this Chapter.  
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3.2. MATERIALS AND METHODS 
3.2.1. GENERATION OF THE E.coli/MYCOBACTERIAL SHUTTLE PLASMIDS 
3.2.1.1. Generation of the parental mycobacterial shuttle vectors 
The E. coli-mycobacterial shuttle plasmid, pRC100 (Appendix E1) constructed by Dr Ros 
Chapman was used to construct the parental mycobacterial shuttle vectors, pNM3 and pNM4. 
The pRC100 vector contains a kanamycin resistance (Kan
R
) gene, a mycobacterial origin of 
replication (oriM) derived from the pAL5000 265, an E. coli origin of replication (oriE) and the 
hsp60 promoter that drives the expression of GFP placed downstream.  
 
The hsp60 promoter in the pRC100 plasmid was replaced with a strong M. smegmatis Psmyc 
promoter (290 bp). The Psmyc promoter was derived from that reported by Ehrt et al., (2005)
222 
and engineered to contain tetO elements that facilitate the regulation of the expression of the 
gene of interest. Different combinations of operator sequences, tetO1 and/or tetO2 were designed 
flanking the -10 region of the Psmyc promoter as shown in the Appendix D3.1, which resulted in 
two parental mycobacterial shuttle vectors, pNM3 and pNM4 (Appendix E4 & 5).  
3.2.1.2. Cloning of the TetRr1.12 expression cassette into the parental vectors 
The mycobacterial shuttle vectors, pNM3 and pNM4 were isolated from E. coli using the large-
scale plasmid isolation procedure (Appendix B1.2), and linearized with the restriction enzyme 
XbaI as described in Appendix B2. The TetRr1.12 expression cassette was synthesized and 
supplied by GeneArt  [Germany]. The cassette was excised from the GeneArt  [Germany] 
pGA1 vector backbone (Appendix E3) by a double digest with the flanking restriction enzymes 
XbaI + SpeI [Roche], which generated compatible ends for cloning into the parental plasmids, 
pNM3 and pNM4 digested with XbaI (as shown in Figure 3.4). All digested fragments were gel 
purified using QIAquick Gel Extraction Kit [Qiagen] according to manufacturer’s instructions 
and quantified on 1% agarose slide gel by comparison to known concentrations of DNA. The 
cassette was cloned into pNM3 and pNM4 using the ligation procedure described in (Appendix 
B4). It was inserted immediately upstream of the Psmyc promoter in two different orientations 
with respect to the gfp gene, and this resulted in the formation of four different episomal 
TetRr1.12 shuttle vector designs (Figure 3.4).  
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Figure 3.4: An illustration of the cloning strategy used for the generation of the TetRr1.12 shuttle 
plasmids. The TetRr1.12 cassette (hsp60 promoter + tetRr1.12) was cleaved off from pGA1 and cloned 
into the pNM3 (Psmyc promoter containing 2x tetO2) and pNM4 (Psmyc promoter containing 2x tetO1) 
vectors to generate four episomal TetRr1.12 shuttle vectors.  
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3.2.2. CONFIRMATION AND SCREENING OF THE POSITIVE RECOMBINANTS  
3.2.2.1. Restriction enzyme mapping of plasmid DNA prepared using a small-scale isolation 
procedure 
Each ligation mix (5 µl) was transformed into E. coli competent cells (Appendix A3). Twenty 
colonies of the transformants were picked off the plates and inoculated into 800 µl of 2YT media 
containing the appropriate antibiotic in a 2 ml eppendorf tube. The cultures were incubated 
overnight standing at 37 C. Reference plates were prepared simultaneously by pricking and 
stabbing each selected transformant onto a numbered grid on a 2YT- kanamycin (Kan) agar 
plate, thus ensuring the maintenance of recombinant clones for further reference. Cultures were 
then subjected to a small-scale plasmid isolation procedure as described in Appendix B1.1. The 
plasmid DNA was digested with a combination of restriction enzymes (Table 3.1) as described in 
Appendix B2 and products were analysed on a 1% agarose gel (Appendix B3). 
 
 
Table 3.1: Plasmid DNA mapping restriction enzymes used to confirm the recombinant plasmids 
RESTRICTION 
ENZYMES 
FUNCTION  
 
EcoRV Confirms the presence of the TetRr1.12 cassette as the site is unique to 
the cassette 
MluI + NotI Confirms the size change from the parental plasmids to the TetRr1.12 
plasmids that contain the TetRr1.12 cassette 
XbaI + NdeI Confirms the orientation of the TetRr1.12 cassette 
3.2.2.2. Restriction enzyme mapping of plasmid DNA prepared using a large-scale isolation 
procedure 
Subsequent to plasmid DNA mapping, selected recombinants were picked off the reference 
plates, each was cultured in 100 ml 2YT broth with selection in a 1 L conical flask, placed on an 
orbital shaker at 37 C and left overnight. From each overnight culture, 5 ml was used to prepare 
15% glycerol stocks that were then stored at -80 C. Plasmid DNA was extracted from the 
remainder of the cultures using a large-scale plasmid isolation procedure (Appendix B1.2). 
Finally, 500 ng - 1 g of the plasmid DNA was subjected to restriction enzyme mapping using 
the enzymes listed in Table 3.1. The products were analysed on a 1% agarose gel. 
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3.2.3. INTRODUCTION OF THE TETRR1.12 PLASMIDS INTO MYCOBACTERIA 
3.2.3.1. Preparation of mycobacterial cell starter cultures 
Two mycobacterial strains were used in this study. M. smegmatis mc
2
155 (BioVac institute, 
Cape Town, S.A) was used as a model strain. To make vaccines we used a pantothenate 
auxotroph derived from M. bovis BCG Pasteur, M. bovis BCG mc26000 (M. bovis BCG 
ΔpanCD) obtained from Dr. William Jacobs Jr. (Albert Einstein College of Medicine, New 
York). 
 
A 15% glycerol stock (0.5 ml) of mycobacterial cells stored at -80 C was thawed on ice. The 
aliquot was used to inoculate 5 ml of sterile MB-7H9 medium (Appendix C1) in a 50 ml conical 
sterile tube [Sterilin]. For M. smegmatis cells MB-7H9 media (Appendix C1) was used and for 
BCG ΔpanCD cells MB-7H9 media containing 24 µg/ml vitamin B5 [Sigma-Aldrich] + 25 
µg/ml hygromycin [Roche diagnostics] was used. The starter cultures were incubated standing 
with loosened lids at 37°C for approximately 2 days (M. smegmatis) and 5 days (BCG ΔpanCD).  
 
To quantify the mycobacterial cultures, a spectrophotometer [Thermo spectronic] was used. The 
cultures were diluted to provide an OD reading between 0.1 and 1.0 in MB-7H9 media in 2.5 ml 
semi-micro disposable OD cuvettes [Sterilin] and the absorbance readings were taken at a 
wavelength of 600 nm. 
3.2.3.2. Preparation of electro-competent mycobacteria cells  
The method described by Parish and Stoker (2001)213 was used to prepare competent 
mycobacterial cells. Starter cultures were used to inoculate 100 ml of MB-7H9 media 
(supplemented with vitamin B5 and hygromycin for BCG ΔpanCD) at a 1:100 dilution. When 
the cultures had reached an OD600 of 0.8 units, they were incubated on ice for 1.5 hrs with slow 
rotation and harvested by centrifugation at 4
o
C, at 5000 rpm for 10 min. Cells were kept cold on 
ice during all subsequent procedures to enhance competency. The pellets were then washed three 
times in pre-chilled 10% glycerol prepared with High performance liquid chromatography 
(HPLC) grade H20 [Merck]. Finally the cells were resuspended in 5 ml pre-chilled 10% glycerol 
representing a 20-fold concentration. The competent cells were subsequently divided into 200 l 
aliquots and either transformed with plasmids immediately or stored at -80
o
C. 
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3.2.3.3. Transformation of plasmid DNA into mycobacterial cells  
The procedure was performed under sterile conditions. Mycobacterial competent cells were 
thawed on ice and washed by centrifugation at room temperature, at 4000 rpm for 1 min. The 
supernatant was discarded, the cells were gently resuspended in 500 l ice-cold, 10% glycerol 
and then kept on ice. An aliquot of 40 l of the competent cells was mixed with plasmid DNA 
(500 ng–1 g) of the confirmed constructs and made up to a final volume of 50 l in 10% 
glycerol and transferred to a pre-chilled 0.1 mm gap cuvette [Biorad]. The competent cell 
mixture was then electroporated using the Gene Pulser  [BioRad] set at Voltage: 1.8 kV, 
Capacitance: 25 F and Resistance: 1000 . Time constants were noted. A laboratory stock of 
pCONEPI plasmid DNA (Appendix E2) was used as a positive control and 5 l of HPLC grade 
H20 served as a negative control for transformation. 
 
A volume of 1 ml MB-7H9 media (expression medium) (containing vitamin B5 and hygromycin 
B for BCG ΔpanCD) was added immediately after electroporation. Transformation mixes were 
transferred into 20 ml tubes [Sterilin] and left standing with loosened lids at 37 C for 5 hrs for 
M. smegmatis and overnight for BCG ΔpanCD. Cultures were plated on the appropriate selective 
MB-7H10-OADC agar containing appropriate supplements for BCG ΔpanCD. Plates were 
sealed in plastic bags to prevent dehydration and incubated at 37 C for 3 days for rM. smegmatis 
and 3 - 5 weeks for rBCG ΔpanCD.  
3.2.3.4. Preparation of stocks of recombinant mycobacteria  
a. Glycerol stocks  
Mycobacterial colonies were picked off the plates and dispersed in 5 ml of MB-7H9 media 
containing appropriate supplements by a gentle pipeting action to make starter cultures. The 
rBCG ΔpanCD colonies were firstly broken apart manually using sterile toothpicks before 
dispersing into 5 ml media. After significant growth was observed, the starters were swirled, the 
larger clumps allowed to settle briefly and the top homogenous layer used to inoculate 10 ml of 
MB-7H9 media in order to eliminate the presence of bacterial clumps in the cultures. When the 
10 ml cultures reached OD600 of approximately 0.8 units, they were used to inoculate 100 ml of 
the same media in 1 L Schott bottles. The cultures were incubated standing at 37 C for 1 day for 
the rM. smegmatis and 3 - 4 days for rBCG ΔpanCD, then placed on slowly turning rollers. 
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These cultures were grown to an OD600 of approximately 0.5 units and used to prepared 15% 
glycerol stocks, which were stored at -80 C.  
b. Vaccine stocks 
The starter cultures were prepared as described in Section 3.2.3.1, in addition 10 µg/ml Kan was 
included for plasmid selection. Once the starter cultures had reached OD600 of 0.8 units, they 
were used to inoculate 100 ml of the same media in 1 L Schott bottles. The cultures were 
incubated standing at 37 C for 1 day for the rM. smegmatis and 3 - 4 days for rBCG ΔpanCD, 
then placed on slowly turning rollers until they reached an OD600 of 0.5 units. A volume of 10 ml 
was taken from each culture and used to prepare 15% glycerol stocks and stored at -80 C. The 
remaining cultures were harvested by centrifugation at 4000 rpm for 10 min at 4
o
C. The pellets 
were resuspended in resuspension buffer (Appendix C3) to an OD600 of 10 to make vaccine 
stocks.  The vaccine stocks were subsequently divided into 200 l aliquots in 2 ml cryovials 
[Greiner Bio-one], which were frozen at -80
o
C.   
3.2.3.5. Evaluation of genetic integrity of the plasmid DNA from the recombinant 
mycobacteria vaccine stocks  
The BCG ΔpanCD or M. smegmatis vaccine stocks (200 l) were thawed and then precipitated 
at 14 000 rpm for 2 min at room temperature using the 5417C bench-top centrifuge [Eppendorf]. 
The pellets were resuspended in 400 µl GTE-lysozyme buffer (Appendix C3) and incubated with 
slight shaking at 37 C for 3 hrs. Plasmid DNA was then isolated from the cell suspensions using 
the Qiaprep  Spin miniprep kit [Qiagen] according to manufacturer’s instructions. The isolated 
plasmid DNA was transformed into E. coli as described in Appendix A3. Twenty colonies of the 
transformants were picked off the plates, the plasmid DNA was isolated using small-scale 
isolation procedure as described in section 3.2.2.1 and subjected to restriction enzyme mapping 
as described in Section 3.2.2.1. 
3.2.4. A PILOT ASSESSMENT OF THE TETRR1.12 SYSTEMS IN M. smegmatis USING 
ANHYDROTETRACYCLINE: PROOF OF THE CONCEPT 
Mayat, (2009)264 established the minimum inhibitory concentration (MIC) of ATc for M. 
smegmatis, i.e. the minimum concentration of ATc that inhibits bacterial growth. She reported 
that M. smegmatis growth was inhibited at 400 ng/ml ATc. Therefore in this study we used ATc 
at < 400 ng/ml for the pilot experiment.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
56 
 
Duplicate starter cultures of rM. smegmatis harbouring the TetRr1.12 plasmids, parental 
plasmids pNM3 and pNM4 (positive controls) and the pCONEPI (negative control) (Appendix 
E2) were prepared as described in section 3.2.3.1. One culture was grown in media containing 10 
µg/ml Kan and 250 ng/ml ATc and the other culture grown in media containing only 10 µg/ml 
Kan. Due to light sensitivity of ATc, the cultures were incubated in the dark and protected from 
light during handling. From each starter culture, 5 ml was inoculated into 100 ml of the same 
media in a 1 L Schott bottle and placed on rollers at 37 C. At OD600 of 0.5 units, 30 ml from 
each culture was subjected to a fluorimetry assay (Appendix B7.1).  
 
To assess induction, ATc was washed from the remainder of the cultures by centrifugation at 
4000 rpm for 10 min at 4 C, the pellets were resuspended in 70 ml of the same media (without 
ATc) and incubated at 37 C on rollers. One hour later, 30 ml was taken from the cultures and 
assayed by fluorimetry. The remainder of the cultures were incubated at 37 C on rollers for a 
further 24 hrs and subsequently assayed as before. 
3.2.5. ASSESSMENT OF THE RM. smegmatis[TETRR1.12] SYSTEMS 
3.2.5.1. Minimum inhibitory concentration of anhydrotetracycline required to repress the 
rM. smegmatis[TetRr1.12] systems 
The first aim was to determine the optimal ATc concentration for each of the rM. smegmatis, that 
is the minimum concentration of ATc that would inhibit the expression of GFP. The second aim 
was to, (i) repress the GFP expression by adding ATc into the cultures and note the repression 
intensity, (ii) remove ATc and monitor the induction, and (iii) note the times at which the highest 
levels of GFP were achieved. The findings from experiment 3.2.4 were used to estimate the ATc 
concentration ranges to use. The constructs that were not completely inhibited by 250 ng/ml ATc 
were subjected to a higher ATc concentration range (200 - 400 ng/ml). The constructs that were 
completely inhibited by 250 ng/ml ATc, were subjected to a lower ATc range (90 - 250 ng/ml).  
 
rM. smegmatis starter cultures containing the TetRr1.12 plasmids were prepared as described in 
Section 3.2.3.1. One culture was grown in ATc-free MB-7H9 media and the rest were grown in 
MB-7H9 media containing varying amounts of ATc (Table 3.2). rM. smegmatis containing the 
positive control pNM3 and negative control pCONEPI were grown in MB-7H9 media containing 
250 ng/ml ATc. The cultures were grown standing in the dark at 37 C and then used to inoculate 
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100 ml of the same MB-7H9 media in 1 L Schott bottles and grown on rollers at 37 C to a high 
OD600 of 0.8. A volume of 10 ml from each culture was assayed by fluorimetry, and 100 µl was 
plated on MB-7H10-Kan agar plates containing the same concentrations of ATc. The plates were 
covered with foil to protect them from the direct light, wrapped in plastic sandwich bags to 
prevent dehydration and incubated at 37 C for 3 - 4 days. The colonies were visualized over a 
UV trans-illuminator Chromato-vue TM-20 Trans-illuminator [UVP] at 245 nm (UV range) and 
photos were taken at various exposures (-0.1s - +0.1s) using a digital camera [Nikon 4500]. The 
images were used to compare the fluorescence levels displayed by the colonies produced on MB-
7H10-Kan agar containing ATc at different concentrations. 
Table 2.2: The concentration ranges of anhydrotetracycline used for the rM. smegmatis[TetRr1.12] 
systems. rM. smegmatis were cultured with the following ATc concentrations in order to determine the 
optimal ATc concentration for each system.  
 PLASMID 
NAMES  
ATC CONCENTRATION  
(ng/ml) 
 
Group 1 
pPM3r2.1 250 - 400  
pPM3r2.2   90 - 250 
 
Group 2 pPM4r2.1 200 - 350 
pPM4r2.2   90 - 250  
 
Group 3 pNM3 250 
pNM4 250 
pCONEPI  250 
GFP expression was induced by removing ATc from the remaining cultures. The cultures were 
centrifuged at 4000 rpm for 15 min, and the pellets were resuspended in fresh MB-7H9 media 
and centrifuged as before. The pellets were then resuspended in 100 ml fresh MB-7H9-Kan 
media, one in media containing ATc and the other in media lacking ATc. The cultures were 
placed back on rollers at 37 C and subsequently assayed by fluorimetry, at 12 hr intervals for a 
period of 72 hours in order to monitor the induction of GFP expression.  
3.2.5.2. Comparison of genetic integrity of the plasmid DNA isolated from rM. smegmatis 
cultured in the presence and absence of ATc 
The optimal ATc concentrations derived in the previous section were used for this experiment. 
Duplicate starter cultures of rM. smegmatis were prepared as described in Section 3.2.3.1, one 
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culture was grown in media containing ATc and the other culture was grown in media lacking 
ATc. ATc was then removed from the cultures as described in the previous section to induce the 
cultures. Seventy-two hours after ATc removal, plasmid DNA was isolated from the rM. 
smegmatis cultures, the genetic integrity of the plasmids was evaluated as described in section 
3.2.3.5 and the percentages of stable clones amongst the selected clones was calculated. 
3.2.5.3. Genetic stability of the recombinant plasmids in the model organism M. smegmatis 
Starter cultures of the rM. smegmatis harbouring the TetRr1.12 plasmids and the control 
plasmids, pNM3 (positive control), and pCONEPI (negative control) were prepared in triplicate 
as described in Section 3.2.3.1. At an OD600 of 0.8 units the starter cultures were used to 
inoculate 100 ml of the MB-7H9 media containing different amounts of Kan and ATc in 1 L 
Schott bottles (cultures were duplicated): the first contained no Kan and no ATc
 
(Kan
–
 ATc
–
), the 
second had Kan (10 µg/ ml) and no ATc (Kan
+
 ATc
–
) and the third contained both Kan (10 µg/ 
ml) and ATc at optimal concentrations
 
(Kan
+
 ATc
+
). The cultures were grown at 37 C on rollers. 
At an OD600 of approximately 0.5 units, each culture was treated according to the following 
steps: 
1. 1 ml was quantified with the spectrophotometer to obtain an accurate OD600 reading.  
2. 1 ml was diluted in resuspension buffer (Appendix C3) to 10-5, 10-6 and 10-7 (the 
dilutions were duplicated), plated on MB-7H10 agar plates containing different amounts 
of Kan and ATc (as described above) and incubated for 3 - 4 days at 37 C.  
3. 500 l was used to inoculate 50 ml of fresh MB-7H9-Kan medium. 
4. The remaining culture was centrifuged at 4000 rpm for 10 min, resuspended in 
resuspension buffer to an OD of 10 units and stored at -80 C.  
 
The above steps were repeated 6 times in order to passage the cultures for approximately  42 
generations. Based on the recorded optical densities, the approximate generation of each culture 
was calculated according to the following equation: Generation = [ln (final OD600) - ln (starting 
OD600)] / ln 2 
266. Colonies were visualized over a UV trans-illuminator at 245 nm (UV range) 
and photos were taken at various exposures using a digital camera. Colony sizes were noted and 
the percentage of colony forming units which maintained GFP fluorescence was calculated. 
Colony counts from plates with and without Kan selection were also used to calculate the 
percentage of colony forming units (cfu) that retained antibiotic resistance. Genetic stability of 
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rM. smegmatis was taken as a measure of the number of colonies that fluoresced after  40 
generations. 
3.2.6.  INTRODUCTION OF THE TETRR1.12 REGULATORY SYSTEM INTO M. bovis 
BCG ΔPANCD 
A pantothenate auxotrophic strain M. bovis BCG mc2 6000 (BCG ΔpanCD) created by Bardarov 
et al., (2002)267 was used as a host strain for recombinant vaccine vectors. 
3.2.6.1. Evaluation of the rBCG ΔpanCD harbouring the TetRr1.12 plasmids in the 
presence of anhydrotetracycline 
The TetRr1.12 plasmids were electro-transformed into BCG ΔpanCD. rBCG ΔpanCD 
responsiveness to ATc was then assessed in order to estimate the concentration range of ATc 
suitable for the regulation of GFP expression. Duplicate starter cultures of the recombinants, 
rBCG ΔpanCD[TetRr1.12], rBCG ΔpanCD[pNM4] positive control and rBCG 
ΔpanCD[pCONEPI] negative control were prepared as described in Section 3.2.3.1, in addition 
10 µg/ml Kan was included for plasmid selection. One culture was grown in ATc-free MB-7H9 
media and the rest were grown in MB-7H9 media containing varying amounts of ATc, 1.5 - 3.0 
µg/ml. The cultures were grown in the dark at 37 C an at an OD600 of 0.8 units, 5 ml from each 
culture was inoculated into 100 ml of the same MB-7H9 media in 1 L Schott bottles. The 
recombinant cultures were grown on rollers at 37 C to a high OD600 of 0.8. From each culture, a 
volume of 10 ml was assayed by fluorimetry and 100 µl was plated on MB-7H10-Kan agar 
plates containing similar varying concentrations of ATc. The plates were covered, wrapped in 
plastic sandwich bags and incubated at 37 C. To note the difference in fluorescence, 3 - 4 weeks 
later the colonies were visualized over a UV trans-illuminator at 245 nm and photographs 
captured using a digital camera. 
 
The remaining cultures were washed in order to induce the expression of GFP by centrifuging at 
4000 rpm for 10 min, resuspending the cell pellets in 70 ml of ATc-free media and centrifuging 
as before. Finally the pellets were resuspended in 70 ml of ATc-free media and incubated at 
37 C on rollers. On a weekly basis for a period of 3 weeks, 20 ml from each culture was 
analysed using fluorimetry and the remaining culture was placed back on rollers at 37 C.  
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3.2.6.2. Assessment of TetRr1.12 plasmid stability in BCG ΔpanCD 
The aim of this experiment was to assess the genetic stability of the recombinant plasmids in the 
presence and absence of the ATc in BCG ΔpanCD. An ATc concentration of 2 µg/ml was used 
for the experiment since this was the optimal concentration for all the constructs (established in 
the previous section). rBCG ΔpanCD starter cultures harbouring the TetRr1.12 and the controls 
plasmids, pNM4 and pCONEPI were prepared in duplicate as described in Section 3.2.3.1, in 
addition 10 µg/ml Kan was included for plasmid selection. One culture was grown in the 
presence of ATc and the other was grown without ATc. The starter cultures were subsequently 
used to inoculate 100 ml of the same media and propagated at 37 C on rollers. At an OD600 of 
approximately 0.5 units, the cultures were processed according to the steps in section 3.2.6, in 
addition, 20 ml of each culture was subjected to a fluorimetry assay. Genetic integrity of plasmid 
DNA isolated from rBCG ΔpanCD cultures produced after the final passage was assessed as 
described in section 3.2.3.5. 
3.3. RESULTS 
3.3.1. CONSTRUCTION OF THE TETRR1.12 SHUTTLE PLASMIDS  
To investigate the TetRr1.12 regulatory system, four different versions of the shuttle plasmid 
were generated, by cloning the TetRr1.12 expression cassette into the parental pNM3 and pNM4 
plasmids that were generated by Mayat, (2009)264 (as demonstrated in Figure 3.4). Restriction 
enzyme mapping was then performed to screen for potentially positive recombinants, where 
small-scale plasmid DNA isolated from E. coli clones transformed with the various ligation 
mixes was subjected to restriction enzyme digestion. An EcoRV digest was performed to 
confirm the presence of the TetRr1.12 cassette since the site is unique to the cassette, the double 
digest MluI + NotI was performed to confirm the presence of the TetRr1.12 cassette as it showed 
the size change from the parental plasmids to the TetRr1.12 plasmids, and finally the double 
digest XbaI + NdeI was performed to confirm the orientation of the TetRr1.12 cassette (the maps 
shown in Figure 3.5).  
Mapping results showed that the tetRr1.12 repressor gene had inserted successfully immediately 
upstream of the strong Psmyc promoter in two different orientations with respect to the gfp gene, 
as shown in Figure 3.5. The constructs are listed in Table 3.3. 
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Table 3.3: Description of E.coli/mycobacterial shuttle vectors containing the TetRr1.12 expression 
cassette. pNM3 contain the full-length Psmyc promoter with two tetO2 sequences situated on either side of 
-10 and pNM4 contain the full-length Psmyc promoter with two tetO1 sequences situated on either side of -
1. 
PLASMID NAME FEATURES 
 
pPM3r2.1 pNM3 containing the TetRr1.12 cassette in the same orientation as the gfp gene 
pPM3r2.2 pNM3 containing the TetRr1.12 cassette in the opposite orientation to the gfp 
gene 
pPM4r2.1 pNM4 containing the TetRr1.12 cassette in the same orientation as the gfp gene 
pPM4r2.2 pNM4 containing the TetRr1.12 cassette in the opposite orientation to the gfp 
gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The maps of the episomal TetRr1.12 dependant regulatory system designs.These 
plasmids were constructed by inserting the TetRr1.12 cassette into the pNM3 and pNM4 vector 
backbones. 
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3.3.2. TRANSFORMATION OF TETRR1.12 SHUTTLE PLASMIDS INTO 
MYCOBACTERIA 
3.3.2.1. Introduction of the TetRr1.12 plasmids into M. smegmatis  
The confirmed TetRr1.12 plasmids were successfully introduced into the model strain M. 
smegmatis by electroporation. This is fast growing, non-pathogenic mycobacteria that has been 
widely used as a model organism to study the biology of other virulent strains and extremely 
slow growing species of mycobacteria 268. rM. smegmatis stocks from the electro-transformants 
were prepared. To verify the genetic integrity of the recombinant M. smegmatis plasmids, 
plasmid DNA was isolated from the stocks and subjected to restriction enzyme mapping using 
the same enzymes shown in Table 3.1. The results showed that all four E.coli/mycobacterial 
shuttle vectors containing the TetRr1.12 cassette remained intact in M. smegmatis. 
 
3.3.2.2. A Pilot experiment performed to test the responsiveness of rM. smegmatis to 
anhydrotetracycline 
This pilot experiment was designed to assess whether GFP expression could be repressed in the 
presence of ATc and induced upon its removal. As mentioned in Chapter 2, the affinity of ATc 
for the repressors is significantly higher than its affinity for the 30S ribosomal subunit of the 
host, thus ATc levels required for protein inhibition are considerably higher than the levels 
required to repress the expression of the recombinant antigen 249, 251. Mayat, (2009)264 reported 
that 400 ng/ml ATc inhibits M. smegmatis growth, therefore ATc concentration of 250 ng/ml 
was used. 
 
The amount of GFP expression in bacterial lysates prepared from rM. smegmatis cultures 
harbouring the recombinant plasmids was measured by a fluorimetry assay. In 2009, Mayat264 
established the optimal cell culture density to be an OD600 of 2 units for fluorimetry experiments, 
which was the similar to that reported by Carroll and Parish in 2005269, and was therefore used in 
this study. The parentals, rM. smegmatis[pNM3] and rM. smegmatis[pNM4] that lack the 
TetRr1.12 cassette were the positive controls as these are not affected by ATc. rM. 
smegmatis[pCONEPI] lacking the gfp gene was the negative control and accounted for the 
background readings, which were subtracted from the experimental sample readings.  
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A comparison was made between the recombinants that were cultured with ATc and those that 
were cultured without ATc, in terms of the levels of GFP expression. As shown in Figure 3.6, it 
is clear that the TetRr1.12 cassette inhibited GFP expression in the presence of ATc as all the 
rM. smegmatis showed low fluorimetry readings as compared to the rM. smegmatis grown 
without ATc. However, rM. smegmatis appeared to be partially repressed since the levels of GFP 
were not as low as the background readings. rM. smegmatis harbouring pPM3r2.2 and  
pPM4r2.2 were more repressed than rM. smegmatis harbouring pPM3r2.1 and pPM4r2.1. 
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Figure 3.6: A fluorimetry assay showing the ATc-dependent repression of GFP expression in the 
rM. smegmatis and corresponding induction upon ATc removal. GFP expressed by the cultures grown 
in the absence of ATc (blue bars), in the presence of 250 ng/ml ATc (pink bars) and readings recorded 24 
hrs after ATc removal (orange bars). The positive controls were pNM3 and pNM4, and negative control 
was pCONEPI. Error bars represent the standard deviations from two experiments. 
ATc was then removed from the recombinant cultures and 24 hrs later the induction was 
assessed, shown by orange bars in Figure 3.6. rM. smegmatis harbouring the plasmids pPM3r2.1 
and pPM4r2.1 were slightly induced, whereas no induction could be seen from rM. smegmatis 
harbouring the plasmids pPM3r2.2 and pPM4r2.2. This data indicates that rM. 
smegmatis[pPM3r2.2] and rM. smegmatis[pPM4r2.2] were more sensitive to ATc.  
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Overall, the experiment demonstrated that the TetRr1.12 regulatory system could repress the 
expression of the recombinant antigen in M. smegmatis in the presence of ATc. However, the 
different rM. smegmatis systems displayed different levels of sensitivity to ATc. The systems 
containing the TetRr1.12 cassette in the opposite orientation to the gfp gene (rM. 
smegmatis[pPM3r2.2] and rM. smegmatis[pPM4r2.2]) were very sensitive to ATc, whereas those 
containing the cassette in the same orientation as the gfp gene (rM. smegmatis[pPM3r2.1] and 
rM. smegmatis[pPM4r2.1]) were less sensitive. The background readings produced by the 
negative controls could be attributed to fluorescence of mycobacterial proteins in the cultures. 
3.3.2.3. Determination of the concentration of anhydrotetracycline needed to regulate GFP 
expression in rM. smegmatis[TetRr1.12] systems  
Having established that the TetRr1.12 regulatory systems displayed dissimilar sensitivity levels 
to ATc, the next task was to determine the minimum concentration of ATc that would inhibit 
GFP expression, and easily be removed to permit induction. The findings from the pilot 
experiment were used to estimate the ATc concentration range to use in this experiment. The 
higher range, 200 - 400 ng/ml was used for the less sensitive systems, rM. smegmatis[pPM3r2.1] 
and rM. smegmatis[pPM4r2.1], and the lower ATc range, 90 - 250 ng/ml was used for more 
sensitive systems, rM. smegmatis[pPM3r2.2] and rM. smegmatis[pPM4r2.2]. Recombinant 
colony fluorescence was compared by visualization over a UV trans-illuminator.  
 
rM. smegmatis colonies are shown in Figure 3.7. Panel A shows the rM. smegmatis controls, as 
you would expect the positive controls, rM. smegmatis[pNM3] and rM. smegmatis[pNM4] 
displayed good fluorescence, and the negative control, rM. smegmatis[pCONEPI] did not 
fluoresce at all. Shown in panels B - E are the recombinant colonies exhibiting different 
fluorescence intensities in the presence of varying amounts of ATc. The minimum 
concentrations of ATc that achieved GFP repression were selected as the optimal concentrations, 
these were 250 ng/ml for rM. smegmatis[pPM3r2.1], 100 ng/ml for rM. smegmatis[pPM3r2.2], 
200 ng/ml for rM. smegmatis[pPM4r2.1] and 100 ng/ml for  rM. smegmatis[pNM4r2.2].  
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A. 
rM. smegmatis[pNM3] 
ATc  250 ng/ml 
 
 
rM. smegmatis[pNM4] 
ATc  250 ng/ml 
 
 
rM. smegmatis[pCONEPI] 
ATc  250 ng/ml 
 
 
B.    ATc  300 ng/ml 
 
ATc  250 ng/ml 
 
ATc  100 ng/ml 
 
 
ATc  0 ng/ml 
 
C.   ATc  250 ng/ml 
 
 
ATc  100 ng/ml 
 
ATc  90 ng/ml 
 
ATc  0 ng/ml 
 
 
D.   ATc  250 ng/ml 
 
 
ATc  200 ng/ml 
 
ATc  100 ng/ml 
 
ATc  0 ng/ml 
 
E.   ATc  250 ng/ml 
 
ATc  100 ng/ml 
 
ATc  90 ng/ml 
 
ATc  0 ng/ml 
 
Figure 3.7: Images taken over UV light illustrating ATc-dependant repression of GFP expression of 
the rM. smegmatis systems. rM. smegmatis[TetRr1.12] systems were exposed to different ATc 
concentration ranges in order to determine the minimum concentration of ATc that would inhibit GFP 
expression. A. Positive controls, rM. smegmatis[pNM3] and rM. smegmatis[pNM4] and negative control, 
rM. smegmatis[pCONEPI]; B. rM. smegmatis[pPM3r2.1]; C. rM. smegmatis[pPM3r2.2]; D. rM. 
smegmatis[pPM4r2.1] and E. rM. smegmatis[pPM4r2.2] 
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The following experiment was performed to confirm whether the repression achieved with the 
optimal ATc levels could be removed and allow induction to occur, to determine the time point 
at which the highest GFP levels were achieved and to compare GFP levels produced from rM. 
smegmatis that were initially repressed to those that were not repressed. Two batches of each rM. 
smegmatis were prepared, one was grown with ATc at optimal concentrations and the other 
without ATc. The recombinant cultures were then washed to remove ATc and induce GFP 
expression and the induction kinetics were monitored for a  70 hr period by the whole cell 
fluorimetry assay. 
 
The results can be seen in Figures 3.8 and 3.9, at time zero, rM. smegmatis that were cultured 
with ATc were still repressed, as the readings were very low compared to those of rM. 
smegmatis grown without ATc. Repression was approximately 1.7-fold for rM. 
smegmatis[pPM3r2.1], 1.4-fold for rM. smegmatis[pPM4r2.1] and 2.5-fold rM. 
smegmatis[pPM3r2.2] and rM. smegmatis[pNM4r2.2].  
 
Slow induction was observed with time and the highest readings were obtained between 12 - 24 
hrs. The GFP expression levels achieved from rM. smegmatis grown with ATc did not reach the 
levels of those achieved by rM. smegmatis grown without ATc, even after a 70/72 hr induction 
period. This indicates that maximal induction was not achieved after ATc was removed from the 
rM. smegmatis cultures. A positive correlation was observed between GFP expression and the 
growth phase of the recombinants.  
 
The optimal levels of ATc were unable to completely repress the rM. smegmatis systems as the 
fluorimetry readings were above the background readings (Figure 3.8 - 3.9), however, the 
amount of ATc could not be increased since ATc above optimal levels was very difficult to 
remove during induction (as shown in the pilot experiment, Figure 3.6). Moreover, as can be 
seen above rM. smegmatis systems did not show complete induction after ATc was removed, yet 
ATc could not be reduced since ATc levels below the optimal levels were unable to repress GFP 
expression (Figure 3.7).  
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Figure 3.8: Relative GFP fluorescence of the cultures, rM. smegmatis[pPM3r2.1] and rM. 
smegmatis[pPM3r2.2] measured after ATc was removed. GFP expression was measured using the 
fluorimetry assay and expressed as relative fluorescence units after subtracting the background readings 
of rM. smegmatis[pCONEPI]. Represented by blue bars are the readings obtained from rM. smegmatis 
lysates after the removal of ATc, the pink bars represent the readings produced by rM. smegmatis grown 
in its absence, the positive control, rM. smegmatis[pNM3] is represented by an orange bar. The error bars 
represent the standard deviations from two experiments. 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
68 
 
 
 
A. 
0 hr 1 hr 6 hrs 12 hrs 24 hrs 48 hrs 72 hrs
0
10
20
30
200 ng/ml
0 ng/ml
pNM4
pPM4r2.1
1.4
Time after ATc removal
R
e
la
ti
v
e
 f
lu
o
r
e
sc
e
n
c
e
 u
n
it
 
 
B. 
0 hr 1 hr 6 hrs 12 hrs 24 hrs 48 hrs 70 hrs
0
10
20
30
100 ng/ml
0 ng/ml
pNM4
pPM4r2.2
2.5
Time after ATc removal
R
e
la
ti
v
e
 f
lu
o
r
e
sc
e
n
c
e
 u
n
it
 
Figure 3.9: Relative GFP fluorescence of the cultures, rM. smegmatis[pPM4r2.1] and rM. 
smegmatis[pPM4r2.2] measured after ATc was removed. GFP expression was measured using the 
fluorimetry assay and expressed as relative fluorescence units after subtracting the background readings 
of rM. smegmatis[pCONEPI]. Represented by blue bars are the readings obtained from rM. smegmatis 
lysates after the removal of ATc, the pink bars represent readings produced by rM. smegmatis grown in its 
absence, the positive control, rM. smegmatis[pNM4] is represented by an orange bar. The error bars 
represent the standard deviations from two experiments. 
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Plasmid instability have been reported in many studies in recombinant mycobacteria utilising 
episomal vectors and constitutive promoters, whereby the recombinant antigen is lost 167, 270. 
Hence in this study rM. smegmatis cultured without regulation were expected to become unstable 
overtime and produce lower levels of GFP. However that was not the case, since rM. smegmatis 
cultured without ATc showed higher  levels of GFP than the systems that were grown with ATc 
(theoretically more stable), despite inducing for  72 hrs. Thus we assessed whether the 
differences in GFP expression levels correlated to plasmid instability by evaluating the genetic 
integrity of plasmid DNA isolated from the cultures 70/72 hrs post induction using restriction 
enzyme mapping.  
 
A total of 20 clones were mapped for each rM. smegmatis. The results showed that rM. 
smegmatis grown without ATc were genetically unstable despite high GFP expression, since the 
percentages of stable clones were 50% for rM. smegmatis[pPM3r2.1], 35% for rM. 
smegmatis[pPM3r2.2], 46% for rM. smegmatis[pPM4r2.1] and 38% for rM. 
smegmatis[pNM4r2.2] (data not shown). As could be seen in the Figures 3.8 and 3.9, the levels 
of GFP started decreasing after 24 hours, we suspect that vector instability took place during 
these time points. In contrast, plasmid DNA isolated from rM. smegmatis that were grown with 
ATc and then induced for  72 hours were genetically stable as these produced the expected 
band patterns following restriction enzyme mapping, i.e.  100% of the mapped clones were 
stable (data not shown). 
 
3.3.2.4. Assessment of the stability of the TetRr1.12 plasmids in M. smegmatis  
This experiment was performed to evaluate the fitness of the TetRr1.12 vectors in M. smegmatis 
over 42 generations with or without ATc and antibiotic selection. This was done to assess 
whether regulating the recombinant antigen expression improves the plasmid stability and to 
determine the percentage of plasmid loss. At each passage (after 7 generations) maintenance of 
GFP fluorescence by the recombinants was assessed and the retention of Kan resistance was 
determined. The summary of the results can be seen in Figures 3.10. Panel A shows the results 
obtained in the presence of both ATc and Kan. rM. smegmatis systems were reasonably stable 
after 14 generations as the percentages of fluorescing colonies were > 70%, however instability 
increased after the 21
st
 generation and the percentages of fluorescing colonies ended up between 
45 and 86% after 42 generations. Panels B and C show colonies produced in the absence of both  
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Figure 3.10: Genetic stability of the rM. smegmatis[TetRr1.12].  GFP expressed by the constructs was assessed in solid medium in the presence of ATc and 
Kan over 42 generations. Colonies were viewed over UV light and the percentage of fluorescing colonies was noted. A. Kan+ ATc+, B. Kan– ATc– media, and C. 
Kan+ ATc– media. Error bars represent the standard deviations from two experiments. 
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Kan and ATc and in the presence of Kan and absence of ATc, respectively. As can be seen in the 
figures instability started occurring after the seventh generation in all the recombinant systems. 
This data indicates that plasmid instability occurred in the recombinant systems over time, 
however it occurred faster in the absence of Kan than in its presence. rM. smegmatis[pPM3r2.1] 
and rM. smegmatis[pPM4r2.1] appeared to be more stable than rM. smegmatis[pPM3r2.2] and 
rM. smegmatis[pPM4r2.2] as they produced a higher percentage of fluorescing colonies after 42 
generations in the presence as well as absence of ATc.  
 
Plasmid stability was also measured by evaluating the colony counts produced by the 
recombinants with and without antibiotic selection over many generations. Duplicate cultures of 
rM. smegmatis were passaged without selection over 42 generations. At each passage, the 
cultures were plated onto media containing and lacking kanamycin. Retention of kanamycin 
resistance was determined by calculating the colony counts from media containing kanamycin as 
a percentage of the colony counts from media lacking kanamycin. The recombinants were 
relatively stable after 7 generations as the percentage of colony forming units (cfu) that retained 
kanamycin resistance in the absence of ATc ranged from 86 - 100% (Table 3.4), however it 
dropped overtime and was <60 % after 42 generations.  
 
Table 3.4: Retention of rM. smegmatis[TetRr1.12] plasmid stability in the absence of selection after 
multiple generations. The recombinants were grown without selection over 42 generations and the 
stability of the plasmids was then evaluated by colony count. 
 
 Kan
-
 Kan
+  
 Average 
colony counts 
from two 
experiments 
Standard 
deviation 
(SD) 
Average 
colony counts 
from two 
experiments 
Standard 
deviation 
(SD) 
Plasmid 
retention 
(%) 
GENERATION  7 
pPM3r2.1 35 5.6 30 5.6 86 
pPM3r2.2 29 2.8 26 4.2 90 
pPM4r2.1 35 7.1 30 8.4 88 
pPM4r2.2 23 5.7 23 4.2 100 
 
GENERATION  42 
pPM3r2.1 58 4.2 28 2.8 48 
pPM3r2.2 69 1.4 27 1.4 40 
pPM4r2.1 53 2.8 26 4.2 59 
pPM4r2.2 56 4.3 23 1.4 41 
SD: Analysed using GraphPad Prism version 5.00 for Windows, GraphPad Software (San Diego 
California USA, www.graphpad.com). 
Plasmid retention %: Average colony count from Kan+/ Average colony count from Kan- 
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Overall, in the absence of kanamycin and ATc, plasmid instability occurred gradually. rM. 
smegmatis containing the tetRr1.12 repressor gene in the same orientation as the gfp gene were 
more stable than the systems containing the gene in the opposite orientation.  
3.3.3. ASSESSMENT OF THE TETRR1.12 REGULATORY SYSTEMS IN M. bovis BCG 
ΔPANCD 
The TetRr1.12 plasmids were introduced into the pantothenic acid-deficient strain, M. bovis 
BCG mc
2 
6000 (M. bovis BCG ΔpanCD). This auxotrophic strain was created by Bardarov et al., 
(2002)267 using a specialized method of mycobacteriophage transduction. It contains deletions in 
the panC and panD genes that are involved in the de novo biosynthesis of pantothenate (vitamin 
B5), which is an essential requirement for lipid biosynthesis and metabolism contributing to the 
very complex and strong cell walls of mycobacteria. Consequently BCG ΔpanCD requires 
supplementation with vitamin B5 for propagation 271.  
 
Due to its auxotrophic nature, the growth of BCG ΔpanCD is impaired in the phagosome 
environment where there is limited pantothenate, and this minimizes the risk of development of 
disseminated BCG 55. As a result the BCG ΔpanCD strain is safer for use in 
immunocompromised hosts than the wild type BCG (Chapter 1.1), thus this strain was used for 
the generation of rBCG ΔpanCD vaccine stocks in this study. Mayat, (2009)264 reported that the 
optimal concentration of vitamin B5 to supplement growth of BCG ΔpanCD in order to 
approximate wild-type BCG growth was 24 µg/ml. Furthermore, this strain has proven to be 
sensitive to ATc, making it an ideal strain for use in the expression of ATc controlled plasmids 
264. 
 
3.3.3.1. Construction of the rBCG ΔpanCD[TetRr1.12] systems 
The TetRr1.12 plasmids were successfully transformed into BCG ΔpanCD by electroporation 
followed by the preparation of rBCG ΔpanCD vaccine stocks. Recombinant mycobacteria were 
then evaluated in terms of vector stability by restriction enzyme mapping of plasmids isolated 
from the vaccine stocks. Mapping verified the genetic integrity of all the rBCG ΔpanCD 
plasmids.  
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3.3.3.2. Determination of the optimal concentration of anhydrotetracycline for rBCG 
ΔpanCD[TetRr1.12] systems 
The following experiment was performed to estimate the minimum ATc concentration that 
would inhibit GFP expression in rBCG ΔpanCD[TetRr1.12] systems. Mayat, (2009)263 reported 
that the auxotrophic BCG ΔpanCD is more resistant to ATc than M. smegmatis. In her study she 
demonstrated that the growth of this BCG ΔpanCD is only significantly affected by ATc at 5 
µg/ml. As a result a higher concentration range of ATc was used for the BCG ΔpanCD as 
compared to the M. smegmatis. The recombinants were subjected to varying concentrations of 
ATc onto solid media in order to compare GFP fluorescence by visualization of the colonies 
(Figure 3.11).  
A.  
rBCG ΔpanCD[pCONEPI] 
ATc 3.0 µg/ml 
 
 
rBCG ΔpanCD[pNM4] 
ATc 3.0 µg/ml 
 
 
 
B.             
rBCG 
ΔpanCD[pPM4r2.1] 
ATc 0 µg/ml 
 
 
rBCG 
ΔpanCD[pPM4r2.1] 
ATc 1.5 µg/ml 
 
 
rBCG 
ΔpanCD[pPM4r2.1] 
ATc 2.0 µg/ml 
 
 
rBCG 
ΔpanCD[pPM4r2.1] 
ATc 3.0 µg/ml 
 
 
Figure 3.11: Images taken over UV light illustrating ATc-dependant repression of GFP expression 
of the rBCG ΔpanCD. A. controls, rBCG ΔpanCD[pNM4] (positive) and rBCG ΔpanCD[pCONEPI] 
(negative). B. Images showing the fluorescence of rBCG ΔpanCD[pPM4r2.1] colonies on MB-7H10 
medium containing various ATc concentrations.  
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All the recombinants displayed similar levels of ATc susceptibility, thus shown in the Figure 
3.11 are the results obtained from one of the recombinants, rBCG ΔpanCD[pPM4r2.1]. The 
different levels of fluorescence exhibited by the colonies on various amounts of ATc are 
depicted. As expected rBCG ΔpanCD[pPM4r2.1] grown on ATc 0 µg/ml displayed the highest 
levels of fluorescence. ATc at 1.5 µg/ml did not completely repress GFP expression as the 
colonies showed a low level of fluorescence. ATc at 2.0 µg/ml was selected as the optimal 
concentration seeing as it was the minimum concentration that repressed GFP expression. As 
expected the control rBCG ΔpanCD colonies containing pNM4 and pCONEPI were not affected 
by the presence of ATc. 
The next aim was to assess GFP expression in the presence and absence of ATc using a 
fluorimetry assay. Triplicate cultures of rBCG ΔpanCD[TetRr1.12] were grown in liquid media, 
one was grown with 2.0 µg/ml ATc, one with 3.0 µg/ml ATc and the other without ATc. The 
cultures were then washed to remove ATc and GFP expression was induced for a period of 3-
weeks. GFP expression was measured at weekly intervals, starting from week 0 (before the 
systems induced). The induction period for rBCG ΔpanCD was lengthened compared to the 
period used for M. smegmatis considering BCG ΔpanCD strain has a very slow growth rate.  
 
Figure 3.12 shows the results obtained from one of the recombinants, rBCG 
ΔpanCD[pPM4r2.1], at week 0 the GFP levels produced by rBCG ΔpanCD[pPM4r2.1] grown 
with 2.0 µg/ml ATc were very low (approximately 2-fold) compared to the system grown 
without ATc, which indicated good repression. The levels of GFP gradually increased from 1 to 
3 weeks post ATc removal and the highest level was obtained after 3 weeks, which were 
approximately 5.7-fold higher than the levels produced prior to ATc removal. rBCG 
ΔpanCD[pPM4r2.1] grown with 3.0 µg/ml ATc showed better repression since the GFP level 
was >2-fold lower than the system grown without ATc, however the system induced very slow 
after ATc was removed.  rBCG ΔpanCD[pPM4r2.1] grown in the absence of ATc produced the 
highest level of GFP after 2 weeks and then started dropping afterwards, which was an indication 
of plasmid instability. 
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Figure 3.12: Assessment of repression and induction of GFP expression in rBCG 
ΔpanCD[pPM4r2.1]. GFP expression was measured by fluorimetry assay and expressed as relative 
fluorescence units after subtracting the background readings of rBCG ΔpanCD[pCONEPI]. The positive 
control was rBCG ΔpanCD[pNM4]. Error bars represent the standard deviations from two experiments. 
3.3.3.3. Assessment of genetic stability of rBCG ΔpanCD[TetRr1.12]  
As previously mentioned, genetic instability is one of the major factors impeding the commercial 
production of rBCG-based vaccines (Chapter 1). This experiment was designed to assess the 
genetic integrity of the rBCG ΔpanCD vaccine vectors expressing GFP after 49 generations. 
Similar to rM. smegmatis systems, the genetic stability of the rBCG ΔpanCD[TetRr1.12] was 
evaluated with and without ATc over many generations, in order to determine the maintenance 
of the gfp gene, retention of the KanR gene and the percentage of plasmid loss. The number of 
passages was increased to seven (  49 generations) in order to lengthen the rBCG ΔpanCD 
vaccine vector assessment period as stability impacts on the preparation of the vaccines on a 
large scale. In addition, the colony morphology was assessed in order to examine the degree at 
which metabolic load was exerted on the BCG strain since the size of colonies reflects their 
growth rate. GFP expressed by the recombinants was monitored by fluorimetry assay. As seen in 
Figure 3.13, the presence of ATc reduced the levels of GFP (panel A) compared to the levels of 
GFP produced in the absence of ATc (panel B). GFP expression in the recombinants grown with 
ATc appeared to be low and consistent for 49 generation, whereas GFP expression in the 
recombinants grown without ATc showed steady reduction overtime.  
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Figure 3.13: Assessing the stability of the rBCG ΔpanCD[TetRr1.12]. GFP expression in the systems 
was assayed in the presence and absence of ATc using fluorimetry and expressed as relative fluorescence 
units after subtracting the background readings of rBCG ΔpanCD[pCONEPI]. Fluorimetry readings of 
the systems in, A. ATc+ and B. ATc-. rBCG ΔpanCD[pNM4] was the positive control. Error bars 
represent the standard deviations from three experiments. 
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In our laboratory it has been demonstrated that reduction in the growth rate of the host cells can 
be linked to an over-expression of recombinant antigens and a build up of metabolic load, where 
the recombinants produce small or unhealthy colonies 
263, 270
. In this experiment a comparison of 
colony morphology between colonies produced after 7 generations and those produced after 49 
generations was done by visualization of the recombinant colony fluorescence over a UV trans-
illuminator.  
 
Figure 3.14 depicts rBCG ΔpanCD colonies after 7 generations. Although the colonies displayed 
slightly lower levels of fluorescence in the presence of 2.0 µg/ml ATc than in its absence, the 
magnitude of repression was not as intense as observed in the liquid media at the same 
concentration of ATc. Moreover, the recombinants produced comparable colonies in the 
presence and absence of ATc, in terms of the size. Figure 3.15 show rBCG ΔpanCD colonies 
produced after 49 generations. In the presence of ATc, the colonies were very similar to those 
produced after 7 generations, in terms of fluorescence intensity and size. Colony sizes were not 
uniform, either in the presence or absence of ATc. However, in the absence of ATc colonies 
showed a general reduction in size and more intense fluorescence. In our experience both 
transformed and untransformed BCG colonies are fairly heterogenous in size. This data indicates 
that the colony sizes were inversely correlated to GFP expression levels. 
 
Plasmid stability of the rBCG ΔpanCD was assessed by counting the colonies produced by the 
recombinants after passaging over 49 generations in the absence of selection as performed in rM. 
smegmatis. The recombinants were relatively stable after 7 generations as the percentage of cfu 
that retained antibiotic resistance in the absence of kanamycin ranged from 82 - 91%, however it 
dropped overtime as instability increased and ended up between 63 and 73% after 49 generations 
(Table 3.5). 
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Figure 3.14: Images of the rBCG ΔpanCD[TetRr1.12] colonies taken over UV light after 7 generations. Colonies produced after culturing the recombinants 
over 7 generations in the presence and absence of anhydrotetracycline.  
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Figure 3.15: Images of the rBCG ΔpanCD[TetRr1.12] colonies taken over UV light after 49 generations. Colonies produced after culturing the 
recombinants over 49 generations in the presence and absence of anhydrotetracycline.  
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Plasmid stability was also evaluated by restriction enzyme mapping of plasmid DNA isolated 
from the rBCG ΔpanCD[TetRr1.12] cultures produced after 49 generations in presence and 
absence of ATc. A total of 20 clones were mapped for recombinant (data not shown), and then 
the percentages of the stable clones were determined. In the presence of ATc the plasmids 
remained genetically stable since 100% of the recombinants tested produced expected band 
patterns, whereas in the absence of ATc the percentage of stability varied between the 
recombinants, rBCG ΔpanCD[pPM3r2.1] displayed 76% stability, rBCG ΔpanCD[pPM3r2.2] 
displayed 74% stability, rBCG ΔpanCD[pPM4r2.1] displayed 81%  stability and rBCG 
ΔpanCD[pPM4r2.2] displayed 57% stability.  
 
Overall, the TetRr1.12 vectors were more genetically stable in BCG ΔpanCD than in M. 
smegmatis. Furthermore, TetRr1.12 vectors containing the tetRr1.12 repressor gene in the same 
orientation as the gfp gene (pPM3r2.1 and pPM4r2.1) were more stable than the systems 
containing the gene in the opposite orientation (pPM3r2.2 and pPM4r2.2) in both mycobacterial 
strains.   
Table 3.5: Assessment of rBCG ΔpanCD[TetRr1.12] plasmid stability retention in the absence of 
selection after multiple generations.  
 Kan
-
 Kan
+
  
 Average 
colony counts 
from two 
experiments 
Standard 
deviation (SD) 
Average 
colony counts 
from two 
experiments 
Standard 
deviation 
(SD) 
Plasmid 
retention 
(%) 
GENERATION  7 
pPM3r2.1 28 9.8 23 4.2 82 
pPM3r2.2 24 7.1 22 7.1 91 
pPM4r2.1 23 2.1 19 5.6 82 
pPM4r2.2 20 8.4 17 7.1 85 
 
GENERATION  49 
pPM3r2.1 23 14.1 17 2.8 73 
pPM3r2.2 20 17.0 13 1.4 65 
pPM4r2.1 21 4.2 15 15.6 71 
pPM4r2.2 19 7.1 12 1.4 63 
The recombinants were grown without selection for  49 generations and the stability of the plasmids 
were then evaluated by colony count as shown below. 
SD: Analysed using GraphPad Prism version 5.00 for Windows, GraphPad Software (San Diego 
California USA, www.graphpad.com). 
Plasmid retention %: Average colony count from Kan+/ Average colony count from Kan- 
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3.4. DISCUSSION 
In this study the aim was to express a recombinant antigen in an episomal vector under a strong 
promoter to ensure sufficient levels were produced. However we wanted to avoid vector 
instability, therefore an expression system was constructed, where a recombinant antigen was 
placed under a regulatable promoter. In the system the regulation of transcription of the 
recombinant antigen was facilitated by switching the promoter controlling it on and off with the 
aid of a TetRr1.12 repressor and a chemical co-repressor, ATc.  
 
Using the TetRr1.7 repressor Guo et al., (2007)197 observed that the silencing of the recombinant 
antigen was only achieved if the repressor was expressed by a strong promoter. From their data 
we can deduce that the regulation of the system is not only influenced by the concentration of the 
co-repressor but also by the quantity of the repressor. Therefore, to ensure efficient regulation of 
the system, the tetRr1.12 gene was placed under the control of a strong promoter (hsp60) in 
order to ensure that sufficient levels of the repressor were produced. 
 
A series of the episomal TetRr1.12 regulatory systems, pPM3r2.1, pPM3r2.2, pPM4r2.1 and 
pPM4r2.2 were constructed. The systems consisted of different combinations of tetO operators 
(in the Pmcyc promoter region) and the TetRr1.12 expression cassette (tetRr1.12 gene expressed 
from the hsp60 promoter) in different orientations. These were evaluated using GFP as a model 
antigen, where the expression was monitored by measuring the intensity of fluorescence using a 
fluorimetry assay. In the proof of concept experiment the systems responded to ATc by showing 
repression of GFP expression in its presence. The systems containing the tetRr1.12 gene in the 
opposite orientation to the gfp gene, pPM3r2.2 and pPM4r2.2 were more sensitive to ATc, 
whereas the systems containing the tetRr1.12 gene in the same orientation as the gfp gene, 
pPM3r2.1 and pPM4r2.1 were less sensitive to ATc. This indicated the existence of a correlation 
between the orientation of the tetRr1.12 gene and ATc sensitivity. We suspect that the DNA 
conformation (the tetRr1.12 gene orientation) around the Pmcyc promoter region may influence 
the binding of the TetRr1.12-ATc complex to the tetO operator sequences. 
 
Next, the optimal concentration of ATc was determined, i.e. the minimum ATc concentration 
that would repress GFP expression and could be removed without difficulty to allow induction of 
recombinant antigen expression. In M. smegmatis the optimal ATc concentration for the systems 
ranged from 100 - 250 ng/ml (Figure 3.7), which lies within the published ATc range of 10 - 300 
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ng/ml that has been used for an efficient silencing of genes in M. smegmatis with the TetRr1.7 
repressor 197, 198. In M. smegmatis up to 2.5-fold repression at a dose of 100 ng/ml ATc was seen 
compared to rM. smegmatis grown in the absence of ATc. In BCG ΔpanCD, although 2.0 µg/ml 
ATc did not achieve complete repression (Figure 3.11 & 3.12), it was selected as the optimal 
ATc concentration for the TetRr1.12 systems since the maximal induction of GFP expression 
following the removal of ATc was not achieved when the cultures were grown in media 
containing higher concentration of ATc. Also a very low level of recombinant antigen expression 
was not expected to cause genetic instability. Repression achieved with 2.0 µg/ml ATc was 
approximately 2-fold in all the systems. In comparison to the codon optimized TetRr1.7 
repressor, which mediated a 3-fold repression in the presence of 100 ng/ml ATc in M. smegmatis 
264, the codon optimized tetRr1.12 was seemingly less efficient as it required a higher 
concentration of ATc to repress GFP. This data is in accordance with the published data as 
Scholz et al., (2004)254 reported that the TetRr1.7 repressor is more efficient than the TetRr1.12 
repressor. Optimal ATc concentrations were favourably lower than the MIC of both of 
mycobacterial strains, which are 400 ng/ml for M. smegmatis and ~5000 ng/ml for BCG 
ΔpanCD 264. 
 
The induction kinetics data showed slow induction of the rM. smegmatis cultures as none of 
these were maximally induced 72 hrs post ATc removal (Figures 3.8 and 3.9). Inefficient 
induction may have been caused by elevated levels of the TetRr1.12 repressor as it was 
expressed from a replicative plasmid and placed under a strong promoter, which might have 
obstructed the initiation of the Psmyc promoter. According to Lutz and Bujard, (1997)
193 if over-
expressed, the repressor can interfere with the induction of the promoter activity by strongly 
binding to the tetO operators. On the other hand, rBCG ΔpanCD showed complete induction 3 
weeks after ATc removal and no indication of genetic instability (Figure 3.12). 
 
This study also showed that the induction of the Psmyc promoter after removal of ATc is time- and 
dose-dependent as the induction kinetics positively correlated with time and the expression 
levels of the recombinant antigen varied in response to the ATc doses. The recombinants 
cultured in the presence of lower ATc concentrations induced faster and achieved the highest 
GFP levels after ATc removal, whereas the recombinants cultured in the presence of higher 
concentrations of ATc induced at a lower rate and produced lower levels of GFP. This may be 
because TetR1.12 repressor protein-ATc complex binds the operator sequences fairly strongly 
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and irreversibly. Thus at higher concentrations of ATc almost all the operator sequences are 
bound inhibiting expression of GFP. This was consistent with the data generated by Mayat 
(2009)264 (reviewed in section 3.1). Also a trend was observed in M. smegmatis, in which there 
was a correlation between the GFP levels and growth phase in the presence and absence of ATc 
(Figures 3.8 and 3.9). The increase in GFP expression during stationary phase growth (12 - 24 
hrs) may have resulted from variations in Psmyc promoter activity. We assume that Psmyc promoter 
expression might be highest during late stationary growth phase.   
 
There were no significant differences between the systems harbouring the pNM3 (tetO2 operator 
sequences) and those harbouring the pNM4 (tetO1 operator sequences) in both mycobacterial 
strains. This was unexpected as the affinities of the TetRr1.12 repressor for the tetO1 and tetO2 
operators are not identical 197, 226. We expected the ATc-TetRr1.12 complexes to bind more 
strongly to the tetO2 and inhibit the expression more intensely, i.e the pNM3 systems to be more 
repressed than the pNM4 systems, and the ATc-TetRr1.12 complexes to dissociate from the 
tetO1 faster and more efficiently, i.e the pNM4 systems to induce faster than the pNM3 systems 
after ATc removal. However, our results were in agreement with the results reported by Mayat 
(2009)264 when she compared the promoter-operator designs in her multicopy episomal system 
(containing the tetRr1.7 gene). She reported that the levels of GFP expression in the pNM3 and 
pNM4 systems were comparable.  
 
The ability of the TetRr1.12 systems to maintain vector genetic stability over a number of culture 
generations in the presence of ATc, and post ATc removal should allow preparation of stable 
vaccines on a large scale and ensure that the vaccines will be intact upon vaccination of the 
animal models and produce sufficient antigen to induce a good immune response. As reviewed in 
Chapter 1, over-expression of a recombinant antigen results in a metabolic load within the host 
cell, which leads to genetic instability of the vaccine vector and a decrease in the growth rate of 
the recombinants. On solid media increased metabolic load is indicated by the reduction in 
relative colony size 167, 272. Genetic stability assessment was analysed after passaging the 
recombinants for many generations (42 generations in M. smegmatis and 49 generations in BCG 
ΔpanCD) with regulation (ATc+) and without regulation (ATc-). In the absence of ATc, rM. 
smegmatis became genetically unstable, which was depicted by the decrease in the number of 
fluorescing colonies overtime. Plasmid instability was observed following restriction enzyme 
mapping as <56% of plasmids isolated from recombinants harbouring the tetRr1.12 gene in the 
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same orientation as the gfp gene and <2% harbouring the tetRr1.12 gene in the opposite 
orientation to the gfp gene were genetically intact (Figure 3.10). Instability occurred as early as 
after the 7
th
 culture generation. In BCG ΔpanCD, the recombinant colonies produced after 7 
generations were comparable to those produced in its presence in terms of size (Figure 3.14), 
indicating that the induced systems were still genetically intact and the metabolic load had not 
built up. However after 49 generations most of the colonies were fluorescing strongly and were 
smaller in size (Figure 3.15), which was an indication of GFP over-expression and thus evidence 
of metabolic load. Plasmid mapping revealed that instability occurred after the 35
th
 culture 
generation in all rBCG ΔpanCD systems, 76 - 81% recombinants harbouring the tetRr1.12 gene 
in the same orientation as the gfp gene and 57 - 74% recombinants harbouring the tetRr1.12 gene 
in the opposite orientation to the gfp gene remained genetically intact. Without regulation 
instability was expected as our systems were vectored by an episomal vector and the 
recombinant antigen was expressed from a strong promoter. Several studies have demonstrated 
in vitro instability displayed by episomal-based rBCG vaccines expressing HIV and SIV 
antigens (Reviewed in Chapter 1). Mederle et al., (2002)95 used the pAL5000-derived replicative 
and the Ms6-derived integrative vectors to generate a rBCG expressing SIV antigens. Although 
the integrative rBCG expressed lower levels of the antigens, it was genetically more stable both 
in vitro and in vivo, whereas the episomal rBCG displayed low genetic stability and rapidly lost 
the plasmid in vivo.  
 
The presence of ATc on the other hand lessened genetic instability. In M. smegmatis there was 
no drastic decrease in the number of fluorescing colonies after 42 generations (Figure 3.10), and 
no colony size reduction was observed. No genetic instability was observed following restriction 
enzyme mapping of plasmid DNA isolated from rM. smegmatis. In BCG ΔpanCD the presence 
of ATc reduced the expression of GFP as signified by low fluorescence intensity, which reduced 
metabolic load and as a result recombinant colonies appeared large and healthy even after 
several generations (Figure 3.15). Furthermore, the rBCG ΔpanCD maintained genetic stability 
for 49 generations as DNA mapping of the plasmids confirmed 100% genetic stability. 
 
In the repression study of rBCG ΔpanCD the results obtained in liquid medium did not 
completely correlate with those obtained on solid medium, i.e. the colonies (solid medium) 
fluoresced brightly in the presence of 2.0 µg/ml ATc (Figure 3.13), whereas low fluorimetry 
readings (liquid medium) were observed in the presence of the same amount of ATc (Figure 
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3.14). Three rationales could explain the differences in results obtained from these two assays. 
The first could be that the amount of active ATc molecules available to repress the recombinants 
were constantly high in liquid media since ATc was added freshly when cultures were passaged, 
whereas on solid media ATc was only added once and the plates were incubated for 4 weeks 
during which time the ATc might have become inactive. There do not seem to be any 
publications on the half-life of ATc in mycobacteria, however it is 6 hours in humans (37
o
C) 273. 
The second could be the dilution of ATc molecules as several numbers of generations of 
bacterial growth occur to form each colony and the rate of diffusion of ATc in solid media may 
be slower than in liquid media, which could result in a lower concentration of ATc around 
mycobactetial colonies on plates as compared to in cultures. The third could be that the 
fluorimetry assay is a more sensitive method than the visualization over UV light. 
 
Overall, our data showed different trends displayed by the TetRr1.12 systems in terms of foreign 
gene expression and genetic instability in M. smegmatis and BCG ΔpanCD. We showed that in 
the absence of ATc, the recombinants over-expressed GFP, which increased toxicity or the 
metabolic load on the cell and in turn slowed down the growth rate. These results were in 
agreement with those reported by Mayat (2009)264 when she compared the levels of GFP 
expression and colony morphology displayed by BCG ΔpanCD and Pasteur transformants 
harbouring different plasmids. She reported that colony sizes were inversely correlated to GFP 
expression levels, such that the high level of GFP expression inflicted metabolic load on the 
bacteria as the smaller colonies fluoresced very highly. Despite incomplete repression of GFP, 
the presence of the ATc reduced the metabolic load on the bacteria, which improved genetic 
stability. Plasmids, pPM3r2.1 and pPM4r2.1 were the most stable TetRr1.12 systems in both 
strains. Furthermore, the rBCG ΔpanCD systems were genetically more stable and displayed 
better induction capacity than the rM. smegmatis after removal of ATc, which was pleasing since 
this strain was to be used for generation of the vaccines expressing HIV antigens.  
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4.1. INTRODUCTION 
Sub-Saharan Africa is greatly affected by the progressive HIV endemic, where millions of 
people die annually from AIDS 274-276. There is an urgent need for a prophylactic HIV vaccine 
that would help prevent new infections and reduce the virus in the infected individuals. rBCG 
expressing HIV antigens have shown potential as good HIV vaccine candidates due to their 
persistent replication following immunization that enable them to continually stimulate the 
immune system (reviewed in Chapter 1). Most rBCG vaccines developed for HIV aim to elicit 
long-lasting antibody-mediated and T-cell-mediated immune responses in both the mucosal and 
systemic components of the immune system 106, 134. These immune responses are able to control 
chronic disease and thus may be able to control HIV viral load and limit progression to AIDS 
given that they target both cell-free and associated modes of HIV infection 143-146.  
 
BCG-based vectors have shown promise as an HIV vaccine vector since the early 1990s, 
however the circuitously linked phenomena, genetic instability and low heterologous antigen 
expression have impeded their use in clinical trials (reviewed in Chapter 1). These negative 
characteristics are thought to result in mutation of the gene of interest or the loss of the entire 
plasmid from the bacterium resulting in low or no heterologous antigen production.  
 
In the previous chapter a comprehensive description and evaluation of the construction of 
various designs of the ATc-dependent TetRr1.12 regulatory systems was given. The TetRr1.12 
regulatory systems contain the regulatory and the responsive components of the TetR system for 
stringent regulation of recombinant antigen expression, i.e. a revTetR cassette; and a strong Psmyc 
mycobacterial promoter engineered to contain tetO operator sequences. These components 
efficiently facilitated the regulation of the expression of GFP in M. smegmatis and BCG 
ΔpanCD strains. We evaluated the genetic stability and the expression capacity of the TetRr1.12 
systems in M. smegmatis and BCG ΔpanCD. Our data showed that the TetRr1.12 systems, 
pPM3r2.1 and pPM4r2.1 containing the tetRr1.12 gene in the same orientation as the gfp gene 
were the most stable in both M. smegmatis and BCG ΔpanCD strains. Thus these systems were 
selected to incorporate the HIV-1 antigens to generate the episomal multicopy HIV-TetRr1.12 
systems.  
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In this chapter we were aiming to develop a stable rBCG ΔpanCD vaccine expressing HIV 
antigens from the HIV-1 subtype C virus. We used HIV-1 subtype C, rt and gag genes because 
the HIV-1 subtype C virus is predominant in southern Africa and is also responsible for the 
majority of the HIV infections globally 277-280.  
 
The HIV gag gene encodes the HIV-1 Gag polyprotein precursor (Pr55gag) that includes the 
matrix protein (p17), the capsid protein (p24), a spacer protein (p2), the nucleocapsid protein 
(p7), spacer protein (p1) and p6 (plays a role in the release of mature HIV virions from the cell) 
281, 282. Gag is the most commonly used HIV antigen in HIV vaccine studies due to its 
conservative nature across the HIV-1 subtypes 281. The HIV rt gene is a part of the pol gene. Not 
only is the pol gene well conserved across the HIV-1 subtypes, but its products also contain 
immunodominant epitopes 283, 284. The rt gene encodes the enzyme, reverse transcriptase, an 
RNA-dependent polymerase that is important for viral replication as it transcribes a single 
stranded RNA from the virion into a double-stranded DNA proviral DNA 282. This enzyme is 
error-prone and thus increases the mutation rate of HIV, which facilitates the virus’s immune 
escape.  
 
It was recently reported that HIV Pol and Gag-specific responses are essential for effective 
cellular immunity 130, 146, 285, as studies have demonstrated that the strongest effective CTL 
specific responses are directed towards these antigens 283, 286, 287. Ramduth et al., (2005)288 
demonstrated that Gag-specific responses are the dominant CD4
+
 T-cell response to HIV and 
that the CD8
+
 T-cells to Gag are associated with lower viraemia. Consequently we utilised the 
HIV-1 genes, rt and gag in our study to construct a candidate vaccine aimed at stimulating good 
and effective CTL responses.  
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4.1.1 STUDY OBJECTIVES  
The objectives were to: 
i) generate the HIV-TetRr1.12 systems by inserting HIV-1 subtype C, rt and gag genes into 
the stable ATc-dependent TetRr1.12 regulatory systems 
ii) introduce the systems into the BCG ΔpanCD strain  
iii) expand the recombinants in vitro in the presence of ATc in order to down-regulate the 
expression of the HIV-1 antigens  
iv) remove ATc to induce the HIV-1 antigen expression  
v) prepare rBCG ΔpanCD vaccines stocks at the time point, where the highest level of 
heterologous antigen expression is achieved  
vi) compare the rBCG ΔpanCD that utilise the TetRr1.12 repressor for regulation to the 
recombinants that utilise the TetRr1.7 repressor, in terms of HIV antigen expression 
genetic stability and immunogenicity. 
The experimental plan is depicted graphically in Figure 4.1. 
 
 
Figure 4.1: A schematic illustration of the project plan for this Chapter.  
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4.2. MATERIALS AND METHODS 
4.2.1. GENERATION OF THE HIV-TETRR1.12 SHUTTLE VECTORS 
4.2.1.1. Insertion of the HIV-1 antigen genes into the TetRr1.12 plasmids  
Mayat, (2009)264 observed that the rM. smegmatis containing tetRr1.7 in the opposite direction to 
the gfp gene were less stable than those containing tetRr1.7 in the same direction as the gfp gene. 
She concluded that rM. smegmatis[pNM3.1] was the most stable system. Consequently this 
plasmid was also selected to incorporate the HIV-1 genes in order to generate the HIV-TetRr1.7 
systems. The HIV-TetRr1.7 systems were constructed by Dr Ros Chapman in our laboratory, 
whereby she removed the gfp gene from the plasmid pNM3.1 and replaced it with the HIV-1 
antigens to generate the plasmids pRC3Gag and pRC3RT (Appendix E10 & 11).  
 
TetRr1.12 plasmids, pPM3r2.1 and pPM4r2.1 (construction described in the chapter 3, maps 
shown in Appendix E6 & 8) were used to incorporate the HIV-1 antigen genes as shown in 
Figures 4.2 & 4.3. A double digest with restriction enzymes EcoRI + HpaI [Fermentas] that flank 
the gfp gene was used to excise it from the TetRr1.12 plasmids. The HIV-1 subtype C gag and rt 
genes were excised from the plasmids pRC3Gag and pRC3RT respectively, using restriction 
enzymes EcoRI + HpaI. The HIV-1 genes are linked to the V3-SV5 epitope, a 10 amino acid V3 
CTL tag and an SV5 monoclonal antibody tag. All the DNA fragments were gel purified using 
QIAquick Gel Extraction Kit [Qiagen] according to the manufacturer’s instructions and then 
ligated according to Appendix B4.  
 
4.2.1.2. Confirmation of the positive HIV-TetRr1.12 plasmids by plasmid DNA mapping 
Ligation mixes (5 µl) were transformed into E. coli (Appendix A3), cultured and the small-scale 
plasmid DNA was isolated from the cultures (Appendix B1.1). To confirm the presence of the 
HIV-1 rt and gag genes restriction enzyme mapping of plasmid DNA was performed using a 
double HpaI + XbaI and a single EcoRV restriction enzyme digest, respectively (Appendix B2). 
The confirmed HIV-TetRr1.12 plasmids were subjected to a large-scale plasmid isolation 
procedure (Appendix B1.2).  
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Figure 4.2: Illustration of the generation of the HIV-1 Gag-TetRr1.12 plasmids. The TetRr1.12 
plasmids containing the TetRr1.12 cassette in the same orientation as the GFP, pPM3r2.1 (Psmyc promoter 
with 2x tetO2) and pPM4r2.1 (Psmyc promoter with 2x tetO1) were linearized and ligated with the HIV-
1gag + V3-SV5 epitope tag from plasmid pRC3Gag to generate plasmids, pPM3Gag and pPM4Gag.  
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Figure 4.3: Illustration of the generation of the HIV-1 RT-TetRr1.12 plasmids. The TetRr1.12 
plasmids containing the TetRr1.12 cassette in the same orientation as the GFP, pPM3r2.1 (Psmyc promoter 
with 2x tetO2) and pPM4r2.1 (Psmyc promoter with 2x tetO1) were linearized and ligated with the HIV-1rt 
+ V3-SV5 epitope tag from plasmid pRC3RT to generate plasmids, pPM3RT and pPM4RT.   
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4.2.2. INTRODUCTION OF THE HIV-TETRR1.12 PLASMIDS INTO M. bovis BCG 
ΔPANCD  
Confirmed HIV-TetRr1.12 plasmids were transformed into BCG ΔpanCD. Plasmid DNA (500 
ng) was made up to a final volume of 5 l in HPLC grade H2O and electro-transformed into M. 
bovis BCG competent cells as describe in Section 3.2.3.3.  The pNM3 plasmid DNA was used as 
a positive control and 5 µl HPLC grade H2O served as a negative control for transformation. In 
addition to the HIV-TetRr1.12 plasmids, two HIV-TetRr1.7 plasmids, pRC3RT and pRC3Gag 
provided by Dr Ros Chapman were transformed into BCG ΔpanCD. Recombinant mycobacterial 
colonies were cultured in MB-7H9 media containing appropriate supplements and rBCG 
ΔpanCD[HIV-TetR] (rBCG ΔpanCD harbouring the HIV-TetRr1.12 and HIV-TetRr1.7 
plasmids) vaccine stocks were made and stored at -80 C as described in Section 3.2.3.4b. The 
genetic stability of the vaccine stocks was evaluated, by treating the stocks according to the 
procedure in Section 3.2.3.5 using the restriction enzymes listed in Table 4.1.  
Table 4.1: Restriction enzymes used for DNA mapping of the HIV-TetR plasmids  
RESTRICTION 
ENZYMES 
RESTRICTED  
PLASMID 
SITE PRODUCTS 
(BP) 
EcoRV 
 
 
 
 
XbaI + HpaI 
pPM3Gag  
pPM4Gag  
pRC3Gag 
 
 
pPM3RT  
pPM4RT  
pRC3RT 
4030, start of the TetRr1.12 gene 
6431, start of the V3-SV5 epitope tag 
 
 
 
4745 (XbaI), start of the Psmyc 
promoter 
6389 (HpaI), at the end of the V3-
SV5 epitope tag 
4232 and 2451 
4232 and 2452 
4232 and 2451 
 
 
4856 and 1644 
4856 and 1645 
4856 and 1644 
4.2.3. EVALUATION OF THE HIV-TETR PLASMID STABILITY BY DNA 
SEQUENCING  
Plasmid DNA from the rBCG ΔpanCD[HIV-TetR] vaccines was isolated as described in section 
3.2.3.5, however a large-scale plasmid isolation procedure (Appendix B1.2) was followed. The 
purified plasmid DNA was then sequenced to confirm genetic integrity. The primer binding sites 
on the plasmid maps are shown in Figure 4.4. The primer sequences are shown in Table 4.3. 
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The primers were designed with the aid of a Primer Design software IDT DNA oligoanalyzer 
and synthesised by Integrated DNA Technologies [Whitehead Scientific]. The sequencing 
procedure was performed at the University of Stellenbosch [Cape Town] and the sequences 
viewed with the Chromas v2.3 software package [Technelysium] and edited and aligned against 
constructed theoretical sequences using DNAMAN bioinformatics software [Lynnon Biosoft, 
version 4.0.0.1].  
 
A. 
 
B.  
Figure 4.4: An illustration of the primer binding sites on the HIV-TetRr1.12 plasmid maps. A. The 
GP1, GP2 and GP3 primers were used to sequence the HIV-1 gag gene; B. The RTP1, RTP2 and RTP3 
were used to sequence the HIV-RT gene containing plasmids. The FP1, FP2, FP3 and FP4 primers were 
used to sequence the tetRr1.12 gene, the hsp60 and the Psmyc promoters and the junctions on the HIV-
TetRr1.12 plasmids. 
4.2.4. ASSESSMENT OF THE REGULATION OF ANTIGEN EXPRESSION IN RBCG 
ΔPANCD[HIV-TETR]  
4.2.4.1. HIV antigen expression in the absence of anhydrotetracycline 
rBCG ΔpanCD[HIV-TetR] were cultured as described in Section 3.2.3.1, the media contained 10 
µg/ml Kan, 24 µg/ml vitamin B5 and 25 µg/ml hygromycin. Once the starter cultures had 
reached OD600 of 0.8 units, they were used to inoculate 100 ml of the same media in 1 L Schott 
bottles and placed on rollers at 37 C. Cell lysates were extracted from the cultures at 3 different 
growth phases: early logarithmic (log) (OD = 0.2 - 0.4), mid-log (OD = 0.6) and late log (OD = 
0.8) using the SDS boiling method as described in Appendix B5.2. The protein samples were 
quantified and separated by SDS-PAGE as described in Appendices B6 and B7.2.1, respectively. 
Laboratory purified proteins, RT and Gag (provided by Dr Nyasha Chin’ombe) were used as 
positive controls and the rBCG ΔpanCD[pCONEPI] cell lysate was used as a negative control.  
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Proteins were transferred to a PVDF membrane according to Appendix B7.2.2. For detection of 
the RT protein, the membranes were probed with anti-RT primary
 
antibody (ARP428) [AIDS 
Reagent Program] at a dilution of 1:5000 and then probed with an anti-goat/sheep monoclonal 
secondary antibody (A8062) [Sigma], which is linked to the alkaline phosphatase (11697 471 
001) [Roche]. For the Gag protein detection, anti-Gag primary antibody (ARP432) [AIDS 
Reagent Program] at a dilution of 1:5000 was used and probed with a goat anti-rabbit 
monoclonal secondary antibody (A3687) [Sigma], which is linked to the alkaline phosphatase.  
4.2.4.2. Repression and induction of HIV antigen expression in the presence and absence of 
anhydrotetracycline 
This experiment was designed to monitor the differences in HIV-1 antigen expression levels 
produced by the rBCG ΔpanCD[HIV-TetR] cultured in the presence and absence of ATc. 
Duplicate starter cultures of rBCG ΔpanCD[HIV-TetR] were prepared as described in Section 
3.2.3.1, the media contained appropriate supplements and  A c (2.0 µg/ml) was included in 
order to repress the expression of the HIV-1 antigens. Once the starter cultures had reached 
OD600 of 0.8 units, they were used to inoculate 100 ml of the same media in 1 L Schott bottles. 
The cultures were grown for a week. To note the repression of HIV-1 antigens, cell lysate was 
prepared from 25 ml of each culture and analysed on SDS-PAGE and Western Blotting as 
described in Appendix B7.2.  
 
The remaining cultures were split into two, each centrifuged at 4 000 rpm for 10 min at 4 C and 
the pellets were resuspended in 100 ml fresh MB-7H9 media and then centrifuged as before. The 
pellets were resuspended in 100 ml fresh media, one in MB-7H9-Kan containing ATc and the 
other in MB-7H9-Kan lacking ATc. The cultures were placed back on rollers at 37 C for another 
week, after which proteins were extracted at the different growth phases as mentioned in Section 
4.2.3.1. The protein samples were quantified and analysed by SDS-PAGE and Western Blotting.  
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4.3. RESULTS 
4.3.1. CONSTRUCTION OF THE HIV-TETRR1.12 PLASMIDS 
The most stable TetRr1.12 plasmids were pPM3r2.1 and pPM4r2.1 for the model antigen GFP 
(Chapter 3). These plasmids were therefore selected to construct the episomal multicopy HIV-
TetRr1.12 systems by removing the gfp gene and replacing it with the full length HIV-1 subtype 
C rt and gag genes as shown in Section 4.2.1.1 (Figures 4.2 & 4.3).  
 
The HIV-1 gag and rt gene were derived from those reported by Burgers et al., (2006)274. The 
HIV-1 genes were linked to the immunodominant V3-SV5 epitope, which was included to 
compare the cellular immunogenicity of different vaccines in mice in our laboratory (not part of 
this study). The V3-SV5 epitope consists of the V3-CTL tag that is derived from the HIV-1 
subtype B envelope protein, and the paramyxo-virus derived SV5 monoclonal antibody tag. The 
HIV-1 rt gene, gag gene and the V3-SV5 epitope tag were codon optimized in our laboratory for 
efficient expression in mycobacteria (Dr Helen Stutz; Dr William Bourn), synthesized and 
supplied by GeneArt  (Germany).  
 
Plasmid mapping was performed to screen for positive recombinants as described in section 
3.2.2, where small-scale plasmid DNA isolated from E. coli clones transformed with the various 
ligation mixes was subjected to restriction enzyme digests. An EcoRV digest was performed to 
confirm the presence of the gag gene, and a double XbaI + HpaI digest was performed to 
confirm the presence of the rt gene. The mapping results showed that the HIV-1 antigens had 
been inserted downstream of the Psmyc promoter generating four new HIV-TetRr1.12 plasmids, 
which are listed in Table 4.2 (plasmid maps in Appendix E12 - 15).  
4.3.2. GENERATION OF RBCG ΔPANCD[HIV-TETR] EXPRESSING HIV ANTIGENS 
The confirmed HIV-TetRr1.12 plasmids, pPM3RT, pPM3Gag, pPM4RT and pPM4Gag and the 
HIV-TetRr1.7 plasmids, pRC3RT and pRC3Gag were transformed into BCG ΔpanCD by 
electroporation. Plasmid pRC3RT contains the tetRr1.7 regulator gene orientated in the same 
direction as the HIV-1 RT gene driven by the full-length Psmyc promoter with two operator 
sequences (tetO2) situated on either side of -10. Plasmid pRC3Gag contains the tetRr1.7 
regulator gene orientated in the same direction as the HIV-1 gag gene that is driven by the full-
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length Psmyc promoter with two operator sequences (tetO2) situated on either side of the -10. 
rBCG ΔpanCD[HIV-TetR] vaccine stocks were prepared in the presence of ATc and plasmid 
DNA was isolated from the vaccine stocks and evaluated for vector stability by restriction 
enzyme mapping.  
Table 4.2: Names and constitution of the HIV-TetRr1.12 systems  
 PLASMID  
NAME 
FEATURES 
 
 
 
 
 
 
 
 
HIV-TetRr1.12  
plasmids 
pPM3RT  
 
Plasmid contains the tetRr1.12 repressor gene orientated in the 
same direction as the HIV-1 rt gene that is driven by the full-
length Psmyc promoter with two operator sequences (tetO2) 
situated on either side of -10   
 
pPM3Gag  
 
Plasmid contains the tetRr1.12 repressor gene orientated in the 
same direction as the HIV-1 gag gene that is driven by the full-
length Psmyc promoter with two operator sequences (tetO2) 
situated on either side of -10  
 
pPM4RT  
 
Plasmid contains the tetRr1.12 repressor gene orientated in the 
same direction as the HIV-1 rt gene that is driven by the full-
length Psmyc promoter with two operator sequences (tetO1) 
situated on either side of -10  
 
pPM4Gag  
 
Plasmid contains the tetRr1.12 repressor gene orientated in the 
same direction as the HIV-1 gag gene that is driven by the full-
length Psmyc promoter with two operator sequences (tetO1) 
situated on either side of -10  
 
 
A total of 20 colonies were mapped for each system, but only 10 are shown in the Figures. The 
plasmids harbouring the gag gene were very unstable. As can be seen in Figure 4.5, none of the 
plasmids produced the expected bands of 4232 bp and 2451 bp after restriction digestion with 
EcoRV as seen in the control lanes. Additionally, no rBCG ΔpanCD[pPM4Gag] transformants 
could be attained following electroporation, indicating this vector was extremely unstable.  
Mapping results of the plasmids harbouring the rt gene can be seen in Figure 4.6. The genetic 
integrity plasmids, pPM3RT and pRC3RT was verified since expected bands of 4856 bp and 
1644 bp were obtained after restriction digestion with HpaI + XbaI as seen in the control lanes 
(panels A and B). However, plasmid pPM4RT was genetically unstable as the expected band 
patterns were not obtained after the restriction digest with HpaI + XbaI (panel C).  
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A.  
                           
B.   
 
Figure 4.5: Plasmid DNA mapping of the HIV-TetR plasmids harbouring the gag gene using 
EcoRV. A. pPM3Gag: Lanes: (1 - 10) plasmid DNA isolated from rBCG vaccine stocks; (11) positive 
control pPM3Gag DNA; (12) uncut pPM3Gag plasmid; (13) 1 kb ladder [promega].  B. pRC3Gag: 
Lanes: (1)1 kb ladder; (2 - 11) plasmid DNA isolated from rBCG vaccine stocks; (12) positive control 
pRC3Gag DNA; and (13) uncut plasmid. 20 colonies of each system were mapped, but only 10 are shown 
in the figure. 
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  A. 
 
B. 
 
C. 
 
Figure 4.6: Plasmid DNA mapping of the HIV-TetR plasmids harbouring the rt gene using HpaI 
and XbaI enzymes. A. pPM3RT: Lanes: (1 - 10) plasmid DNA isolated from rBCG ΔpanCD vaccine 
stocks; (11) positive control pPM3RT DNA; (12) uncut pPM3RT plasmid; and (13) 1 kb ladder 
[promega]. B. pRC3RT: Lanes: (1 - 10) plasmid DNA isolated from rBCG vaccine stocks; (11) positive 
control pRC3RT DNA; (12) uncut pRC3RT plasmid; and (13) 1 kb ladder. C. pPM4RT: Lanes (1) 1 kb 
ladder; (2 - 11) plasmid DNA isolated from rBCG vaccine stocks; (12) positive control pPM4RT DNA; 
and (13) uncut plasmid DNA. 20 colonies of each system were mapped, but only 10 are shown in the 
figure. 
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Sequencing reactions were performed on the plasmid DNA isolated from rBCG ΔpanCD[HIV-
TetR] in order to confirm genetic integrity of the stable plasmids and identify the 
unstable/deleted regions in the unstable plasmids. The primers used are listed in Table 4.3. 
Primers RTP1, RTP2 and RTP3 were used to sequence the plasmids harbouring the rt gene as 
these primers span the entire rt gene and the restriction sites flanking it. Primers GP1, GP2 and 
GP3 that span the entire gag gene and the restriction sites flanking the gene were used to 
sequence the plasmids harbouring the gag gene. Furthermore a series of four forward primers, 
FP1, FP2, FP3 and FP4 were used to sequence all HIV-TetR plasmids since these allow for the 
sequencing of the tetRr1.12 gene, the hsp60 and the Psmyc promoters plus the junctions on the 
plasmids. 
Table 4.3: List of primers used to confirm the integrity of the HIV-TetRr1.12 by DNA sequencing. 
TEMPLATE NAME POSITION ON THE 
PLASMID MAP 
SEQUENCE 
pPM3RT/ RTP1 5329 5’-CTACTTCTCGGTGCCGC-3’ 
pPM4RT RTP2 5769 5’-TCGGCAAGCTGAACTGGA-3’ 
 RTP3 6186 5’-TCTGGTGGACCGACTACTG-3’ 
 
pPM3Gag/ GP1 5329 5’-GAAGACCCAGCAGGCCA-3’ 
pPM4Gag GP2   5929 5’-GAACTGGATGACCGACACC-3’ 
 GP3   6529 5’-CTTCAAGCAGATCCCGAACC-3’ 
 
pPM3Gag/ 
pPM4Gag 
FP1 3821 5’-TGAATATCGTGGAGCTCACC-3’ 
FP2 4182 5’-CCTGTACTGGCACGTGAAGA-3’ 
FP3 4462 5’-ATCTCGGCCGTGTCGCACTT-3’ 
FP4 4729 5’-CTCCTCTGGTTGGTACTCTA-3’ 
 
 
Sequencing confirmed the genetic integrity of the plasmids, pPM3RT and pRC3RT as output 
showed complete sequence identity to the sequences designed by the manufacturer (GeneArt ). 
Deletions on the unstable plasmids were identified. A 1170 bp fragment containing p24, p6 and 
the V3-SV5 epitope tag (Appendix D4&5) was deleted from the plasmids, pPM3Gag and 
pRC3Gag, and a 1452 bp fragment containing the rt gene and the V3-SV5 epitope tag (Appendix 
D6) was deleted from the pPM4RT plasmid. The restriction sites EcoRV (6431) on the plasmids 
harbouring gag and HpaI (6572) on plasmids harbouring rt, lie within the deleted regions, and 
thus were lost. This data explains the unexpected band patterns produced following restriction 
digests of the plasmids (Figures 4.5 and Figures 4.6 C). 
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4.3.3. THE EXPRESSION OF THE HIV-1 ANTIGENS IN RBCG ΔPANCD[HIV-TETR] IN 
THE PRESENCE AND ABSENCE OF ANHYDROTETRACYCLINE 
HIV-1 antigen expression levels were investigated by Western blot analysis. Initially antigen 
expression was evaluated in the absence of ATc. rBCG ΔpanCD were cultured without ATc and 
the cell lysates were extracted from the cultures at early log growth phase (OD = 0.2 - 0.4), mid-
log growth phase (OD = 0.6) and late log growth phase (OD = 0.8). Protein expression levels 
were analysed from the extracted lysates. Figures 4.7 and 4.8, respectively depict Western blot 
results from the rBCG ΔpanCD[HIV-TetR] systems displaying the expressed Gag and RT 
proteins. Without ATc a small quantity of Gag protein was produced by rBCG 
ΔpanCD[pPM3Gag] and rBCG ΔpanCD[pRC3Gag] during early log and mid-log growth 
phases, however there was no visible Gag protein detected during late log growth phase (Figure 
4.7). As expected the negative control, rBCG ΔpanCD [pCONEPI] did not express any HIV 
protein and the positive control, purified HIV-1 Gag produced a 56 kD protein. 
 
Figure 4.7: Detection of the Gag protein from rBCG ΔpanCD[HIV-TetR] cell lysate extracted 
during different growth phases in the absence of ATc. Roman letters represent the growth phases, i. 
Early log; ii. Mid-log; iii. Late log. Lanes 1. Dual color standard [Biorad]; 2. Negative control rBCG 
ΔpanCD[pCONEPI] cell lysate; 3. Positive control, purified HIV-1 Gag (60 ng/ml). The ARP 432 anti-
Gag antibody [Sigma] was used to detect the Gag proteins. The yellow arrow represents the HIV-1 Gag 
protein. 
Similarly the recombinants harbouring rt, rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT] showed detectable RT protein levels during the early growth phases, which 
was lost during culturing as no antigen was detected during the late-log phase (Figure 4.8). rBCG 
ΔpanCD[pPM4RT] on the other hand displayed very high instability as no detectable levels of 
RT were seen. The positive and negative controls gave expected results, rBCG ΔpanCD 
[pCONEPI] negative did not produce any detectable HIV proteins and the purified HIV-1 RT 
that served as a positive showed a very clear band of expected size (49 kD). 
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Figure 4.8: Detection of the RT protein from rBCG ΔpanCD[HIV-TetR] cell lysate extracted during 
different growth phases in the absence of ATc. Roman letters represent the growth phases, i. Early-log; 
ii. Mid-log; iii. Late-log. Lanes 1. Kaleidoscope [Biorad]; 2. positive control, purified HIV-1RT (60 
ng/ml) shown by the green arrow; 3. Negative control rBCG ΔpanCD[pCONEPI] cell lysate. ARP 428 
anti-RT antibody [Sigma] was used for detection.The red arrows represent the HIV-1 RT proteins and the 
green arrow indicates the purified HIV-1 RT protein, used as a positive control. 
 
Expression of the HIV-1 antigens was then monitored in the presence of ATc in order to assess if 
regulating the expression improved the retention of the HIV-1 genes. The rBCG were grown 
with ATc and the HIV-1 antigen expression was noted. Subsequently the cultures were divided 
into two. One culture was washed to remove ATc and the induction rate was noted to determine 
the time point at which the highest levels HIV-1 antigens were produced. The other culture was 
not washed but was also monitored from the early to the late log growth phase.  
 
Repression of the HIV-1 antigen expression was observed in the presence of ATc as shown by 
the faint bands detected at the early log growth phase (Figure 4.9). However, the systems were 
not completely repressed, which is similar to the results obtained in Chapter 3, where the rBCG  
ΔpanCD protein expression was kept at low levels in the presence of ATc. A gradual induction 
was observed after the removal of the repressor, from the washed cultures, from mid-log to late-
log growth phase. The highest levels of protein production were observed at the late-log growth 
phase. Additionally, the cultures that were not washed (ATc
+
), displayed low levels of protein 
expression during early log phase growth, which increased slightly with time, this could have 
resulted from the depletion of ATc molecules as the culture density was increasing or ATc may 
have reached its half-life. Some protein bands larger than the RT protein (Figure 4.9 B) were 
seen. These bands were probably due to non-specific binding of the primary antibody to 
myobacterial proteins in the BCG cell lysate. This could be due to the use of Freund’s complete 
adjuvant in the generation of the anti-RT antibody. Fruend’s complete adjuvant contains 
mycobacterial proteins 
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A. 
 
B.  
 
Figure 4.9: Detection of HIV-1 antigens from rBCG ΔpanCD[HIV-TetR] cell lysate extracted during different growth phases. Roman letters represent the 
growth phases, i. Early-log; ii. Mid-log; iii. Late-log. A. Detection of the Gag protein using the ARP 432 anti-Gag antibody [AIDS Reagent program]: Lanes 1. 
Dual color standard [Biorad]; 2. Positive control, purified HIV-1 Gag (60 ng/ml) shown by the yellow arrows; 3. Negative control, rBCG ΔpanCD[pCONEPI] 
cell lysate. B. Detection of the RT protein using the ARP 428 anti-RT antibody [AIDS Reagent program]: Lanes 1. Kaleidoscope [Biorad]; 2. Positive control, 
purified HIV-1 RT (60 ng/ml) shown by the green arrow; 3. Negative control, rBCG ΔpanCD[pCONEPI] cell lysate. The red arrows represent the HIV-1 RT and 
Gag proteins. 
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Figure 4.10: Overall summary of the construction and evaluation of the expression systems, from the episomal TetRr1.12 regulatory systems to the 
multicopy HIV-TetRr1.12 systems. The plasmids named with pPM3 prefix contain the full-length Psmyc promoter with two tetO2 sequences situated on either 
side of -10 and those named with pPM4 prefix contain the full-length Psmyc promoter with two tetO1 sequences situated on either side of -1.      
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4.4.  DISCUSSION  
We have successfully constructed the episomal multicopy HIV-TetRr1.12 expression systems by 
cloning the HIV-1 subtype C, rt and gag genes into the TetRr1.12 regulatory systems. The HIV-
TetRr1.7 constructs, pRC3RT and pRC3Gag were also included in the study. In all the HIV-
TetR systems the HIV-1 antigens were expressed from the inducible Psmyc promoter containing 
the tetO operator sequences, which allowed for the control of expression in vitro. All HIV-TetR 
plasmids maintained genetic stability in E. coli, however in some of the vectors structural 
instability occurred after introduction into BCG ΔpanCD, even in the presence of the ATc. The 
unstable plasmids were pPM3Gag, pRC3Gag and pPM4RT.  
 
DNA Sequencing of the unstable plasmids revealed that the HIV-1 antigens were truncated and 
the V3-SV5 epitope was completely removed from the plasmids, thus these systems were not 
used for immunogenicity assays. A similar incidence of instability was reported by Joseph et al., 
(2010)125 when they generated an rBCG expressing HIV-1 gp120 gene from a strong hsp60 
promoter. They observed deletions in the HIV-1 gp120 gene which resulted in loss of an 
immunodominant CTL epitope. The stability of the rBCG vaccine was improved by using a 
weak promoter. They hypothesized that the loss of the immunodominant epitopes represent part 
of an adaptation process of the mycobacteria to survive in the hosts as this could assist it to 
escape the host’s immune response. 
 
Evaluation of the antigen expression showed that Gag was produced at lower levels compared to 
RT, which was not surprising given the instability of the plasmids expressing Gag. Low 
production levels of Gag have been reported in other studies 107, 182. The instability of the Gag 
antigen could be attributed to the complex nature of the Gag protein and the requirement for 
post-translational processing, which would not occur in rBCG ΔpanCD. The bacteria might not 
have the necessary machinery to fold the Gag protein correctly, which could result in the build-
up of misfolded proteins within the cells that might be detrimental.  
 
The presence of ATc improved the stability of rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT], which in turn improved the expression of RT (Figure 4.8). The highest RT 
levels were obtained during the late-log growth phase, a phase at which no HIV antigens were 
detected in the absence of ATc (due to instability).  
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As mentioned in Chapter 1, generally instability of the vaccine vectors occurs in episomal 
vectors expressing viral antigens from strong promoters. However instability was not expected in 
our systems in the presence of ATc since the expression of HIV antigens was down-regulated 
and the data obtained in Chapter 3, indicated that although low levels of GFP expression were 
observed in the presence of 2.0 µg/ml ATc, the recombinants maintained genetic stability. The 
basal expression of the HIV antigens caused by incomplete switch-off of the Psmyc promoter by 
2.0 µg/ml ATc (Figure 4.9) could account for instability of the vectors in this case.  
 
In the induction kinetics study we observed that the levels of the HIV-1 antigens produced by the 
stable recombinants after ATc was removed were similar to those produced by the stable 
recombinants that were not induced (Figure 4.9). This was unexpected as we expected the rBCG 
ΔpanCD containing ATc to remain repressed. This may have been caused by insufficient ATc in 
the cultures, which may have resulted from the dilution of ATc molecules as the culture density 
was increasing or ATc may have reached its half-life.  
 
Overall, the presence of ATc improved the stability of the rBCG ΔpanCD expressing the HIV-1 
RT antigen. In addition, there was no significant difference in antigen expression levels between 
the rBCG ΔpanCD harbouring the HIV-TetRr1.12 systems and those harbouring the HIV-
TetRr1.7 systems. 
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CHAPTER 5: IMMUNOGENICITY STUDIES OF RBCG HIV-1 SUBTYPE C 
VACCINE IN BALB/C MICE 
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5.1. INTRODUCTION 
The current study explored the use of a controllable rBCG expressing the HIV-1 RT antigen as 
an effective vaccine to induce a protective immune response. In the previous chapter we 
generated various designs of an episomal multicopy HIV-1-TetR system that harbour the HIV-1 
RT antigen under the control of an inducible Psmyc promoter. The HIV-1-TetR systems contain 
the components of the TetR system to stringently regulate expression of the HIV antigens. This 
regulation mechanism is ATc-dependent, such that if ATc is added to the culture, it binds to the 
TetR repressor and forms the ATc-TetR complex. The formation of the complex changes the 
structural conformation of the TetR repressor, which enables it to bind to the Psmyc promoter on 
the tetO operator sequences. The occupation of the tetO operators shuts down the Psmyc promoter 
activity and thus the expression of the antigen is suppressed. This repression of the HIV-1 
antigen expression prevents the occurrence of metabolic burden during in vitro preparation of the 
vaccine stocks. The repression is then removed by washing ATc from the cultures to detach it 
from the TetR repressor. These results in the dissociation of the ATc-TetR complex from the 
tetO operators and subsequently the Psmyc promoter is activated which results in HIV-1 antigen 
expression.  
 
Stability analysis of the HIV-1-TetR systems indicated that the rBCG ΔpanCD[pPM3RT] and 
rBCG ΔpanCD[pRC3RT] were the most stable systems. Consequently these were selected to 
generate rBCG HIV-1 subtype C vaccines for immunogenicity studies. The repression of the 
HIV-1 RT antigen was mediated by the TetRr1.12 repressor in rBCG ΔpanCD[pPM3RT] and by 
the TetRr1.7 repressor in rBCG ΔpanCD[pRC3RT].  
 
Hypothetically this rBCG vaccine invention will enable the vaccines to remain stable in vitro and 
in vivo, and provide the host with an adequate HIV antigen load after vaccination to elicit an 
effective immune response. The implementation of the TetR system concept in rBCG HIV 
vaccine development is novel and intended to contribute effectively towards an rBCG HIV-1 
subtype C vaccine development. 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
109 
 
5.1.1. STUDY OBJECTIVES  
Two sets of rBCG ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT] vaccine stocks were 
prepared, the first was the induced batch, whereby ATc was removed to up-regulate the 
expression prior to vaccination. The second batch was the uninduced, whereby ATc was not 
removed. The objective was to investigate and compare the immune response of BALB/c mice to 
these vaccines for providing usefulness of the concept of the HIV-1-TetR system-based strategy. 
The mice were primed with the rBCG vaccines and boosted with a recombinant pox virus 
vaccine expressing a matching antigen. The experimental plan is depicted graphically in Figure 
5.1. 
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Figure 5.1: A schematic illustration of the vaccination regimen of BALB/c mice:  rBCG HIV-1 subtype C vaccine prime, SAAVI MVA-C boost. The 
vaccines are listed in Table 5.1.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
111 
 
5.2. MATERIALS AND METHODS 
5.2.1.  PREPARATION OF RBCG HIV-1 SUBTYPE C VACCINE STOCKS  
The stable rBCG ΔpanCD[HIV-TetR] systems harbouring pPM3RT and pRC3RT plasmids 
(Appendix E14 & 15) generated in chapter 4 were used to prepare vaccine stocks. Cultures of 
rBCG ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT] were prepared in selective MB-7H9 
media containing 10 µg/ml Kan, 2 µg/ml ATc, 24 µg/ml vitamin B5 and 25 µg/ml hygromycin. 
A week later the cultures (OD600 of 0.8) were centrifuged at 4 000 rpm for 10 min at 4 C and the 
pellets were resuspended in fresh MB-7H9 media and centrifuged as before, this step was 
performed to wash off ATc. The pellets were then resuspended in 100 ml fresh media either with 
or without ATc. The cultures were placed back on rollers at 37 C, grown to an OD600 of 
approximately 0.6 (mid to late - log growth phase). The rBCG HIV-1 subtype C vaccine stocks 
were then prepared by centrifuging the cultures at 4 000 rpm for 10 min at 4 C and resuspending 
the pellets in 5 ml resuspension buffer. The absorbance adjusted to a final OD600 of 10 using 
resuspension buffer. Aliquots of the vaccine stocks were frozen at -80°C. Vaccine stocks of 
rBCG ΔpanCD[pCONEPI] were prepared as a negative control. In addition, a multi-gene HIV-1 
subtype C recombinant MVA vaccine, SAAVI MVA-C was used as a vaccine boost 289, 290. The 
vaccines are listed in Table 5.1. 
 
Prior to vaccination, aliquots of the vaccine stocks were defrosted on ice, and diluted to the 
required dose dilutions with resuspension buffer. Vaccine dose was based on the absorbance 
readings. One absorbance unit was taken to be equivalent to 1x10
7cfu/100μl bacteria 99. 
5.2.2.  VACCINATION REGIME FOR BALB/C MICE: RBCG ΔPANCD PRIME - SAAVI 
MVA-C BOOST  
The female BALB/c mice (4 - 6 weeks of age) were purchased from the South Africa Vaccine 
Producers Pty Ltd (Johannesburg, South Africa). They were housed in the University of Cape 
Town Animal Unit (University of Cape Town, South Africa) for 10 days to acclimatise before 
vaccination. Vaccination and further handling were performed by Mr R. Lucas. Ethics approval 
for the experiments was obtained from the University of Cape Town Research Ethics Committee 
(Approval number: ref 007/017A).  
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Table 5.1: Names and features of the vaccine vectors used to vaccinate BALB/c mice 
VACCINE VECTORS FEATURES 
rBCG ΔpanCD[pPM3RT]  
 
Plasmid contains the tetRr1.12  regulator gene orientated in the same 
direction as the HIV-1 RT gene that is driven by the full-length Psmyc 
promoter with two operators (tetO2) sequences situated on either side of 
-35   
 
rBCG ΔpanCD[pRC3RT]  
 
Plasmid contains the tetRr1.7 regulator gene orientated in the same 
direction as the HIV-1 RT gene that is driven by the full-length Psmyc 
promoter with two operators (tetO2) sequences situated on either side of 
-35  
 
rBCG ΔpanCD[pPM3RT]+ 
 
rBCG ΔpanCD[pPM3RT] cultured with ATc  
 
rBCG ΔpanCD[pRC3RT]+ 
 
rBCG ΔpanCD[pRC3RT] cultured with ATc  
 
rBCG ΔpanCD[pCONEPI]   
 
Empty vector control, expressing no HIV antigen 
 
SAAVI MVA-C  
 
A double recombinant, produced by inserting Grttn (HIV-1 subtype C 
genes, gag, reverse transcriptase, tat, and nef) and gp150 (a truncated 
HIV-1 subtype C env) into two different sites in MVA. The Env protein 
has a C-terminus BALB/c mouse CD8 epitope from the HIV-1 subtype 
B envelope protein (V3-CTL) with amino acid sequence which 
corresponds to the amino acid sequence of the NIH  CD8 tag on the 
rBCG vaccines expressing the RT antigen274 
 
 
For the experiments, mice were divided into 6 groups with 5 mice per group, and 5 groups were 
each given a rBCG ΔpanCD vaccine or control vaccine (Table 5.1) at a dose of 1 x 107 cfu in 
200 µl of resuspension buffer via intraperitoneal injection on Day 0. The mice were boosted 28 
days later with 10
4
 plaque forming units (pfu) SAAVI MVA-C in 100 µl PBS [Gibco], with 50 
µl injected into each quadriceps muscle. The sixth group of the mice was vaccinated with 
SAAVI MVA-C only at a dose of 10
4
 pfu in 100 µl PBS, with 50 µl injected into each 
quadriceps muscle on day 28. The experiment was ended on day 40. All mouse groups were 
killed by cervical dislocation without anaesthesia, the spleens were harvested and five spleens 
from the same group were pooled for isolation of a single cell suspension of splenocytes.  
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5.2.3. IMMUNOGENICITY ASSAYS 
5.2.3.1. Preparation of mouse splenocytes 
The following procedure was performed to generate a single cell suspension of splenocytes from 
the spleens under sterile conditions. The spleens (1 spleen/10 ml RPMI [Gibco]) were poured 
into a cell strainer (70 µm) placed in a petri dish and mashed with a 2 ml syringe rubber plunger 
[Sigma]. The cell suspension was transferred to a 50 ml centrifuge tube [Falcon]. The petri dish 
was washed with 10 ml RPMI to collect residual cells, then added to the cell suspension. The cell 
suspension was made up to 50 ml with RPMI and centrifuged at 1 500 rpm for 5 min to pellet the 
cells. The supernatant was discarded and the cell pellet was resuspended in 50 ml of RPMI. The 
cells were then washed twice with 50 ml of RPMI (before centrifuging the cells at the last wash, 
fibrin clots were removed using a pasture pipette to ensure that any extracellular matter was 
eliminated). The supernatant was discarded and the pellet resuspended in a final volume of 50 ml 
RPMI. The red blood cells (RBC) were lysed by addition of 1 ml of the RBC lysis buffer 
(Appendix C3) to the 1 ml of splenocyte suspension. The suspension was mixed gently, 
centrifuged as before, and then the supernatant was removed and the cell pellet was resuspended 
in 1 ml R10 medium (Appendix C1).  
 
Cell counts were performed and viability determined as follows: a 1:10 dilution of the 
suspension was made in Trypan Blue (T8154) [Sigma] and Turks (Appendix C2), and counted in 
a Neubauer counting chamber [Superior, Germany]. The cell concentration in the suspension 
was calculated and adjusted to the appropriate cell concentration required for Enzyme Linked 
Immunospot (ELISPOT) assay and Fluorescence-activated cell sorting (FACS) by adjusting the 
volume.  
5.2.3.2. Detection of IFN-γ secreting HIV specific splenocytes using ELISPOT assay 
An IFN-γ ELISPOT assay was used to determine the frequency of HIV-specific cells producing 
IFN-  in the splenocyte population in response to stimulation with the MHC class II-restricted 
CD4 peptide (RT-CD4), the H-2Kd-restricted RT peptide (RT-CD8) and V3-CTL CD8 (from 
HIV-1 subtype B) peptides (Table 5.2).  
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5.2.3.3. Coating ELISPOT plates with the capture antibody 
The IFN-  assay was carried out using the BD Biosciences kit according to the manufacturer’s 
manual. The 96 well plates [BD Biosciences, USA] were pre-wetted with 35% Ethanol (15 
µl/well) for 60 seconds and then washed three times with 200 µl of PBS. The plates were coated 
with capture antibody (anti-IFN-  at 5 µg/ml in PBS), 100 µl of the diluted antibody was added 
per well. The plates were then sealed and incubated overnight at 4 C. The coating antibody was 
discarded and the wells were washed once with 200 µl/well blocking solution (Appendix C2). 
Blocking solution (200 µl/well) was added and the plates incubated for 2 hrs at room 
temperature.  
Table 5.2: Stimulants and peptides used in the ELISPOT assay (all peptides were > 95% pure from 
Bachem) 
STIMULANT CONCENTRATION/ 
REACTION 
DESCRIPTION PEPTIDE SEQUENCE 
R10 medium only N/A No antigen 
(background  
response) 
 
N/A 
Irrelevant peptide  2 µg/ml Negative peptide 
control 
 
-H-TXSTVASSL-OH- 
V3-CTL CD8 
peptide 
 
2 µg/ml  -RGPGRAFVTI- 
RT-CD8 peptide 
 
2 µg/ml  -VYYDPSKDLIA- 
RT-CD4 peptide 
 
2 µg/ml  -PKVKQWPLTEVKIKAL 
TAI- 
BCG Pasteur lysate 5 µg protein/ml Response to vector 
 
N/A 
ConA
a 
 1 µg/ml Non-specific 
polyclonal stimulus 
positive control 
N/A 
a 
ConA: Concavalin A [Sigma, MO, USA] 
BCG Pasteur lysate: [Appendix B5.1] 
N/A: Not applicable 
5.2.3.4. Plating of the splenocytes and peptides  
After blocking for 2 hr, the blocking solution was discarded and the wells were plated in 
triplicate with splenocytes (100 µl/well of the cell suspension, that is, 0.5 x 10
6 
cells/well). The 
peptides and other stimulants listed in Table 5.2 were added (100 µl/well) to triplicate wells. A 
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lysate of BCG was used to determine responses to the vector. Concavalin A (ConA) was used as 
a positive control and the irrelevant peptide was used as a negative control.  
 
The plates were then covered with the lids and aluminium foil and incubated at 37 C with 5% 
CO2. After 24 hr incubation, the IFN-  ELISPOT plates were processed to detect IFN-  forming 
units. The well contents were discarded and wells were washed twice with 200 µl/well of 
deionized H2O (wells were allowed to soak for 3 - 5 minutes at each wash step). Wells were 
washed three times with wash buffer I (Appendix C3) (the washes were programmed on the 
ELx50 Auto Strip Plate Washer [Analytic and Diagnostic Products, SA]). Excess wash buffer 
from the wells was removed by blotting the plate on a piece of paper towel. 
 
5.2.3.5. Plate development 
To detect spots, the detection antibody, biotinylated anti-IFN-  was diluted in dilution buffer 
(Appendix C3) to 2 µg/ml and added to the plates at 100 µl/well. The plates were sealed and 
incubated at room temperature for 2 hrs. The detection antibody solution was then discarded and 
the wells were washed three times with Wash buffer I. Avidin-horseradish peroxidise (Avidin-
HRP) [BioCom Biotechnology, SA] was diluted 1:100 in dilution buffer and 100 µl/ well was 
added to the plates. The plates were incubated for 1 hr at room temperature. The avidin-HRP 
solution was discarded and the plates were washed three times with Wash buffer I followed by 
another three washes with Wash buffer II (Appendix C3). The Nova Red Substrate solution 
(Appendix C2) was prepared and added to the plates, 100 µl/well. The spots were allowed to 
develop for 5 - 10 min in the dark. The development of the spots was stopped by washing the 
cells with cold running tap water (5 - 6 washes). The plates were air-dried at room temperature 
overnight and stored in the dark until analysis.  
The plates were scanned using the ELISPOT CTL Analyzer [Series 3B) and the number of spots 
enumerated using computerized Immunospot Image Analyzer [Cellular Technology Ltd] with 
Immunospot Version 3.2 software. For each reaction, the mean number of spots from triplicate 
wells and standard deviation (SD) of this mean were calculated and adjusted to spot forming 
units (sfu)/10
6
 splenocytes. The mean number of spots and its SD in the absence of peptide or in 
the presence of an irrelevant peptide for each group was used as a background response for the 
group and were subtracted from the response to the HIV-1 peptides. Responses of the 
splenocytes to the HIV-1 peptides in each group were considered positive if ≥ 1.5 fold the 
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individual peptide response for a prime with the control BCG ΔpanCD and SAAVI MVA-C 
boost.  
5.2.4. QUANTIFICATION OF CYTOKINES SECRETED BY SPLENOCYTES USING 
CYTOKINE BEAD ARRAY (CBA) ASSAY 
The CBA employs a number of inert particles with different fluorescent intensities that are 
coated with specific anti-cytokine antibodies and can be used simultaneously to detect multiple 
cytokines in a single specimen. The splenocytes (1.5 x 10
6 
cells/299 µl/well) were cultured with 
the HIV-1 peptides (Table 5.2) for 48 hrs and the cytokine content of the extracellular 
supernatant was determined using a Mouse Inflammation Cytokine Bead Array (CBA) kit [BD 
Pharmingen] according to manufacturer’s manual that allowed for detection of the amount of 
IFN-γ, TNF-α , IL-6, IL-10, MCP-1, and IL-12p70 released during culture of splenocytes with 
the RT-CD8 peptide, the RT-CD4 peptide or the V3-CTL CD8 peptide.  
 
A six bead population with distinct fluorescence intensities have been coated with capture 
antibodies specific for the proteins listed above and mixed together to form the CBA, which is 
resolved in the FL3 channel of the BD FACSCalibur
TM
 flow cytometer. Cytokine standards from 
0 - 5000 pg cytokine/ml that were provided in the kit were prepared for each cytokine by serial 
dilutions. Capture beads (50 µl/sample) were added to the appropriate test or standard tubes. Test 
sample or standard, 50 µl, was then added to the capture beads, followed by the addition of 50 µl 
of the Mouse Inflammation PE detection reagent. The assay tubes were incubated for 2 hrs at 
room temperature in the dark. A volume of 1 ml of Wash buffer I (Appendix C3) was added to 
each assay tube and centrifuged at 1500 rpm for 5 min. The supernatant was discarded and the 
bead pellets suspended in 300 µl of the wash buffer I. The samples were vortexed and analyzed 
on the BD FACSCalibur  [BD BioSciences, USA] with the BD CBA software. The standard 
curves for the cytokines were then generated. The results were calculated as pg cytokine per 10
6
 
splenocytes.  
 
Background cytokine responses in the absence of peptide or in response to the irrelevant peptide 
were not more than 5 pg per 10
6
 splenocytes. Cytokine values obtained with the individual 
peptide stimuli for the prime-boost regimen were considered positive if ≥ 1.5-fold above the 
response for a prime with the control BCG ΔpanCD and SAAVI MVA-C boost.  
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5.2.5. DETERMINATION OF LYMPHOCYTE PHENOTYPES IN THE SPLENOCYTE 
POPULATION POST VACCINATION USING FLOW CYTOMETRY 
T and B cell proportions in the splenocyte population were determined using specific fluorescent 
antibodies that bind to receptors on B- and T-cells. The detection was done using flow 
cytometry. Cell surface receptors were stained with a fluorescent antibody mix listed in Table 
5.3. A suspension of 1 x 10
6
 splenocytes were added into a 50 ml skirted tube [Falcon], 25 µl 
blocking solution was added to each tube and mixed. The tubes were then incubated on ice for 
20 min. The cells were washed with 1 ml FACS buffer (Appendix C3) and centrifuged at 1500 
rpm for 5 min. The supernatants were discarded and the cells were resuspended in the residual 
FACS buffer (small amount of FACS buffer left in the tubes after centrifugation).  
 
A volume of 50 µl of the fluorescent antibody mix was added into each tube, mixed and 
incubated on ice in the dark for 30 min. The cells were then washed t ice in 2 ml of the FACS 
buffer and resuspended in the residual volume of the FACS buffer. FACS buffer (400 µl) was 
added to each tube and then the cells were acquired using a BD FACSCalibur  [BD 
BioSciences, USA]. The data was analysed using DB Cell-quest Pro software. 
Table 5.3: Fluorescing Antibodies used to detect cell surface receptors.  
ANTIBODIES DILUTION IN FACS BUFFER 
CD3-APC 1:50 
CD8-PerCP 1:50 
CD4-FITC 1:400 
CD19-PE 1:50 
  
These antibodies were previously titrated and confirmed to stain optimally at the following dilutions.  
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5.2.6. RECOVERY OF RBCG ΔPANCD FROM MOUSE SPLEENS AND DETECTION OF 
THE PLASMID INSERT 
Following plating for the ELISPOT assay, rBCG present in the remaining splenocyte 
suspensions was grown and assessed for the presence of the plasmid used to transform the 
bacteria. For this the splenocytes from Section 5.2.3 were centrifuged at 1 200 rpm for 10 min 
and diluted 1:1 and 1:2 in resuspension buffer. These samples were then plated on MB-7H10 
agar (containing 24 µg/ml vitamin B5, 25 µg/ml hygromycin and 10 µg/ml Kan. The plates were 
incubated at 37 C for 3.5 - 4 weeks.  
 
From the resulting rBCG ΔpanCD colonies, 5 colonies were picked from each vaccination 
group. The rBCG ΔpanCD colonies were mechanically lysed to release plasmid DNA using the 
Fastprep procedure. Approximately 100 µl of Silica/Zirconia beads (0.1 mm) [BioSpec] were 
added to the bottom of the 2 ml screw top eppendorf tubes [BioSpec]. A single colony of 
rBCGΔpanCD resuspended in 100 µl of HPLC H2O was added to the beads and mixed. The 
tubes were placed in a Fastprep machine [Southern Cross Biotechnology] and spun at speed 6 for 
40 sec (the step was repeated twice). The contents were then centrifuged at 14 000 rpm for 5 min 
and the supernatant, containing plasmid DNA was transferred into a new 1.5 ml eppendorf tube 
[Merck]. 
 
Plasmid DNA was electroporated into E. coli as described in Appendix A5. Four colonies from 
each transformations were picked off the plates and cultured as described in Section 3.2.2.1. 
Thus, 20 plasmid DNA samples were generated from each splenocyte suspension (vaccine 
group). The small-scale plasmid DNA was isolated from the cultures according to Appendix 
B1.1 and restriction enzyme mapping was performed as described in Appendix B2. An HpaI + 
XbaI double digest was used to confirm the size of the plasmid containing the RT gene to 
confirm genetic stability of the plasmids. A XhoI digest was used to confirm the pCONEPI 
harbouring plasmids. 
5.2.7. STATISTICAL ANALYSES 
IFN-γ ELISPOT responses to an individual peptide induced by each of the rBCG ΔpanCD 
vaccines were statistically analyzed using Student’s t test for unpaired data and p values of <0.05 
were considered significant. 
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5.3. RESULTS 
5.3.1.  IMMUNOGENICITY OF THE RBCG HIV-1 SUBTYPE C VACCINE VECTOR 
EXPRESSING THE RT ANTIGEN  
Immune responses of mice to the vaccines, rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT] were studied since these vaccines displayed good vector stability and 
consistent expression of HIV-1 antigens (Chapter 4). rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT] were cultured in vitro by growing in the presence of ATc for 1 week to 
ensure the HIV-1 RT antigen expression was repressed. The cultures were then washed and half 
were grown in the presence of ATc (ΔpanCD[pPM3RT]+ and rBCG ΔpanCD[pRC3RT]+) and 
half in the absence of ATc (ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT]). Vaccine stocks 
were prepared when the cultures reached mid to late log growth.  
5.3.1.1. Assessment of the cellular immune responses in spleens 
BALB/c mice were used to examine the rBCG ΔpanCD immunogenicity, since these animals 
carry the BCG-s (sensitive) allele that makes them sensitive to BCG infection 93, 99. The mice 
were primed with rBCG ΔpanCD via the intraperitoneal route. A dose of 1 x 107cfu was used, as 
previous studies carried out in our laboratory where doses of 1 x 10
3
, 1 x 10
5
, 1 x 10
7
 and 1 x 10
8
 
cfu were compared (unpublished data) indicated that a dose of 1 x 10
7
cfu BCG induced the 
highest number of HIV antigen-specific T cells. The rBCG vaccine vector replicates slowly and 
this site of immunization is well tolerated as it allows BCG replication and stimulation of the 
immune response without causing any abscess. Mice were boosted 28 days later via the 
intramuscular route with SAAVI MVA-C 290.  
 
The frequency of antigen specific RT-CD8, RT-CD4 and V3-CTL CD8 cells induced in mice 
after vaccination were evaluated 12 days after the SAAVI MVA-C boost using an IFN-γ 
ELISPOT assay. Peptide IFN-  ELISPOT responses to a rBCG ΔpanCD vaccine prime and 
SAAVI MVA-C boost of > 1.5 fold that of the peptide response to the control rBCG 
ΔpanCD[pCONEPI]-prime and SAAVI MVA-C-boost regimen were considered positive 
responses and occurring as a result of the boost. Additionally, the responses in the absence of 
peptide (R10 medium only) and an irrelevant peptide served as background responses for the 
assay and were less than 7 ± 4 sfu/10
6
 splenocytes and were subtracted from the response to the 
stimulant.  
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As can be seen in Figure 5.2 panel IFN-γ ELISPOT responses were induced in vaccinated mice. 
The responses to the three peptides varied in magnitude. A prime with the rBCG 
ΔpanCD[pPM3RT] vaccine and a boost with SAAVI MVA-C yielded an average response of 
858 ± 14 sfu/10
6
 splenocytes to the V3-CTL CD8 peptide which was 3-fold above the response 
induced by a rBCG ΔpanCD[pCONEPI] prime and SAAVI MVA-C boost. A prime with the 
rBCG ΔpanCD[pRC3RT] vaccine and a boost with SAAVI MVA-C yielded an average response 
of 1183 ± 20 sfu/10
6
 splenocytes to the V3-CTL CD8 peptide which was 4.2-fold higher than 
that induced by the rBCG ΔpanCD[pCONEPI] prime and SAAVI MVA-C boost. RT-CD8 
peptide responses induced by a prime with rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT] and SAAVI MVA-C boost ranged from 132  to 232 ± 10 sfu/106 
splenocytes, which was 3.3 - 5.6-fold above the responses induced by a rBCG 
ΔpanCD[pCONEPI] prime and SAAVI MVA-C boost. Responses to the RT-CD4 peptide 
ranged from 90  to 193 ± 10 sfu/10
6
 splenocytes, which was 1.1 - 2.4-fold above the responses 
induced by a rBCG ΔpanCD[pCONEPI] prime and SAAVI MVA-C boost. These responses to 
the RT-CD8 and RT-CD4 peptides were weaker than the responses to the V3-CTL peptide 
suggesting these RT epitopes were subdominant to the V3-CTL epitope. Thus when the 
cumulative response to the HIV peptides is considered, rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT] can be concluded to be  immunogenic in that they primed the immune 
system to a boost with SAAVI MVA-C. 
 
The effect of growing the vaccines in the presence of ATc and not removing it prior to 
vaccination on immune response was evaluated. As shown in Figure 5.2 panel A, the responses 
elicited by the rBCG ΔpanCD[pPM3RT]+ and rBCG ΔpanCD[pRC3RT]+ to HIV-1 peptides 
were not different from those induced by rBCG ΔpanCD[pPM3RT] and rBCG 
ΔpanCD[pRC3RT], p = 0.2500 (value for the V3-CTL peptide). Additionally, there were no 
significant differences between the responses induced to the RT peptide (p > 0.05). Thus 
removing ATc from the vaccines prior to vaccination did not alter the immune response 
significantly.  
 
The immunogenicity of the rBCG HIV-1 subtype C vaccine experiment was repeated to assess 
reproducibility of the results. However, in this experiment only the rBCG ΔpanCD[pPM3RT] 
and rBCG ΔpanCD[pRC3RT]  vaccines were tested. The results in Figure 5.2 panel B are the 
average of two independent experiments. The same trends of immune responses were obtained 
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as those shown in Figure 5.2 panel A, as both vaccines displayed good priming immunogenicity 
and the V3-CTL CD8 epitope induced the strongest responses.  
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Figure 5.2: IFN-  ELISPOT responses induced by the rBCG HIV-1 subtype C vaccines grown in 
absence and presence (+) of ATc. The IFN-  ELISPOT responses were determined on day 40 in mice 
after priming with the rBCG HIV-1 RT vaccines (107 cfu) on day 0 and boosting with SAAVI MVA-C 
(104 pfu) on day 28. A. Bars represent the mean response of triplicate reactions to the indicated peptides 
and the standard deviation of the mean response, for a single experiment. B. Bars represent the mean 
responses from 2 independent experiments. For both A and B, IFN-γ ELISPOT responses to an individual 
peptide induced by each of the rBCG ΔpanCD vaccines were statistically analyzed using the Student’s t 
test for unpaired data and p values were found to be > 0.05, indicating thus that there is no significant 
difference in the responses to the peptides induced by the individual vaccines. 
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The magnitude of the responses stimulated by the rBCG ΔpanCD vaccines harbouring the 
tetRr1.7 mutant was compared to those stimulated by the rBCG ΔpanCD vaccines harbouring 
tetRr1.12 mutant. As can be seen in Figure 5.2 the V3-CTL CD8 responses induced by tetRr1.7 
harbouring rBCG ΔpanCD vaccines were approximately 1.3-fold stronger than those induced by 
the tetRr1.12 harbouring rBCG ΔpanCD vaccines. However these responses are not significantly 
different as p = 0.1250 (panel B).  
 
The V3-CTL and RT IFN-γ ELISPOT responses induced by a rBCG ΔpanCD[pCONEPI] prime 
and SAAVI MVA-C boost were lower than those induced by SAAVI MVA-C alone (Figure 
5.3). When mice were primed with the control BCG ΔpanCD and boosted with SAAVI MVA-C 
the response to the V3-CTL peptide was 2.2-fold lower, to the RT-CD8 peptide 5.0-fold lower 
and to the RT-CD4 peptide 2.5-fold lower than the responses observed with only a SAAVI 
MVA-C vaccination and no rBCG ΔpanCD vaccine prime. This indicates that BCG infection 
leads to suppression of immune responses to SAAVI MVA-C. 
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Figure 5.3: IFN-  ELISPOT responses induced by the rBCG ΔpanCD[pCONEPI] prime plus 
SAAVI MVA-C boost and responses induced by SAAVI MVA-C alone. The IFN-  ELISPOT 
responses were determined on day 40 in mice after priming with the rBCG ΔpanCD[pCONEPI] vaccine 
(107 cfu) on day 0 and boosting with SAAVI MVA-C (104 pfu) on day 28. The group of the mice that was 
vaccinated with SAAVI MVA-C only was vaccinated on day 28. Bars represent the mean responses from 
3 independent experiments. Statistical analysis was done using the Student’s t test for unpaired data and p 
values were found to be > 0.05, indicating that there were significant differences in the responses to the 
peptides induced by the different vaccine combinations. 
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In the IFN-γ ELISPOT assay the non-specific polyclonal stimulant ConA was used as a positive 
control. Splenocytes from all groups of vaccinated mice responded to ConA to a level of 800-
1000 sfu/10
6
 splenocytes (data not shown). These results fit with similar data available in the 
Immunology laboratory (University of Cape Town). Responses induced to the BCG vector were 
monitored using a lysate of BCG as the stimulant. All the rBCG ΔpanCD vaccines used to prime 
the immune system induced BCG responses to a level of 450 - 560 sfu/10
6
 splenocytes (Figure 
5.4). As can be seen in the Figure, there were no significant differences between the responses 
induced by rBCG ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT] in the presence or absence 
of ATc. 
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Figure 5.4: IFN-γ ELISPOT assay responses induced on day 40 after a prime with the indicated 
rBCG ΔpanCD vaccines (107 cfu, i.p.) on day 0 and boost with SAAVI-MVA C (104 pfu; i.p.) on day 
28. Bars represent the mean response of triplicate reactions to the indicated peptides and the standard 
deviation of the mean response, for a single experiment. 
5.3.1.2. Assessment of the cytokines released by the splenocytes 
The CBA assay was used to quantify a spectrum of cytokines released into the culture 
supernatant during stimulation with RT-CD4, RT-CD8 and V3-CTL CD8 peptides. Figure 5.5 
shows data for the four different rBCG ΔpanCD vaccinations and SAAVI MVA-C boost. The 
V3-CTL CD8 cells produced predominantly IFN-γ following priming with rBCG 
ΔpanCD[pRC3RT], rBCG ΔpanCD[pPM3RT]+ or rBCG ΔpanCD[pRC3RT]+ vaccines and 
boosting with MVA as the level was 1.5 times greater than that of a prime with the control rBCG 
ΔpanCD[pCONEPI] and SAAVI MVA-C boost (panel A). TNF-α was also produced 
predominantly from the V3-CTL CD8 specific cells and was positive for the following vaccine 
regimens, the prime with rBCG ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT] and SAAVI  
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Figure 5.5: Cytokines measured (pg cytokine released /10
6
 splenocytes) in the supernatant 
harvested from splenocyte cultures that have been stimulated for 48 h with the indicated HIV-1 
peptides.  Mice were primed with the rBCG ΔpanCD (colour coded) vaccines and then boosted on day 
28 with SAAVI MVA-C. Dark green group received SAAVI MVA-C only on day 28. Splenocytes 
prepared on day 40 from a pool of spleens for each group (5 mice per group) were stimulated in culture 
with the indicated peptide. Culture supernatants were collected 48 h later. The cytokines released in the 
supernatant were determined using a CBA assay.  
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MVA-C boost as the level was 1.5 times greater than that of a prime with the control rBCG 
ΔpanCD[pCONEPI]  and SAAVI MVA-C boost (panel B). No inflammatory HIV specific IL-6, 
MPC-1, IL-10, and IL-12p70 was detected in the culture supernatant from any of the rBCG 
ΔpanCD vaccine prime SAAVI MVA-C boost regimens.  
 
Splenocytes from mice vaccinated with SAAVI MVA-C only produced IFN-γ and TNF-α when 
stimulated with the V3-CTL CD8 and RT-CD4 peptide and TNF-α only when stimulated with 
the RT-CD8 peptide (Figure 5.5 panel A). No IL-6, IL-10, MCP-1 or IL-12p70 was detected 
(data not shown).  ConA was used to stimulate the cells non-specifically as a positive control for 
cytokine release. ConA stimulation of splenocytes for all mouse groups produced IFN-γ, TNF-α, 
IL-6, IL-10, MCP-1 in the culture supernatant. IL-12p70 was not produced since this cytokine is 
produced by dendritic cells that are not sensitive to ConA (data not shown). 
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Figure 5.6: Cytokines measured (pg cytokine released /10
6
 splenocytes) in the supernatant 
harvested from the 48 h BCG stimulated splenocyte cultures. Mice were primed with the rBCG 
ΔpanCD vaccines (colour coded) and then boosted on day 28 with SAAVI MVA-C. Dark green group 
received SAAVI MVA-C only on day 28. Splenocytes prepared on day 40 from a pool of spleens for each 
group (5 mice per group) were stimulated in culture with BCG lysate. Culture supernatants were collected 
48 h later. The cytokines released in the supernatant was determined using a CBA assay. 
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The CBA assay was able to detect IFN-γ, TNF-α, IL-6, IL-10 and MCP-10 in the culture 
supernatant from splenocytes stimulated with BCG lysate, whereas IL-12p70 could not be 
detected in the culture supernatant (Figure 5.6). This is thought to be because the BCG lysate is 
not pure and may contain endotoxins and cross reactive antigens that would account for this 
response. Splenocytes from mice vaccinated with SAAVI-MVA-C have been shown to release 
cytokines in response to stimulation with BCG lysate in other experiments carried out by 
members of our research group too. 
 
5.3.2. SPLENOCYTE NUMBERS AND LYMPHOCYTE PHENOTYPE AFTER 
VACCINATION  
The phenotype of lymphocytes in the spleens was determined by flow cytometry after staining 
the cells with specific fluorescent antibodies that label CD3 T-cells and the CD4 and CD8 T-cell 
subsets as well as B-cells. Shown in Table 5.4 are the splenocyte numbers and lymphocyte 
phenotype. The naïve mice data was obtained from other studies in our Immunology laboratory 
(University of Cape Town). In comparison to the naive group, it is clear that the rBCG ΔpanCD 
vaccination increased the total number of cells in the spleen. This was seen for all groups primed 
with the rBCG ΔpanCD vaccines. In addition priming with the rBCG ΔpanCD vaccines, rBCG 
ΔpanCD[pPM3RT] and rBCG ΔpanCD[pRC3RT] did not alter the proportion of CD4 and CD8 
T-cells, as indicted by the CD4/CD8 ratio, from that of naïve mice. This was confirmed (data not 
shown) with splenocytes from 2 further experiments where these vaccines were used (the 
splenocytes were used in the ELISPOT assay data given in Figure 5.2). A prime with rBCG 
∆panCD[pPM3RT]+ and rBCG ΔpanCD[pRC3RT]+ appeared to increase the CD4/CD8 T-cell 
ratio. However these vaccines were not tested further to confirm this change.  
5.3.3. CONFIRMATION OF THE GENETIC INTEGRITY OF THE RBCG HIV-1 
SUBTYPE C VACCINE VECTORS POST IMMUNIZATION  
To verify the stability of the rBCG ΔpanCD vaccines, the splenocytes suspensions isolated from 
the mouse spleens 40-days post vaccination were diluted appropriately and plated in the presence 
and absence of antibiotic selection. There was very little or no difference in the number of rBCG 
ΔpanCD colonies grown in the presence or absence of antibiotic selection, indicating that very 
little or no plasmid loss from the rBCG ΔpanCD had occurred. 
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Table 5.4: The percentage of B- and T-cells in the mice spleens of the groups vaccinated with the respective rBCG ΔpanCD vaccines (Table 5.1).  
VACCINE NEGATIVE CD3 CD3/CD4 CD3/CD8 CD4/CD8 
RATIO 
CD19 CELL/SPLEEN 
(x10
6
) 
 
rBCG ΔpanCD[pPM3RT]  
 
11.9 
 
36.1 
 
24.0 
 
11.1 
 
2.2 
 
52.0 
 
118 
 
rBCG ΔpanCD[pRC3RT]  13.3 40.9 27.5 12.6 2.2 45.8 83 
 
rBCG ΔpanCD[pPM3RT]+ 11.8 39.6 31.3 7.7 4.1 48.6 80 
 
rBCG ΔpanCD[pRC3RT]+ 14.2 42.4 31.1 10.3 3.0 43.4 107 
 
rBCG ΔpanCD[pCONEPI]   13.5 38.0 25.5 11.6 2.2 48.5 96 
 
SAAVI MVA-C  18.1 42.6 28.3 13.4 2.1 39.3 46 
 
Naïve mice  15.9  41.4  28.3  12.3  2.3  42.7  45  
The splenocytes obtained were stained with CD3-APC, CD4-FITC, CD8-PerCP and CD19-PE fluorescing antibodies and analysed with BD FACS Calibur . 
These splenocytes were used in the IFN-γ ELISPOT assay, data shown in Figure 5.2A, and the CBA assay, data shown in Figure 5.4, and assessment of responses 
to BCG lysate, Figure 5.3 and 5.5. 
NEGATIVE: The cells that did not bind to the fluorescing antibodies. 
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To confirm the genetic integrity of the rBCG ΔpanCD vaccines, plasmid DNA was isolated from 
rBCG ΔpanCD colonies. The DNA was subjected to restriction enzyme mapping using 
restriction enzymes. The plasmid DNA isolated from the rBCG HIV-1 subtype C vaccine vectors 
produced the expected banding patterns after a XbaI + HpaI double digest, however the bands 
did not align exactly with the control DNA (Figures 5.7 and 5.8). Consequently plasmid DNA 
samples from the vaccines were cleaned using the MinElute reaction clean-up kit [Qiagen] and 
then remapped. The results are shown in Figure 5.9, expected band sizes of 4856 bp and 1644 bp 
were obtained, which aligned exactly with the control plasmid DNA (two maps from each 
vaccine are shown). The rBCG ΔpanCD[pCONEPI] appeared to be intact since expected 2259 
bp and 1814 bp fragments (produced when the pCONEPI plasmid is digested with XhoI) were 
obtained after restriction digest with this enzyme (Figure 5.10). 
A. 
 
 
 
B. 
 
 
Figure 5.7: Mapping of plasmid DNA extracted from rBCG ΔpanCD[pPM3RT] vaccines isolated 
from mice splenocyte cultures 40 days post vaccination using HpaI and XbaI. A. rBCG 
ΔpanCD[pPM3RT]: Lanes, (1) 1 kb ladder [Fermentas]; (2 - 21) plasmid DNA isolated from rBCG 
ΔpanCD vaccines; (22) purified pPM3RT plasmid DNA; and (23) uncut pPM3RT plasmid DNA. B. 
rBCG ΔpanCD[pPM3RT]+: Lanes, (1) 1 kb ladder [Fermentas]; (2 - 21) plasmid DNA isolated from 
rBCG ΔpanCD vaccines; (22) purified pPM3RT plasmid DNA; and (23) uncut pPM3RT plasmid DNA. 
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A. 
 
 
 
B. 
 
 
Figure 5.8: Mapping of plasmid DNA extracted from rBCG ΔpanCD[pRC3RT] vaccines isolated 
from mice splenocyte cultures 40 days post vaccination using HpaI and XbaI. A. rBCG 
ΔpanCD[pRC3RT]: Lanes, (1) 1 kb ladder [Fermentas]; (2 - 21) plasmid DNA isolated from rBCG 
ΔpanCD vaccines; (22) purified pRC3RT plasmid DNA; and (23) uncut pRC3RT plasmid DNA. B. 
rBCG ΔpanCD[pRC3RT]+: Lanes, (1) 1 kb ladder [Fermentas]; (2 - 21) plasmid DNA isolated from 
rBCG ΔpanCD vaccines; (22) purified pRC3RT plasmid DNA; and (23) uncut pRC3RT plasmid DNA.  
 
  
 
 
Figure 5.9: Mapping of plasmid DNA extracted from rBCG HIV-1 subtype C vaccines isolated 
from mice splenocyte cultures 40 days post vaccination using HpaI +XbaI. Lanes, (1) 1 kb ladder 
[Fermentas]; (2) purified pPM3RT plasmid DNA; (3) purified pRC3RT plasmid DNA; (4 - 5) plasmid 
DNA isolated from rBCG ΔpanCD[pPM3RT] vaccines; (6 - 7) plasmid DNA isolated from rBCG 
ΔpanCD[pRC3RT] vaccines; (8 - 9) plasmid DNA isolated from rBCG ΔpanCD[pPM3RT]+ vaccines 
and (10 - 11) plasmid DNA isolated from rBCG ΔpanCD[pRC3RT]+ vaccines.   
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Figure 5.10: Mapping of plasmid DNA extracted from rBCG ΔpanCD[pCONEPI] vaccine isolated 
from mice splenocyte cultures 40 days post vaccination using the XhoI digest. Lanes, (1-20) plasmid 
DNA isolated from rBCG ΔpanCD[pCONEPI] vaccines; (21) purified pCONEPI plasmid DNA; and (23) 
uncut pCONEPI plasmid DNA; and (23) 1 kb ladder [Fermentas]. 
 
5.4.  DISCUSSION 
The aim of the study was to evaluate the immunogenicity of the ATc-dependent rBCG ΔpanCD 
vaccines and was done in BALB/c mice given their common use in various studies for the testing 
of rBCG vaccines. Both cellular and humoral immune responses have been elicited in these mice 
to both the bacteria and expressed recombinant antigens 107, 112, 116, 133, 134.  
 
Immune responses to the recombinant RT antigen (tagged with a BALB/c V3-CTL CD8 peptide) 
expressed by the rBCG ΔpanCD vaccines in this study was investigated using a prime-boost 
vaccine regimen, where the rBCG ΔpanCD vaccines were used to prime the immune system and 
a recombinant pox virus vaccine expressing a matching immunogen to boost the induced primary 
immune response. This approach was based on results from several studies, where although 
modest responses to the recombinant immunogen could be detected when the rBCG vaccine was 
used on its own, high cellular responses to the recombinant protein was detected after a 
heterologous booster vaccine was administered 131, 132, 156, 159. It was concluded from these studies 
that rBCG vaccines efficiently prime the immune system and elicit immunogen-specific memory 
CD8 lymphocytes that expand in response to a boost for a heterologous vaccine. Thus the most 
efficient way of enhancing an immune response to the recombinant BCG antigen is by priming 
the immune system with an rBCG vaccine followed by a heterologous boost vaccine.  
 
The ability of rBCG to efficiently prime the immune system to the recombinant gene may be 
linked to the fact that it is a replicating vaccine. Due to its slow replication ability, BCG 
replication within the host is expected to be slow occurring over a period of 3 weeks post 
vaccination and would favour a low level of antigen expression within the bacteria together with 
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a low level of antigen presentation 7, 291, 292. Subsequently a low magnitude of antigen specific T-
cells would be induced. We suspect that such cells differentiate very soon after vaccination to the 
memory phenotype. These memory T cells expand rapidly and differentiate into effector cells 
that produce cytokines following re-exposure to the antigen via the boost 293, 294. Inflammatory 
signals from the BCG vector may also play a major role in the induction of the recombinant 
antigen-specific memory cells 295. M. smegmatis expressing HIV-1 gp120 induced antigen 
specific helper CD4 T-cells and memory CD8 T-cells 295. These memory T-cells rapidly 
expanded to recombinant adenovirus expressing the same antigen.  
 
Our rBCG HIV-1 subtype C vaccines remained genetically stable during in vitro replication of 
the vaccine vectors and post vaccination, which is important for the induction of the immune 
responses against the RT antigen that we observed. IFN-γ producing V3-CTL-specific CD8 T-
cells as well IFN-γ producing RT- specific CD8 and CD4 T-cells were generated by all the 
rBCG ΔpanCD vaccines when used as a priming vaccine and followed by a SAAVI MVA-C 
boost. The responses achieved were above those to the control, rBCG ΔpanCD[pCONEPI] prime 
and SAAVI MVA-C boost by 3 - 4.2-fold (to the V3-CTL CD8 peptide), 3.3 - 5.6-fold (to the 
RT-CD8 peptide) and 1.1 - 2.4-fold (to the RT-CD4). Our findings were in accord with data 
reported from numerous studies using rBCG as a priming vaccine together with a heterologous 
vaccine as a booster vaccine in mice 111, 131. Promkhaykaew et al., (2009)147 demonstrated 
induction of specific CTLs against the Gag epitope in BALB/c mice immunized with 
rBCG/HIV-1gagE (Chapter 1, Table 1.1). However, using the same vaccine they showed 
increased levels of CTLs that were long lasting where the animals were primed with rBCG/HIV-
1gagE and boosted with rVaccinia/HIV-1gagE (Table 1.1). Most recently Rosario et al., 
(2010)131 tested the immunogenicity of their novel candidate vaccine, rBCG expressing an HIV-1 
clade A-derived immunogen in BALB/c mice and rhesus macaques. On its own the rBCG 
induced very weak T-cell responses, whereas as a prime followed by a boost with recombinant 
MVA and ovine adenovirus expressing the same immunogen, the vaccine induced robust HIV-1-
specific T-cell responses. Generally the BCG primed heterologous boost regimen increases 
vaccine take by the host by boosting the pathogen insert-specific responses whilst avoiding the 
accumulation of anti-vector immunity 125. 
 
Ideally the vaccines should induce a durable HIV-1-specific cell-mediated immune response as 
these responses have been associated with the anti-viral effect 146, 283, 296. Vaccine specific 
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polyfunctional CD8
+
 T-cells (CTLs) can be predicted to be beneficial for protection against viral 
infection based on the role HIV-specific CD8 T-cells play in the control of viral infection in SIV 
infected non-human primates 144, 297-299. Virus-specific CTLs are also considered to control 
viremia in HIV infected humans 145, 146, 296. Virus-specific CTLs mediate the anti-HIV immunity 
by killing the infected CD4 T-cells 146.  
 
Even though the CD4 T- helper cells are the primary HIV infected cells, uninfected CD4 T-
helper cells found during the long asymptomatic phase function to help maintain an effective 
immunity against the virus 300-302. Additionally, the role of CD4 T-cells can be both through 
direct and indirect protection, since HIV specific CTLs decline overtime when virus-specific 
CD4
+
 T-cells have been depleted. The RV 144 HIV vaccine trial in Thialand in 2009 has 
indicated that HIV specific CD4 T-cells appear to play an important role in protection 303. Thus 
we can deduce from our results that the rBCG ΔpanCD vaccines could have the potential to 
control the viral infection seeing that they were able to induce these responses.  
 
Valor et al., (2008)296 reported that the ability of CD8 T-cells to produce cytokines is one of the 
main ways in which they display their cytotoxic activity, as the cells producing these cytokines 
have been associated with cytotoxic activity in HIV-1 infected individuals. Furthermore, 
cytokines released from HIV-specific cells in response to stimulation with HIV peptides defines 
the anti-viral effector functions of the vaccine induced cells as well as whether the vaccine 
induced response is predominantly a Th1 or Th2 response. In the CBA assay, the HIV-1 peptide-
specific lymphocytes induced by the rBCG ΔpanCD vaccine prime SAAVI MVA-C boost 
regimens produced mainly IFN-  and TNF-α cytokines, and no peptide specific IL-10 was 
produced (Figure 5.5), indicating that the HIV response was predominantly Th1. These results 
were in agreement with many rBCG studies that have demonstrated that Th1 cytokines, 
particularly IFN-  and TNF-α, are produced in response to the recombinant antigen subsequent 
to rBCG vaccination 102, 105-108. The mechanisms that lead to the induction of predominantly Th1 
cytokine production following rBCG immunization were reviewed in Chapter 1. 
 
The immune response is influenced by the quantity of the recombinant antigen presented to the 
host, which in turn is influenced by the antigen expression levels within the vaccine 291, 292. In our 
system the levels of the antigen expression were influenced by the induction kinetics of the 
rBCG ΔpanCD vaccines after removal of ATc. In Chapter 4 we demonstrated that the 
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recombinant antigen levels produced in rBCG ΔpanCD after removing ATc were equivalent to 
the levels produced in rBCG ΔpanCD containing ATc (Figure 4.9). It is expected that the rBCG 
ΔpanCD vaccines that contained ATc and those without ATc produced comparable levels of the 
HIV-1 RT antigen within the mice, and hence it was not surprising the vaccines displayed 
similar immunogenicity. This also indicates that the vaccines could be produced without having 
to remove ATc before vaccination of the animals. 
 
The V3-CTL and RT responses induced by a rBCG ΔpanCD[pCONEPI] prime and SAAVI 
MVA-C boost were lower than those induced by the control SAAVI MVA-C boost only (Figure 
5.3). The expression of suppressor of cytokine signalling (SOCS) could account for the reduction 
in responses to the SAAVI MVA-C boost following a BCG prime. Imai et al., (2003)304 reported 
that BCG infection induces the production of SOCS in dendritic cells and macrophages as well 
as SOCS negative regulators of IFN-  signal transduction, and that this correlates with the 
suppression of activation of non-receptor tyrosine kinases, Janus kinase 1 and 2 and 
phosphorylation of the signal transducer and activator of transcription 1 (JAK/STAT) signalling 
stimulated by IFN-  and thus results in a poor immune response.On the other hand the responses 
induced in the SAAVI MVA-C vaccinated mice were not suppressed and consequently were 
very high.  
 
The data obtained from genetic stability evaluation confirmed that the rBCG ΔpanCD vaccines 
recovered from the spleens 40-days post vaccination were genetically intact since they retained 
both the antibiotic resistant gene as well as the HIV-1 rt gene.  
 
Overall, this experiment demonstrated that our rBCG HIV-1 subtype C vaccines could remain 
stable within the host and deliver T cell epitopes to the MHC class I and II molecules for 
processing and presentation to the CD8 and CD4 cells. Additionally, it was established that the 
levels of IFN-γ induced after priming with rBCG ΔpanCD[pRC3RT], harbouring the tetRr1.7 
mutant were above those induced after priming with rBCG ΔpanCD[pPM3RT], containing the 
tetRr1.12, however this was not significant. This data indicates that the vaccines harbouring the 
TetRr1.7 repressor and those harbouring the TetRr1.12 repressor were similar in terms of 
immunogenicity.
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CHAPTER 6: SUMMARY AND CONCLUSION 
In this study a TetRr1.12 dependant regulatory system was constructed, which consisted of the 
regulatory and the responsive components of the TetR system for stringent regulation, i.e. a 
TetRr1.12 repressor; and a strong Psmyc mycobacterial promoter engineered to contain tetO 
operator sequences. This system was designed to regulate the expression of the recombinant HIV 
antigens in M. bovis BCG ΔpanCD in the presence of the co-repressor, ATc. We aimed to apply 
the regulatory system to vaccine design, such that the recombinant antigen expression is 
repressed in vitro by the presence of ATc to ensure genetic stability during manufacture and then 
the lack of ATc will result in higher antigen expression in vivo in order to elicit strong immune 
responses. The tetracycline regulated system (harbouring the Tet system) has been employed in 
vaccine design 305, however, the tetracycline inducible system was used thus the vaccinees have 
to be given tetracycline to activate the expression of the vaccine antigens, which is undesirable. 
In this current study we employed the reverse tetracycline regulated system in rBCG ΔpanCD 
expressing GFP or HIV-1 antigens, which is novel. In this system recombinant antigen 
expression occurs in the absence of tetracycline, so vaccinees do not have to be given 
tetracycline.  
 
By assessing the TetRr1.12 system in M. smegmatis and BCG ΔpanCD using GFP as a model 
antigen, we confirmed that the levels of GFP expressed could be modified by varying the amount 
of ATc. The minimum ATc concentration required to repress GFP expression was determined. 
The induction of GFP expression upon ATc removal was poor in M. smegmatis none of the 
recombinants showed maximal induction, whereas rBCG ΔpanCD showed complete induction, 
This data indicates that the TetRr1.12 system would be ideal for repression and gene silencing 
studies, as Ehrt et al., 2005, Kamionka et al., 2005 and Gandotra et al., 2007200, 222, 255 have shown 
using the TetRr1.7 repressor.  
 
The stability assessment of the recombinants showed that in vitro regulation of the recombinant 
antigen expression improved genetic stability when GFP and HIV-1 RT were used as the 
antigens. However, the recombinants expressing the Gag antigen were not stable. Increasing the 
concentration of ATc in the cultures during vaccine preparation to 3.0 µg/ml would have 
completely repressed Gag expression, which may have improved stability of the recombinants. 
However, following removal of ATc (at 3.0 µg/ml) induction of recombinant expression was 
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slow and did not reach maximal levels. This revTetR regulatory system will need further 
optimisation to be used as a rBCG-based AIDS vaccine to ensure stable rBCG vaccines 
expressing HIV-1 Gag and envelope can be generated. 
 
Klotzsche et al., (2009)198 have constructed two new revTetRs, TetR#27 and TetR#28 that 
repress the expression of the target gene more efficiently than the TetRr1.7 repressor in the 
presence of ATc. These repressors may suppress expression of HIV-Gag sufficiently to allow the 
preparation of stable vaccine stocks. However, Klotzsche et al., (2009)198 did not evaluate the 
induction of the expression of the target gene upon removal of ATc. Thus maximal levels of the 
target gene induction following ATc removal may also be difficult to achieve using the TetR#27 
and TetR#28 repressors, as we have found using the TetRr1.7 and TetRr1.12 repressors. 
 
Having tested the TetRr1.12 system we established that proper functioning lies in the 
combination of the intensity of repression in the presence of ATc and subsequent induction upon 
its removal, which is influenced by the following factors: 
 The ATc concentration.  
 The amount of TetRr1.12 repressor produced, which depends on the strength of the 
promoter responsible for its expression (Guo et al., 2007)197.  
 Affinity of the repressor for the tetO operators in the presence of ATc, since it influences 
the release of the TetRr1.12 repressor from the tetO operators upon ATc removal. 
 The orientation of insertion of the TetRr1.12 expression cassette relative to the 
recombinant antigen, as placing the cassette in the same orientation as the recombinant 
antigen improved the stability of the systems. 
Investigation of the immunogenicity of rBCG ΔpanCD vaccines expressing RT in BALB/c mice 
showed that the vaccines were immunogenic, as antigen-specific intracellular IFN-  expression 
was induced in mice splenocytes in response to stimulation with HIV-1 peptides following a 
prime with rBCG ΔpanCD vaccines and a boost with SAAVI MVA-C. These results indicate 
that we overcame the challenges of low antigen expression caused by genetic instability that can 
lead to the weak immunogenicity usually associated with expression of viral antigens in BCG. 
As the rBCG ∆panCD strain shows limited replication in vivo it may be suitable for 
administration to HIV-infected individuals. Development of a vaccine against both tuberculosis 
and HIV would be highly beneficial in the developing world. Thus futures studies using this 
system could include the development of a dual HIV/TB vaccine. 
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APPENDICES 
 
APPENDIX A: STRAINS AND CULTURE TECHNIQUES 
 
A1 Culturing conditions of E. coli 
E. coli DH5α strain from our laboratory stocks was used for plasmid DNA replication. E. coli DH5α was 
grown on 2YT agar (Appendix C) at 37oC and propagated in 2YT broth (Appendix C) at 37°C on shakers 
for aeration. Recombinant E. coli clones were grown in 2YT broth supplemented with 25 µg/ml Kan 
[Sigma-Aldrich]. For plasmid selection, cells were plated on 2YT agar supplemented with 25 µg/ml Kan 
and incubated overnight at 37°C. 
 
A2 E. coli competent cells preparation  
E. coli cells were made competent using a modification of the dimethyl sulphoxide (DMSO) method by 
Chung and Miller in 1988306. A single colony of E. coli was picked off a freshly streaked 2YT agar plate, 
used to inoculate 5 ml of 2YT broth without antibiotic selection and incubated overnight at 37°C. The 
culture was diluted 1:100 in 100 ml of 2YT broth and propagated for approximately 3 hrs to early log 
phase (OD600 0.2 - 0.4). The cells were harvested by centrifugation at 5000 rpm for 5 min at 4°C. The 
pellet was resuspended in 1:10 volume (10 ml) of ice-cold sterile TSB buffer (Appendix C). The cells 
were placed on ice for 10 min and either transformed with plasmids immediately or stored in sterile 
glycerol to a final concentration of 10% v/v in 100 µl aliquots at -80°C. 
 
A3 Transformation of plasmid DNA into E. coli 
The standard cold-shock transformation methodology was used for transformation into E. coli cells 307. 
The glycerol stock aliquots of competent cells (100 l) were thawed on ice. Plasmid DNA (0.1 - 100 ng) 
was mixed with the cells and placed on ice immediately and incubated for 20 min. The cells were heat-
shocked at 37°C for 5 min. A volume of 1 ml 2YT broth pre-warmed to room temperature was added.  
The vials were incubated at 37°C for 60 min to allow for expression of the antibiotic resistance marker. 
During this incubation step, the tubes were gently mixed by inversion three to four times. Aliquots of 50 
µl, 100 µl and 200 µl were plated onto the appropriate selective 2YT solid media. The remaining 
transformation mix was pelleted, resuspended in 100 µl 2YT broth and plated as well. 
 
A4 Preparation of E. coli electro-competent cells 
A single colony of E. coli was picked off a freshly streaked LB agar plate, used to inoculate 5 ml of LB 
broth (Appendix C) and incubated overnight at 37°C. The culture was diluted 1:1000 in 100 ml of LB 
broth pre-warmed to 37°C and propagated at 37°C. At mid-log phase (OD600 = 0.8) the culture was 
divided into 2 in 50 ml sterile tubes and centrifuged at 4000 rpm at 4°C for 20 min. The supernatants 
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were discarded. The cells were washed twice by, resuspending the pellets in 50 ml of 10% glycerol, 
centrifuging at 4000 rpm at 4°C for 20 min and discarding the supernatants. After washing, each pellet 
was resuspended in 25 ml of 10% glycerol. The cells were then pooled into 50 ml sterile tube, centrifuged 
at 4000 rpm at 4°C for 20 min and resuspended in 2 ml of 10% glycerol.  The cell suspension was 
aliquoted in volumes of 100 µl in 1.5 ml sterile eppendorf tubes [Merck] and stored at -80°C. 
 
A5 Electroporation into E. coli 
The Gene Pulser  [Bio-Rad] set at Resistance: 200 ohms, Voltage: 2.5 kV, Capacitance: 125 μFD was 
used to electroporate the cells.  The glycerol stock aliquots of E. coli electro-competent cells (100 l) 
were thawed on ice. Plasmid DNA (5 µl) was mixed with the cells and made up to a final volume of 50 l 
in 10% glycerol, transferred to a pre-chilled 0.1 mm gap cuvette [Bio-Rad] and then electroporated. A 
volume of 500 μl of SOC media (Appendix C) was added after electroporation, and the mixture was 
incubate at 37°C for 1 hr. Aliquots of 100 µl and 200 µl of the transformation cultures were plated on LB 
Agar (Appendix C) containing Kan (25 μg/ml) and incubated at 37°C overnight. 
 
 
APPENDIX B: STANDARD PROTOCOLS 
 
B1 Plasmid isolation 
B1.1 Small-scale plasmid isolation procedure  
Small-scale plasmid DNA isolations were performed using the alkaline lysis method 308. Single E. coli 
bacterial colonies were used to inoculate 800 µl 2YT medium containing Kan (25 μg/ml) in 1.5 ml 
eppendorf tubes [Merck] and grown overnight at 37°C.  The bacteria containing tubes were centrifuged at 
14 000 rpm for 2 min at room temperature in the centrifuge 5417C [Eppendorf].  The supernatant was 
discarded and the remaining cells were resuspended in 200 μl solution I (Appendix C) and incubated at 
room temperature for 10 min.  A volume of 400 µl of solution II (Appendix C) was added to each tube of 
the resuspended cells and the tubes were placed on ice for 10 min. A volume of 300 μl of solution III 
(Appendix C) was added to each tube and mixed gently. The tubes were then placed on ice for 10 min in 
order to precipitate cell debris, protein and chromosomal DNA.  The mixture was centrifuged at 14 000 
rpm for 5 min at room temperature. A volume of 900 μl of each supernatant was transferred to a new 
eppendorf tube, to which 600 μl of isopropanol [Merck] was added and mixed. The tubes were left at 
room temperature for 2 min to allow the plasmid DNA to precipitate.  The samples were then centrifuged 
at 14 000 rpm for 15 min at room temperature to pellet plasmid DNA. The supernatants were discarded 
and the remaining pellets were washed in 0.5 ml ice cold 70% ethanol and then air dried for 5 min.  The 
pellets were dissolved in 50 μl TE buffer [Appendix C] and stored at -20°C until further required.  
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B1.2 Large-scale plasmid isolation procedure  
Plasmid DNA was isolated using the Genopure plasmid midi kit [Roche] for low-copy plasmids.  A 
single bacterial colony of E. coli containing the appropriate plasmid was inoculated into 100 ml 2YT 
broth containing Kan (25 μg/ml).  The inoculated culture was grown overnight at 37°C, shaking 
vigorously.  From the overnight culture, 700 l was removed and added to 300 l of 50% (v/v) glycerol 
for storage at –80oC in a 1.5 ml sterile eppendorf tube.  The remaining culture was harvested by 
centrifugation at 4 000 rpm in the centrifuge 5810R [Eppendorf] for 15 min at 4oC. The rest of the 
procedure was done according to manufacturer’s instructions.  For maximum plasmid recovery, 
subsequent to the elution step, 5 ml of eluent was divided into five 800 l aliquots in 2 ml eppendorf 
tubes [Merck], followed by the addition of 700 l of isopropanol to each tube to precipitate plasmid DNA 
and then centrifugation at 15000 rpm for 15 min at 4 C. Supernatant was removed, each pellet washed 
with 500 l of 70% ethanol and the tubes were then centrifuged at 15000 rpm for 15 min at 4 C. The 
supernatants were removed and the pellets were air dried for 10 min. Finally the pellets were resuspended 
in 50 l HPLC grade H2O, pooled and quantified using a Nanodrop Spectrophotometer [Inqaba Biotech].  
 
B2 Restriction digests 
The purified plasmid DNA was restricted with restriction endonucleases in a 1.5 ml eppendorf tube to a 
final volume of 20 l unless otherwise indicated. For a single digest, the reaction contained: 1 μl (10 U) 
enzyme, 1X reaction buffer, 500 ng DNA and H2O to make it up to 20 μl. For a double digest, the 
reaction contained: 1 μl (10 U) of each enzyme, 1X reaction buffer, 500 ng DNA and H2O to make it up 
to 20 μl. The contents were mixed by pulse spinning and incubated in a water bath at 37°C (unless 
otherwise specified) for 2 hrs.  Digested products were analyzed on a 1% agarose gel (Appendix B3).  
 
B3 Agarose gel electrophoresis 
Following any purification procedure, the integrity and concentration of DNA was confirmed on a 1% 
(w/v) mini agarose slide gel (10 ml) prepared using electrophoresis grade agarose [Sigma], dissolved in 
Tris-borate-EDTA (TBE) buffer (Appendix C) by heating and after cooling to 55oC, 0.5 µg/ml ethidium 
bromide (EtBr) (Appendix C) was added and the gel was allowed to solidify.  The mini gel was 
electrophoresed at 10 V for 15 min. Restriction digests were analysed on 1% standard agarose gels (150 
ml) for 1.5 hrs at 90 V or on maxi agarose gels (250 ml) for 1.5 hrs at 140 V using the PstI [Roche] 
digested DNA [Roche] as a marker or 1 kb size marker [Promega]. All the agarose gels were visualised 
over a UV box and digital images captured and edited with Uvipro [Uvitech Silver] equipment and 
software. 
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B4 Cloning of DNA  
The desired DNA fragments were purified from agarose gels using the QIAquick Gel Extraction Kit 
[Qiagen] according to manufacturer’s instructions. When necessary, to prevent spontaneous religation of 
the plasmid backbone, dephosphorylation reactions were performed with the Shrimp Alkaline 
Phosphatase (TSAP) [Roche] to remove 5’phosphate groups and a T4 DNA polymerase kit [Roche] was 
used for filling in 5’ overhangs with unlabelled dNTPs. Ligation reactions were performed using a T4 
DNA ligase kit [Roche] according to manufacturer’s instructions in 1.5 ml sterile eppendorf tubes and 
incubated overnight at room temperature. The vector: insert ratio used was 1:3, using plasmid DNA at 50 
ng. Plasmid DNA was purified from reaction mixes using a QIAquick Purification Kit [Qiagen] according 
to manufacturer’s instructions. 
 
B5 Protein extraction 
B5.1 Bead-beating/Fastprep method of cell free lysate preparation 
Proteins were extracted from mycobacterial cultures propagated at 37°C.  The cultures were centrifuged 
at 10 000 rpm  (25 ml per tube) for 10 min at 4 C, and the pellets were resuspended in 5 ml of ice cold 
sterile PBS pH 7.2 [Gibco].  
 
The samples were transferred into FastRNA tubes [Bio 101] containing 0.1 mm zirconia-silica beads 
[BioSpec] that had been sterilised by autoclaving, 1 ml culture per 0.5 g beads. The cells were then lysed 
using the FastPrep machine [Bio 101 MP Biomedicals]. The samples were processed for 30 seconds at 
speed 6 and then placed on ice until cool. This regime was repeated three times. The samples were then 
centrifuged at 14000 rpm at room temperature for 10 min. The supernatants were retained and centrifuged 
a second time to remove residual debris. The supernatants (cell lysates) were retained, divided into three 
aliquots and stored at -20˚C for use as a control for ELISPOT. One of these was quantified as in 
Appendix B6.  
 
B5.2 SDS boiling method 
Cultures of the selected recombinant mycobacterial colonies were prepared and grown to a desired OD. A 
volume of 20 ml from each culture was centrifuged at 4 000 rpm at room temperature for 5 min in the 
Centrifuge 5417C [Eppendorf]. The pellets were resuspended in 20 ml of PBS, centrifuged as before and 
resuspended in 250 μl SDS lysis buffer (Appendix C). Samples were then boiled for 30 min and then 
allowed to cool to room temperature before being centrifuged at 14 000 rpm for 5 min. The supernatants 
were aliquoted into fresh 1.5 ml eppendorf tubes and stored at -80˚C. Protein concentration of all samples 
was determined (Appendix B6).  
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 B6 Protein concentration determination using Bio-Rad DC protein assay  
The concentration of protein lysates was quantified using the standard Dc-Bio-Rad protein quantification 
assay kit [Bio-Rad] according to manufacturer’s instructions, which utilises the Bovine Serum Albumin 
(BSA) as a standard [Roche]. The DC protein assay is for protein concentration determination following 
detergent solubilisation and the reaction is based on the Lowry assay 309. Several dilutions of the BSA 
standard were prepared ranging from 0.1 to 2.0 g/ l in SDS lysis buffer.  The protein samples were 
diluted 10 fold in SDS lysis buffer.  
Protein lysates and BSA standards were dispensed into a 96-well flatbottom MicroWell™ plate [Greiner 
Bio-one GmBH], 5 l sample per well and each sample was loaded in triplicate.  A volume of 25 l 
Reagent A’ (Appendix C) was added to each well followed by the addition of 200 l Reagent B. SDS 
lysis buffer was used as a blank to ensure that it did not affect OD readings. The mixtures were vortexed 
and then incubated at room temperature for 15 min. The absorbances were measured at 750 nm using the 
VERSAmax microplate reader [Molecular Devices]. The microplate reader subtracted the blank values 
and plotted the standard curve using the BSA standard absorbance values. The standard curve was then 
used to determine the unknown protein concentrations by extrapolation using the absorbance values of the 
protein samples. 
 
B7 Protein Assessment Procedures 
Fluorimetry assay and Western blotting were used to assess comparative levels of protein expression 
resulting from the recombinant mycobacteria. Fluorimetry was used to assay GFP levels and SDS-PAGE 
+ Western blotting were used to determine HIV antigen expression levels.  
 
B7.1 Fluorimetry assay  
The expression of GFP was assessed with the use of the whole-cell GFP Fluorescence assay described by 
Carroll and Parish, 2004. This method detects fluorescence from the samples and thus in our case it 
measured the amount of GFP activity of the recombinant constructs. Recombinant mycobacterial cultures 
(20 - 30 ml) from the mid-logarithmic growth phase (OD = 0.5) were centrifuged at 4 000 rpm for 15 min 
in 50 ml tubes [Cording]. The pellets were resuspended in PBS to OD600 of 2 units/100 l. The samples 
were vortexed briefly and then loaded into a 96-well white Fluorimetry plate [NUNC], 100 l of sample 
per well and each sample was loaded in triplicate. PBS was loaded as a blank to ensure that it did not 
affect fluorescence readings. rM. smegmatis[pCONEPI], was used as a negative control to account for 
background interference caused by mycobacterial proteins. Fluorescence readings were taken using a 
Varian Cary Eclipse Fluorimeter [Seco Mann] set to read GFP fluorescence at an excitation wavelength 
of 485 nm and emission wavelength of 515 nm.  
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To correct for any inaccuracies encountered during the concentration process, the following calculation 
was done: OD600 readings of the sample pellets resuspended in PBS were taken to determine the 
correction factor (2OD units/ OD600 reading). Fluorimetry results were calculated by taking an average of 
the triplicate readings, multiplying it by the correction factor, subtracting the average of the rM. 
smegmatis[pCONEPI] readings, and then expressing GFP expression as relative fluorescence units (rfu). 
 
B7.2 HIV Antigen expression analysis  
B7.2.1 Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were isolated from recombinant mycobacterial cultures using the SDS boiling method 
(Appendix B5.2). Each protein sample (60 µg) was mixed with (20%) Sample buffer (Appendix C).  The 
samples were boiled for 5 min, cooled in ice and analyzed on 12.5% Criterion XT Tris acetate denaturing 
gel [Bio-Rad]. Kaleidoscope Molecular Weight Marker [Bio-Rad] was used as a standard. Purified RT 
and Gag proteins from our Laboratory were used as positive controls and cell lysate from rBCG 
ΔpanCD[pCONEPI] was used as a negative control. Initially the SDS-PAGE was run at 100 V for 20 
min, and later increased to 150 V for 55 min using 1X Tricine Running Buffer [Bio-rad].  
 
B7.2.2 Western Blotting Analysis 
Prior to protein transfer, the gels, the extra thick filter papers and the PVDF membranes were pre-treated 
in separate plastic dishes. The gels and the extra thick filter papers were equilibrated in 20 ml Transfer 
buffer (Appendix C) in small open containers for a maximum period of 30 min. The PVDF membranes 
were soaked in 20 ml 100% methanol for 2 min, the methanol was poured off and the membranes were 
then rinsed in distilled H2O with intermittent shaking. After 5 min, the water was discarded and 20 ml 
protein transfer buffer (Appendix C) was added to the membranes and left for 20 min. A TransBlot semi-
dry transfer cell [BioRad] set at 25 V for 60 min was used to transfer proteins. 
 
The membranes were briefly washed with room temperature TBS (Appendix C), and incubated in 
Ponceau S (Appendix C) for 2 min to check for proteins on the membrane and finally rinsed with distilled 
H2O.  Subsequently the membranes were incubated in Block /Wash buffer (Appendix C) on a shaker for 2 
hrs and then probed with the primary antibody diluted in Block/Wash buffer (1:5000) overnight at 4ºC, 
slightly shaking. The membranes were washed 4 times in Block/Wash buffer (4 x 15 min) at room 
temperature after which they were hybridised with the secondary antibody diluted 1:10 000 in 
Block/Wash buffer and incubated for 1 hr at room temperature. The membranes were then washed 4 
times in Block/Wash buffer (4 x 15 min) and then developed using Nitro blue tetrazolium chloride/ 5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) [Roche].  
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APPENDIX C: LIST OF MEDIA AND SOLUTIONS 
1. MEDIA 
2YT agar: 16 g tryptone powder; 10 g yeast extract; 5 g NaCl; 15 g agar per litre. 
2YT broth: 16 g tryptone powder; 10 g yeast extract; 5 g NaCl per litre. 
LB Agar: 10 g tryptone; 5 g yeast extract; 5 g NaCl2; 12 g bacto agar per litre. 
LB broth: 10 g tryptone; 5 g yeast extract; 5 g NaCl2 per litre. 
MB-7H10 agar: 19 g MB-7H9 agar [Difco]; 100 ml OADC [Biolabs]; 0.63% w/v glycerol) per litre.  
MB-7H9 broth: 4.7 g MB-7H9 broth [Difco]; 100 ml OADC [Biolabs]; 0.025% v/v tyloxapol [Sigma-
Aldrich]; 0.25% w/v glycerol per litre.  
R10: 88.9% RPMI 1640 with Glutamax [Gibco] + 10% FBS + 1% Pen/Strep; 50 µM 2-ME. 
RPMI complete: RPMI + 10% v/v FCS; 1% Pen/Strep; 10 µM/ml fungin; 50 µM 2-ME. 
SOC: 20 g tryptone; 5 g yeast extract; 0.5 g NaCl2; 1.86 g; KCl; 5 ml 1M MgCl2; 20 ml 1M glucose per 
litre. 
 
2. SOLUTIONS 
ATc: ATc powder [BDH] dissolved in HPLC H2O.  
Blocking: 1% rat serum; 1% mouse serum; CD16/CD32 mix, antibody mix in FACS buffer. 
EtBr: EtBr powder [BDH] dissolved in distilled H2O. 
GTE-lysozyme: 20 mg/ml lysozyme powder [Sigma] dissolved in GTE buffer. 
Kan: kanamycin powder [Sigma-Aldrich] dissolved in HPLC H2O.  
Nova Red Substrate [Sothern Cross]: 3 drops of Reagent 1; 2 drops Reagent 2; 2 drops Reagent 3 and 2 
drops H2O2 to 15 ml H2O. 
Pen-Strep: 10,000 units (g/ml) Penicillin; 10,000 µg /ml Streptomycin in normal saline. 
Ponceau S stain: 0.1% w/v ponceau S; 5% v/v acetic acid. 
Reagent A’: 1:50 reagent S [Bio-Rad] in reagent A [Bio-Rad]. 
Solution I: 1 M Tris-Cl pH 8.0; 20% w/v glucose; 0.5 M EDTA pH 8.0. 
Solution II: 10% SDS; 10 M NaOH. 
Solution III: 11.5% v/v glacial acetic acid; 5 M potassium acetate pH 4.8 per 100 ml. 
Turks: 0.02% w/v gentian/crystal violet; 7% v/v glacial acetic acid per 100 ml. 
 
3. BUFFERS 
Block /Wash: 1 X TBS; 0.5 % v/v Tween-20; 4 % w/v elite milk powder. 
Coating: 1x PBS pH 7.2 [Gibco]. 
Dilution: 1x PBS + 10% FBS. 
FACS: PBS containing 1% FCS and 0.1% NaN3. 
Lysis: 5 mM Tris-HCL; 140 mM NH4Cl, pH 7.3. 
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Protein transfer: 0.303% Tris; 1.44% glycine. 
SDS lysis: 3% w/v SDS; 10% v/v glycerol; 62.5 mM Tris-HCl, pH 6.8. 
Sample: 0.5 M Tris-HCL, pH 6.8; 2% SDS, 5% ß- mercaptoethanol, 15% Glycerol; 1% bromophenol 
blue. 
RBC lysis: 0.15 M NH4Cl. 10 mM KHCO3, 0.1 mM EDTA and distilled H2O [Sigma-Aldrich, SA] 
Resuspension: 8.5% w/v NaCl; 10% glycerol; 10% tyloxapol. 
TBE: 10.8 g Tris; 5.5 g boric acid; 0.5 M EDTA, pH 8.0 per litre. 
TBS: 50 mM Tris; 150 mM NaCl, pH to 7.5. 
TE: 10 mM Tris-Cl, pH 7.5; 1 mM EDTA. 
Tricine running: 20x Tricine running buffer [Biorad] diluted to 1X in distilled H2O. 
TSB: 16 g peptone powder; 11 g yeast extract powder; 5 g NaCl; 10% w/v PEG, 5%  v/v DMSO, 10 mM 
MgCl2, 10 mM MgSO4 per litre. 
TSBG: 20% w/v glucose; 100 ml TSB. 
Wash buffer I: 1x PBS - 0.05% Tween 20, pH 7.4 [Sigma]. 
Wash buffer II: 1x PBS pH 7.4 [Sigma]. 
 
 
APPENDIX D: SEQUENCES 
 
D1 TetRr1.7 protein showing the following amino acid mutations in the protein sequence:  E to A at 
position 15; L to G at position 17; L to V at position 25 
                                         M__S__R__L__D__K__S__K_ 
    _V__I__N__S__A__L__A__L__G__N__E__V__G__I__E__G__V__T__T__R_ 
    _K__L__A__Q__K__L__G__V__E__Q__P__T__L__Y__W__H__V__K__N__K_ 
    _R__A__L__L__D__A__L__A__V__E__I__L__A__R__H__H__D__Y__S__L_ 
    _P__A__A__G__E__S__W__Q__S__F__L__R__N__N__A__M__S__F__R__R_ 
    _A__L__L__R__Y__R__D__G__A__K__V__H__L__G__T__R__P__D__E__K_ 
    _Q__Y__D__T__V__E__T__Q__L__R__F__M__T__E__N__G__F__S__L__R_ 
    _D__G__L__Y__A__I__S__A__V__S__H__F__T__L__G__A__V__L__E__Q_ 
    _Q__E__H__T__A__A__L__T__D__R__P__A__A__P__D__E__N__L__P__P_ 
    _L__L__R__E__A__L__Q__I__M__D__S__D__D__G__E__Q__A__F__L__H_ 
    _G__L__E__S__L__I__R__G__F__E__V__Q__L__T__A__L__L__Q__I__V_ 
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D2 TetRr1.12 protein showing the following amino acid mutations in the protein sequence: V to G at 
position 20; G to R at position 21; I to N at position 22 
                               M__S__R__L__D__K__S__K__V__I__N__ 
    S__A__L__E__L__L__N__E__G__R__N__E__G__L__T__T__R__K__L__A__ 
    Q__K__L__G__V__E__Q__P__T__L__Y__W__H__V__K__N__K__R__A__L__                                                  
    L__D__A__L__A__V__E__I__L__A__R__H__H__D__Y__S__L__P__A__A__ 
    G__E__S__W__Q__S__F__L__R__N__N__A__M__S__F__R__R__A__L__L__ 
    R__Y__R__D__G__A__K__V__H__L__G__T__R__P__D__E__K__Q__Y__D__ 
    T__V__E__T__Q__L__R__F__M__T__E__N__G__F__S__L__R__D__G__L__ 
    Y__A__I__S__A__V__S__H__F__T__L__G__A__V__L__E__Q__Q__E__H__ 
    T__A__A__L__T__D__R__P__A__A__P__D__E__N__L__P__P__L__L__R__ 
    E__A__L__Q__I__M__D__S__D__D__G__E__Q__A__F__L__H__G__L__E__ 
    S__L__I__R__G__F__E__V__Q__L__T__A__L__L__Q__I__V__*__ 
 
 
Table D3.1: Description of the Psmyc promoter-operator sequences on the parental plasmids 
(modified Mayat, (2009)
263
). 
PLASMID 
NAME 
SEQUENCE 
LENGTH 
(BP) 
SEQUENCE FEATURES 
pNM3 199 5’-TCTAGAGGATCCTGTGCGTTCGCACGCACAGGC 
CCGGTGTGAGAAGGGTCTCTGCAGAGCGGGAGAACT 
CCCTATCAGTGATAGAGTTTGTCCTCCCTATCAGTG 
ATAGATAGGCTCTGGGAGTACCCGTGTGTACGACCA 
GCACGGCATACATCATTTCGACGCCGAGAGATTCGC 
CGCCCGAAATGAGCACGAATTC-3’ 
Full-length Psmyc 
promoter with two tetO2 
sequences situated on 
either side of -10 
 
 
 
pNM4 
 
200 
 
5’-TCTAGAGGATCCTGTGCGTTCGCACGCACAGGC 
CCGGTGTGAGAAGGGTCTCTGCAGAGCGGGAGAACA 
CTCTATCATTGATAGAGTTTGTCCACTCTATCATTG 
ATAGAGTAGGCTCTGGGAGTACCCGTGTGTACGACC 
AGCACGGCATACATCATTTCGACGCCGAGAGATTCG 
CCGCCCGAAATGAGCACGAATTC-3’ 
 
Full-length Psmyc 
promoter with two tetO1 
sequences situated on 
either side of -10 
 
 
 
Transcription start sites (+1) are boxed. 
Blue sequences represent tetO2 and those in  
Red sequences represent tetO1  
Underlined 6bp sequences represent –35 and -10 regions 
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Table D3.2: Description of the episomal TetRr1.7 dependant regulatory system designs. These 
plasmids were constructed by inserting the TetRr1.7 cassette into the pNM3 and pNM4 vector backbones. 
 PLASMID NAME FEATURES 
TetRr1.7 
plasmids 
pNM3.1 pNM3 containing the TetRr1.7 cassette in the same 
orientation as the gfp gene 
pNM3.2 pNM3 containing the TetRr1.7 cassette in the 
opposite orientation to the gfp gene 
pNM4.1 pNM4 containing the TetRr1.7 cassette in the same 
orientation as the gfp gene 
pNM4.2 pNM4 containing the TetRr1.7 cassette in the 
opposite orientation to the gfp gene 
 
 
 
D4 pPM3Gag sequence: Showing the following fragments highlighted in:  
 TetRr1.12 cassette:  pink,  
 Psmyc promoter:         blue with the operators underlined,  
 HIV-1 gag gene       yellow,  
 V3-SV5 epitope:      grey and  
The deleted fragment underlined. 
 
1      GCTAGCAACAAAGCGACGTTGTGTCTCAAAATCTCTGATGTTACATTGCACAAGATAAAA 
61     ATATATCATCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGTTA    
121    TGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATG 
181    CTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCT 
241    ATCGCTTGTATGGGAAGCCCCATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCG 
301    TTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTC 
361    TTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGA 
421    TCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTG 
481    TTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTT 
541    TTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGG 
601    TTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAG 
661    AAATGCATAATCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCAC 
721    TTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCG 
781    GAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTC 
841    CTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAAT 
901    TGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTGGTTAATTGGTTGTAAC 
961    ACTGGCAGAGCATTACGCTGACTTGACGGGACGGCGGCTTTGTTGAATAAATCGAACTTT 
1021   TGCTGAGTTGAAGGATCAGATCACGCATCTTCCCGACAACGCAGACCGTTCCGTGGCAAA 
1081   GCAAAAGTTCAAAATCACCAACTGGTCCACCTACAACAAAGCTCTCATCAACCGTGGCTC 
1141   CCTCACTTTCTGGCTGGATGATGGGGCGATTCAGGCCTGGTATGAGTCAGCAACACCTTC 
1201   TTCACGAGGCAGACCTCACTAGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG 
1261   ATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACC 
1321   GCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAC 
1381   TGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCA 
1441   CCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGT 
1501   GGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACC 
1561   GGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCG 
1621   AACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCC 
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1681   CGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCAC 
1741   GAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCT 
1801   CTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGC 
1861   CAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTT 
1921   TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATAC 
1981   CGCTCGCCGCAGCCGAACGACCGAGCGCAACGCGTGAGCCCACCAGCTCCGTAAGTTCGG 
2041   GTGCTGTGTGGCTCGTACCCGCGCATTCAGGCGGCAGGGGGTCTAACGGGTCTAAGGCGG 
2101   CGTGTACGGCCGCCACAGCGGCTCTTAGCGGCCCGGAAACGTCCTCGAAACGACGCATGT 
2161   GTTCCTCCTGGTTGGTACAGGTGGTTGGGGGTGCTCGGCTGTCGCTGGTGTTTCATCATC 
2221   AGGGCTCGACGGGAGAGCGGGGGAGTGTGCAGTTGTGGGGTGGCCCCTCAGCGAAATATC 
2281   TGACTTGGAGCTCGTGTCGGACCATACACCGGTGATTAATCGTGGTTTATTATCAAGCGT 
2341   GAGCCACGTCGCCGACGAATTTGAGCAGCTCTGGCTGCCGTACTGGTCCCTGGCAAGCGA 
2401   CGATCTGCTCGAGGGGATCTACCGCCAAAGCCGCGCGTCGGCCCTAGGCCGCCGGTACAT 
2461   CGAGGCGAACCCAACAGCGCTGGCAAACCTGCTGGTCGTGGACGTAGACCATCCAGACGC 
2521   AGCGCTCCGAGCGCTCAGCGCCCGGGGGTCCCATCCGCTGCCCAACGCGATCGTGGGCAA 
2581   TCGCGCCAACGGCCACGCACACGCAGTGTGGGCACTCAACGCCCCTGTTCCACGCACCGA 
2641   ATACGCGCGGCGTAAGCCGCTCGCATACATGGCGGCGTGCGCCGAAGGCCTTCGGCGCGC 
2701   CGTCGATGGCGACCGCAGTTACTCAGGCCTCATGACCAAAAACCCCGGCCACATCGCCTG 
2761   GGAAACGGAATGGCTCCACTCAGATCTCTACACACTCAGCCACATCGAGGCCGAGCTCGG 
2821   CGCGAACATGCCACCGCCGCGCTGGCGTCAGCAGACCACGTACAAAGCGGCTCCGACGCC 
2881   GCTAGGGCGGAATTGCGCACTGTTCGATTCCGTCAGGTTGTGGGCCTATCTTCCCGCCCT     
2941   CATGCGGATCTACCTGCCGACCCGGAACGTGGACGGACTCGGCCGCGCGATCTATGCCGA 
3001   GTGCCACGCGCGAAACGCCGAATTTCCGTGCAACGACGTGTGTCCCGGACCGCTACCGGA       
3061   CAGCGAGGTCCGCGCCATCGCCAACAGCATTTGGCGTTGGATCACAACCAAGTCGCGCAT 
3121   TTGGGCGGACGGGATCGTGGTCTACGAGGCCACACTCAGTGCGCGCCATGCGGCCATCTC 
3181   GCGGAAGGGCGCAGCAGCGCGCACGGCGGCGAGCACAGTTGCGCGGCGCGCAAAGTCCGC 
3241   GTCAGCCATGGAGGCATTGCTATGAGCGACGGCTACAGCGACGGCTACAGCGACGGCTAC 
3301   AACTGGCAGCCGACTGTCCGCAAAAAGCGGCGCGTGACCGCCGCCGAAGGCGCTCGAATC 
3361   ACCGGACTATCCGAACGCCACGTCGTCCGGCTCGTGGCGCAGGAACGCAGCGAGTGGTTC 
3421   GCCGAGCAGGCTGCACGCCGCGAACGCATCCGCGCCTATCACGACGACGAGGGCCACTCT      
3481   TGGCCGCAAACGGCCAAACATTTCGGGCTGCATCTGGACACCGTTAAGCGACTCGGCTAT 
3541   CGGGCGAGGAAAGAGCGTGCGGCAGAACAGGAAGCGGCTCAAAAGGCCCACAACGAAGCC 
3601   GACAATCCACCGCTGTTCTAACGCAATTGGGGAGCGGGTGTCGCGGGGGTTCCGTGGGGG 
3661   GTTCCGTTGCAACGGGTCGGACAGGTAAAAGTCCTGGTAGACGCTAGTTTTCTGGTTTGG 
3721   GCCATGCCTGTCTCGTTGCGTGTTTCGTTGCGTCCGTTTTGAATACCAGCCAGACGAGAC 
3781   GGGGTTCTACGAATCTTGGTCGATACCAAGCCATTTCCGCTGAATATCGTGGAGCTCACC 
3841   GCCAGAATCGGTGGTTGTGGTGATGTACGTGGCGAACTCCGTTGTAGTGCTTGTGGTGGC 
3901   ATCCGTGGCGCGGCCGCGGTACCAGATCTTTAAATGGGCGAATTGGGGCGCGCCACTAGT 
3961   CTGCAGCAAGGTCGAACGAGGGGCATGACCCGGTGCGGGGCTTCTTGCACTCGGCATAGG 
 
                EcoRV 
4021   CGAGTGCTAAGAATAACGTTGGCACTCGATATCTGACACTTGAGGAGGAGAGCAAAATTC 
4081   TCATGTCGCGCCTGGACAAGTCGAAGGTCATCAACTCGGCCCTGGAGCTGCTGAACGAGG 
4141   GCCGCAACGAGGGCCTGACCACCCGCAAGCTGGCCCAGAAGCTGGGCGTCGAGCAGCCGA 
4201   CCCTGTACTGGCACGTGAAGAACAAGCGCGCCCTGCTGGACGCCCTGGCCGTGGAGATCC 
4261   TGGCCCGCCACCACGACTACTCGCTGCCGGCCGCAGGCGAGTCGTGGCAGTCGTTCCTGC 
4321   GCAACAACGCCATGTCGTTCCGCCGCGCACTGCTGCGCTACCGCGACGGCGCGAAGGTGC 
4381   ACCTGGGCACCCGCCCCGACGAGAAGCAGTACGACACCGTGGAGACCCAACTGCGCTTCA 
4441   TGACCGAGAACGGCTTCTCGCTGCGCGACGGCCTGTACGCCATCTCGGCCGTGTCGCACT 
4501   TCACCCTGGGCGCGGTGCTGGAGCAGCAGGAGCACACCGCCGCCCTGACCGACCGCCCGG 
4561   CAGCCCCGGACGAGAACCTGCCGCCGCTGCTGCGGGAGGCCCTGCAAATCATGGACTCGG 
4621   ACGACGGCGAGCAGGCGTTCCTGCACGGCCTGGAGTCGCTGATCCGCGGCTTCGAGGTGC 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
147 
 
4681   AACTGACCGCCCTGCTGCAAATCGTGTGAGGGCCCGAGCGAGGAGCCCGGTCCCTTTGTG 
 
           XbaI 
4741   GGGCCGGGCTCCTCTGGTTGGTACTCTAGATTAATTAATCCAGCTTTTGTTCCCTCTACA 
4801   GAGCGGGAGAACTCCCTATCAGTGATAGAGTTTGTCCTCCCTATCAGTGATAGATAGGCT 
4861   CTGGGAGTACCCGTGTGTACGACCAGCACGGCATACATCATTTCGACGCCGAGAGATTCG 
        
                        EcoRI 
4921   CCGCCCGAAATGAGCACGAATTCTGACACTTGAGGAGGAGAGCAAAATTCTCATGGGTTA 
4981   CGTAATCGATATGGGCGCGCGCGCCTCGATCCTGCGCGGCGAGAAGCTGGACAAGTGGGA 
5041   AAAGATCCGCCTGCGCCCGGGCGGCAAAAAGCACTACATGCTGAAGCACATCGTGTGGGC 
5101   CTCGCGCGAGCTGGAACGCTTCGCCCTGAACCCCGGCCTGCTGGAAACCTCGGAAGGCTG 
5161   CAAGCAGATCATGAAGCAGTTGCAGCCGGCCTTGCAGACCGGCACCGAAGAGCTGAAGTC 
5221   GCTGTACAACACCGTGGCCACCCTGTACTGCGTGCACGAGAAGATCGAAGTGCGCGACAC 
5281   CAAGGAAGCCCTGGACAAGATCGAAGAAGAACAGAACAAGTGCCAGCAGAAGACCCAGCA 
5341   GGCCAAGGCCGCCGACGGCAAGGTGTCGCAGAACTACGGATCCCCGATCGTGCAGAACCT 
5401   GCAAGGCCAGATGGTGCACCAGGCCATCTCGCCGCGCACCCTGAACGCCTGGGTGAAGGT 
5461   GATCGAAGAAAAGGCCTTCTCGCCGGAAGTGATCCCGATGTTCACCGCCCTGTCGGAAGG 
5521   CGCGACCCCGCAGGACCTGAACACCATGCTGAACACCGTGGGCGGCCACCAGGCCGCCAT 
5581   GCAGATGCTGAAGGACACCATCAACGAAGAAGCGGCCGAATGGGACCGCCTGCACCCGGT 
5641   GCACGCCGGCCCGATCGCCCCGGGCCAGATGCGCGAGCCCCGCGGCAGCGACATCGCCGG 
5701   CACCACCTCGACCCTGCAAGAACAGATCGCCTGGATGACCTCGAACCCCCCGATCCCGGT 
5761   GGGCGACATCTACAAGCGCTGGATCATCCTGGGCCTGAACAAGATCGTGCGCATGTACTC 
5821   GCCGGTGTCGATCCTGGACATCCGCCAGGGTCCGAAGGAACCGTTCCGCGACTACGTGGA      
5881   CCGCTTCTTCAAGACCCTGCGCGCCGAGCAGGCCACCCAAGAGGTGAAGAACTGGATGAC 
5941   CGACACCCTGCTGGTGCAGAACGCCAACCCCGACTGCAAGACCATCCTGCGCGCCCTGGG 
6001   TCCCGGCGCGACCCTGGAAGAGATGATGACCGCCTGCCAGGGCGTGGGCGGCCCGGGCCA 
6061   CAAGGCCCGCGTGCTGAATATTGCCGAAGCCATGTCGCAGACCAACTCGGGCAACATCAT 
6121   GATGCAGCGCTCGAACTTCAAGGGTCCGCGCCGCATCGTGAAGTGCTTCAACTGCGGCAA 
6181   GGAAGGCCACATCGCCCGCAACTGCCGCGCCCCGCGCAAGAAAGGCTGCTGGAAGTGTGG 
6241   CAAGGAAGGTCATCAGATGAAGGACTGCACCGAGCGCCAGGCCAACTTCCTGGGCAAGAT 
6301   CTGGCCGTCGCACAAGGGCCGCCCGGGCAACTTCCTGCAAAACCGCCCGGAACCGACCGC 
6361   CCCGCCGGCCGAGTCGTTCCGCTTCGAAGAGACCACCCCGGCCCCGAAGCAGGAACCGAT 
6421   CGAGCGCGAACCGCTGACCTCGCTGAAGAGCCTGTTCGGCTCGGACCCGCTGTCGCAGGA 
 
       EcoRV 
6481   TATCGGCGCCCGCCTGCGCGGCCCCGGCCGCGCCTTCGTGACCATCACCTTCAAGCAGAT 
        
                                      HpaI 
6541   CCCGAACCCCCTGCTGGGCCTGGACCAGGGTTAACTAGCGTACGATCGACTGCCAGGCAT 
6601   CAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCC 
6661   GGCCATCATGGCCGCGGTGATCA 
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D5 pRC3Gag sequence: Showing the following fragments highlighted in::  
TetRr1.7 cassette:  red,  
Psmyc promoter:      blue with the operators underlined,  
HIV-1 gag gene:   yellow,  
V3-SV5 epitope:   grey and  
The deleted fragment underlined. 
 
1      GCTAGCAACAAAGCGACGTTGTGTCTCAAAATCTCTGATGTTACATTGCACAAGATAAAA 
61     ATATATCATCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGTTA 
121    TGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATG 
181    CTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCT 
241    ATCGCTTGTATGGGAAGCCCCATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCG 
301    TTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTC 
361    TTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGA 
421    TCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTG 
481    TTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTT 
541    TTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGG 
601    TTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAG 
661    AAATGCATAATCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCAC 
721    TTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCG 
781    GAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTC 
841    CTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAAT 
901    TGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTGGTTAATTGGTTGTAAC 
961    ACTGGCAGAGCATTACGCTGACTTGACGGGACGGCGGCTTTGTTGAATAAATCGAACTTT 
1021   TGCTGAGTTGAAGGATCAGATCACGCATCTTCCCGACAACGCAGACCGTTCCGTGGCAAA 
1081   GCAAAAGTTCAAAATCACCAACTGGTCCACCTACAACAAAGCTCTCATCAACCGTGGCTC 
1141   CCTCACTTTCTGGCTGGATGATGGGGCGATTCAGGCCTGGTATGAGTCAGCAACACCTTC 
1201   TTCACGAGGCAGACCTCACTAGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG 
1261   ATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACC 
1321   GCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAC 
1381   TGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCA 
1441   CCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGT 
1501   GGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACC 
1561   GGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCG 
1621   AACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCC 
1681   CGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCAC 
1741   GAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCT 
1801   CTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGC 
1861   CAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTT 
1921   TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATAC       
1981   CGCTCGCCGCAGCCGAACGACCGAGCGCAACGCGTGAGCCCACCAGCTCCGTAAGTTCGG 
2041   GTGCTGTGTGGCTCGTACCCGCGCATTCAGGCGGCAGGGGGTCTAACGGGTCTAAGGCGG 
2101   CGTGTACGGCCGCCACAGCGGCTCTTAGCGGCCCGGAAACGTCCTCGAAACGACGCATGT 
2161   GTTCCTCCTGGTTGGTACAGGTGGTTGGGGGTGCTCGGCTGTCGCTGGTGTTTCATCATC 
2221   AGGGCTCGACGGGAGAGCGGGGGAGTGTGCAGTTGTGGGGTGGCCCCTCAGCGAAATATC 
2281   TGACTTGGAGCTCGTGTCGGACCATACACCGGTGATTAATCGTGGTTTATTATCAAGCGT 
2341   GAGCCACGTCGCCGACGAATTTGAGCAGCTCTGGCTGCCGTACTGGTCCCTGGCAAGCGA 
2401   CGATCTGCTCGAGGGGATCTACCGCCAAAGCCGCGCGTCGGCCCTAGGCCGCCGGTACAT 
2461   CGAGGCGAACCCAACAGCGCTGGCAAACCTGCTGGTCGTGGACGTAGACCATCCAGACGC 
2521   AGCGCTCCGAGCGCTCAGCGCCCGGGGGTCCCATCCGCTGCCCAACGCGATCGTGGGCAA 
2581   TCGCGCCAACGGCCACGCACACGCAGTGTGGGCACTCAACGCCCCTGTTCCACGCACCGA 
2641   ATACGCGCGGCGTAAGCCGCTCGCATACATGGCGGCGTGCGCCGAAGGCCTTCGGCGCGC 
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2701   CGTCGATGGCGACCGCAGTTACTCAGGCCTCATGACCAAAAACCCCGGCCACATCGCCTG 
2761   GGAAACGGAATGGCTCCACTCAGATCTCTACACACTCAGCCACATCGAGGCCGAGCTCGG 
2821   CGCGAACATGCCACCGCCGCGCTGGCGTCAGCAGACCACGTACAAAGCGGCTCCGACGCC 
2881   GCTAGGGCGGAATTGCGCACTGTTCGATTCCGTCAGGTTGTGGGCCTATCTTCCCGCCCT 
2941   CATGCGGATCTACCTGCCGACCCGGAACGTGGACGGACTCGGCCGCGCGATCTATGCCGA 
3001   GTGCCACGCGCGAAACGCCGAATTTCCGTGCAACGACGTGTGTCCCGGACCGCTACCGGA 
3061   CAGCGAGGTCCGCGCCATCGCCAACAGCATTTGGCGTTGGATCACAACCAAGTCGCGCAT 
3121   TTGGGCGGACGGGATCGTGGTCTACGAGGCCACACTCAGTGCGCGCCATGCGGCCATCTC 
3181   GCGGAAGGGCGCAGCAGCGCGCACGGCGGCGAGCACAGTTGCGCGGCGCGCAAAGTCCGC 
3241   GTCAGCCATGGAGGCATTGCTATGAGCGACGGCTACAGCGACGGCTACAGCGACGGCTAC 
3301   AACTGGCAGCCGACTGTCCGCAAAAAGCGGCGCGTGACCGCCGCCGAAGGCGCTCGAATC 
3361   ACCGGACTATCCGAACGCCACGTCGTCCGGCTCGTGGCGCAGGAACGCAGCGAGTGGTTC 
3421   GCCGAGCAGGCTGCACGCCGCGAACGCATCCGCGCCTATCACGACGACGAGGGCCACTCT       
3481   TGGCCGCAAACGGCCAAACATTTCGGGCTGCATCTGGACACCGTTAAGCGACTCGGCTAT 
3541   CGGGCGAGGAAAGAGCGTGCGGCAGAACAGGAAGCGGCTCAAAAGGCCCACAACGAAGCC 
3601   GACAATCCACCGCTGTTCTAACGCAATTGGGGAGCGGGTGTCGCGGGGGTTCCGTGGGGG 
3661   GTTCCGTTGCAACGGGTCGGACAGGTAAAAGTCCTGGTAGACGCTAGTTTTCTGGTTTGG 
3721   GCCATGCCTGTCTCGTTGCGTGTTTCGTTGCGTCCGTTTTGAATACCAGCCAGACGAGAC 
3781   GGGGTTCTACGAATCTTGGTCGATACCAAGCCATTTCCGCTGAATATCGTGGAGCTCACC 
3841   GCCAGAATCGGTGGTTGTGGTGATGTACGTGGCGAACTCCGTTGTAGTGCTTGTGGTGGC 
3901   ATCCGTGGCGCGGCCGCGGTACCAGATCTTTAAATCTAGTCTGCAGCAAGGTCGAACGAG 
3961   GGGCATGACCCGGTGCGGGGCTTCTTGCACTCGGCATAGGCGAGTGCTAAGAATAACGTT      
 
                EcoRV 
4021   GGCACTCGATATCTGACACTTGAGGAGGAGAGCAAAATTCTCATGTCGCGCCTGGACAAG 
4081   TCGAAGGTCATCAACTCGGCCCTGGCCCTGGGCAACGAGGTGGGCATCGAGGGCGTGACC 
4141   ACCCGCAAGCTGGCCCAGAAGCTGGGCGTCGAGCAGCCGACCCTGTACTGGCACGTGAAG 
4201   AACAAGCGCGCCCTGCTGGACGCCCTGGCCGTGGAGATCCTGGCCCGCCACCACGACTAC 
4261   TCGCTGCCGGCCGCAGGCGAGTCGTGGCAGTCGTTCCTGCGCAACAACGCCATGTCGTTC 
4321   CGCCGGGCGCTGCTGCGCTACCGCGACGGCGCGAAGGTGCACCTGGGCACCCGCCCGGAT 
4381   GAGAAGCAGTACGACACCGTGGAGACCCAACTGCGCTTCATGACCGAGAACGGCTTCTCG 
4441   CTGCGCGACGGCCTGTACGCCATCTCGGCCGTGTCGCACTTCACCCTGGGCGCGGTGCTG 
4501   GAGCAGCAGGAGCACACCGCCGCCCTGACCGACCGCCCGGCAGCCCCGGACGAGAACCTG 
4561   CCGCCGCTGCTGCGGGAGGCCCTGCAAATCATGGACTCGGACGACGGCGAGCAGGCGTTC 
4621   CTGCACGGCCTGGAGTCGCTGATCCGCGGCTTCGAGGTGCAACTGACCGCCCTGCTGCAA 
4681   ATCGTGTGAGGGCCCGAGCGAGGAGCCCGGTCCCTTTGTGGGGCCGGGCTCCTCTGGTTG        
 
           XbaI 
4741   GTACTCTAGAGGATCCTGTGCGTTCGCACGCACAGGCCCGGTGTGAGAAGGGTCTCTGCA 
4801   GAGCGGGAGAACTCCCTATCAGTGATAGAGTTTGTCCTCCCTATCAGTGATAGATAGGCT 
4861   CTGGGAGTACCCGTGTGTACGACCAGCACGGCATACATCATTTCGACGCCGAGAGATTCG   
 
                        EcoRI 
4921   CCGCCCGAAATGAGCACGAATTCTGACACTTGAGGAGGAGAGCAAAATTCTCATGGGTTA 
4981   CGTAATCGATATGGGCGCGCGCGCCTCGATCCTGCGCGGCGAGAAGCTGGACAAGTGGGA 
5041   AAAGATCCGCCTGCGCCCGGGCGGCAAAAAGCACTACATGCTGAAGCACATCGTGTGGGC 
5101   CTCGCGCGAGCTGGAACGCTTCGCCCTGAACCCCGGCCTGCTGGAAACCTCGGAAGGCTG 
5161   CAAGCAGATCATGAAGCAGTTGCAGCCGGCCTTGCAGACCGGCACCGAAGAGCTGAAGTC 
5221   GCTGTACAACACCGTGGCCACCCTGTACTGCGTGCACGAGAAGATCGAAGTGCGCGACAC 
5281   CAAGGAAGCCCTGGACAAGATCGAAGAAGAACAGAACAAGTGCCAGCAGAAGACCCAGCA 
5341   GGCCAAGGCCGCCGACGGCAAGGTGTCGCAGAACTACGGATCCCCGATCGTGCAGAACCT 
5401   GCAAGGCCAGATGGTGCACCAGGCCATCTCGCCGCGCACCCTGAACGCCTGGGTGAAGGT 
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5461   GATCGAAGAAAAGGCCTTCTCGCCGGAAGTGATCCCGATGTTCACCGCCCTGTCGGAAGG 
5521   CGCGACCCCGCAGGACCTGAACACCATGCTGAACACCGTGGGCGGCCACCAGGCCGCCAT 
5581   GCAGATGCTGAAGGACACCATCAACGAAGAAGCGGCCGAATGGGACCGCCTGCACCCGGT 
5641   GCACGCCGGCCCGATCGCCCCGGGCCAGATGCGCGAGCCCCGCGGCAGCGACATCGCCGG 
5701   CACCACCTCGACCCTGCAAGAACAGATCGCCTGGATGACCTCGAACCCCCCGATCCCGGT 
5761   GGGCGACATCTACAAGCGCTGGATCATCCTGGGCCTGAACAAGATCGTGCGCATGTACTC 
5821   GCCGGTGTCGATCCTGGACATCCGCCAGGGTCCGAAGGAACCGTTCCGCGACTACGTGGA   
5881   CCGCTTCTTCAAGACCCTGCGCGCCGAGCAGGCCACCCAAGAGGTGAAGAACTGGATGAC 
5941   CGACACCCTGCTGGTGCAGAACGCCAACCCCGACTGCAAGACCATCCTGCGCGCCCTGGG 
6001   TCCCGGCGCGACCCTGGAAGAGATGATGACCGCCTGCCAGGGCGTGGGCGGCCCGGGCCA 
6061   CAAGGCCCGCGTGCTGAATATTGCCGAAGCCATGTCGCAGACCAACTCGGGCAACATCAT 
6121   GATGCAGCGCTCGAACTTCAAGGGTCCGCGCCGCATCGTGAAGTGCTTCAACTGCGGCAA 
6181   GGAAGGCCACATCGCCCGCAACTGCCGCGCCCCGCGCAAGAAAGGCTGCTGGAAGTGTGG 
6241   CAAGGAAGGTCATCAGATGAAGGACTGCACCGAGCGCCAGGCCAACTTCCTGGGCAAGAT 
6301   CTGGCCGTCGCACAAGGGCCGCCCGGGCAACTTCCTGCAAAACCGCCCGGAACCGACCGC 
6361   CCCGCCGGCCGAGTCGTTCCGCTTCGAAGAGACCACCCCGGCCCCGAAGCAGGAACCGAT        
6421   CGAGCGCGAACCGCTGACCTCGCTGAAGAGCCTGTTCGGCTCGGACCCGCTGTCGCAGGA   
 
       EcoRV 
6481   TATCGGCGCCCGCCTGCGCGGCCCCGGCCGCGCCTTCGTGACCATCACCTTCAAGCAGAT 
        
                                      HpaI 
6541   CCCGAACCCCCTGCTGGGCCTGGACCAGGGTTAACTAGCGTACGATCGACTGCCAGGCAT 
6601   CAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCC 
6661   GGCCATCATGGCCGCGGTGATCA 
       
 
D6 pPM4RT sequence:  Showing the following fragments highlighted in:  
TetRr1.12 cassette: in pink  
Psmyc promoter:     blue,  
HIV-1 rt gene:        green,  
V3-SV5 epitope:     grey and  
The deleted fragment underlined 
 
1      GCTAGCAACAAAGCGACGTTGTGTCTCAAAATCTCTGATGTTACATTGCACAAGATAAAA 
61     ATATATCATCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGTTA 
121    TGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATG 
181    CTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCT 
241    ATCGCTTGTATGGGAAGCCCCATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCG 
301    TTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTC 
361    TTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGA 
421    TCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTG 
481    TTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTT 
541    TTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGG 
601    TTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAG 
661    AAATGCATAATCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCAC 
721    TTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCG 
781    GAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTC 
841    CTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAAT 
901    TGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTGGTTAATTGGTTGTAAC   
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961    ACTGGCAGAGCATTACGCTGACTTGACGGGACGGCGGCTTTGTTGAATAAATCGAACTTT 
1021   TGCTGAGTTGAAGGATCAGATCACGCATCTTCCCGACAACGCAGACCGTTCCGTGGCAAA 
1081   GCAAAAGTTCAAAATCACCAACTGGTCCACCTACAACAAAGCTCTCATCAACCGTGGCTC 
1141   CCTCACTTTCTGGCTGGATGATGGGGCGATTCAGGCCTGGTATGAGTCAGCAACACCTTC 
1201   TTCACGAGGCAGACCTCACTAGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG 
1261   ATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACC 
1321   GCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAC 
1381   TGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCA 
1441   CCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGT 
1501   GGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACC 
1561   GGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCG 
1621   AACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCC 
1681   CGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCAC 
1741   GAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCT 
1801   CTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGC 
1861   CAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTT 
1921   TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATAC 
1981   CGCTCGCCGCAGCCGAACGACCGAGCGCAACGCGTGAGCCCACCAGCTCCGTAAGTTCGG 
2041   GTGCTGTGTGGCTCGTACCCGCGCATTCAGGCGGCAGGGGGTCTAACGGGTCTAAGGCGG 
2101   CGTGTACGGCCGCCACAGCGGCTCTTAGCGGCCCGGAAACGTCCTCGAAACGACGCATGT 
2161   GTTCCTCCTGGTTGGTACAGGTGGTTGGGGGTGCTCGGCTGTCGCTGGTGTTTCATCATC       
2221   AGGGCTCGACGGGAGAGCGGGGGAGTGTGCAGTTGTGGGGTGGCCCCTCAGCGAAATATC 
2281   TGACTTGGAGCTCGTGTCGGACCATACACCGGTGATTAATCGTGGTTTATTATCAAGCGT 
2341   GAGCCACGTCGCCGACGAATTTGAGCAGCTCTGGCTGCCGTACTGGTCCCTGGCAAGCGA 
2401   CGATCTGCTCGAGGGGATCTACCGCCAAAGCCGCGCGTCGGCCCTAGGCCGCCGGTACAT 
2461   CGAGGCGAACCCAACAGCGCTGGCAAACCTGCTGGTCGTGGACGTAGACCATCCAGACGC 
2521   AGCGCTCCGAGCGCTCAGCGCCCGGGGGTCCCATCCGCTGCCCAACGCGATCGTGGGCAA 
2581   TCGCGCCAACGGCCACGCACACGCAGTGTGGGCACTCAACGCCCCTGTTCCACGCACCGA 
2641   ATACGCGCGGCGTAAGCCGCTCGCATACATGGCGGCGTGCGCCGAAGGCCTTCGGCGCGC 
2701   CGTCGATGGCGACCGCAGTTACTCAGGCCTCATGACCAAAAACCCCGGCCACATCGCCTG 
2761   GGAAACGGAATGGCTCCACTCAGATCTCTACACACTCAGCCACATCGAGGCCGAGCTCGG 
2821   CGCGAACATGCCACCGCCGCGCTGGCGTCAGCAGACCACGTACAAAGCGGCTCCGACGCC 
2881   GCTAGGGCGGAATTGCGCACTGTTCGATTCCGTCAGGTTGTGGGCCTATCTTCCCGCCCT 
2941   CATGCGGATCTACCTGCCGACCCGGAACGTGGACGGACTCGGCCGCGCGATCTATGCCGA 
3001   GTGCCACGCGCGAAACGCCGAATTTCCGTGCAACGACGTGTGTCCCGGACCGCTACCGGA 
3061   CAGCGAGGTCCGCGCCATCGCCAACAGCATTTGGCGTTGGATCACAACCAAGTCGCGCAT 
3121   TTGGGCGGACGGGATCGTGGTCTACGAGGCCACACTCAGTGCGCGCCATGCGGCCATCTC 
3181   GCGGAAGGGCGCAGCAGCGCGCACGGCGGCGAGCACAGTTGCGCGGCGCGCAAAGTCCGC 
3241   GTCAGCCATGGAGGCATTGCTATGAGCGACGGCTACAGCGACGGCTACAGCGACGGCTAC 
3301   AACTGGCAGCCGACTGTCCGCAAAAAGCGGCGCGTGACCGCCGCCGAAGGCGCTCGAATC 
3361   ACCGGACTATCCGAACGCCACGTCGTCCGGCTCGTGGCGCAGGAACGCAGCGAGTGGTTC 
3421   GCCGAGCAGGCTGCACGCCGCGAACGCATCCGCGCCTATCACGACGACGAGGGCCACTCT      
3481   TGGCCGCAAACGGCCAAACATTTCGGGCTGCATCTGGACACCGTTAAGCGACTCGGCTAT 
3541   CGGGCGAGGAAAGAGCGTGCGGCAGAACAGGAAGCGGCTCAAAAGGCCCACAACGAAGCC 
3601   GACAATCCACCGCTGTTCTAACGCAATTGGGGAGCGGGTGTCGCGGGGGTTCCGTGGGGG 
3661   GTTCCGTTGCAACGGGTCGGACAGGTAAAAGTCCTGGTAGACGCTAGTTTTCTGGTTTGG 
3721   GCCATGCCTGTCTCGTTGCGTGTTTCGTTGCGTCCGTTTTGAATACCAGCCAGACGAGAC 
3781   GGGGTTCTACGAATCTTGGTCGATACCAAGCCATTTCCGCTGAATATCGTGGAGCTCACC 
3841   GCCAGAATCGGTGGTTGTGGTGATGTACGTGGCGAACTCCGTTGTAGTGCTTGTGGTGGC 
3901   ATCCGTGGCGCGGCCGCGGTACCAGATCTTTAAATCGGGCGAATTGGGGCGCGCCACTAGT 
3961   CTGCAGCAAGGTCGAACGAGGGGCATGACCCGGTGCGGGGCTTCTTGCACTCGGCATAGG    
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                EcoRV 
4021   CGAGTGCTAAGAATAACGTTGGCACTCGATATCTGACACTTGAGGAGGAGAGCAAAATTC 
4081   TCATGTCGCGCCTGGACAAGTCGAAGGTCATCAACTCGGCCCTGGAGCTGCTGAACGAGG 
4141   GCCGCAACGAGGGCCTGACCACCCGCAAGCTGGCCCAGAAGCTGGGCGTCGAGCAGCCGA 
4201   CCCTGTACTGGCACGTGAAGAACAAGCGCGCCCTGCTGGACGCCCTGGCCGTGGAGATCC 
4261   TGGCCCGCCACCACGACTACTCGCTGCCGGCCGCAGGCGAGTCGTGGCAGTCGTTCCTGC 
4321   GCAACAACGCCATGTCGTTCCGCCGCGCACTGCTGCGCTACCGCGACGGCGCGAAGGTGC 
4381   ACCTGGGCACCCGCCCCGACGAGAAGCAGTACGACACCGTGGAGACCCAACTGCGCTTCA 
4441   TGACCGAGAACGGCTTCTCGCTGCGCGACGGCCTGTACGCCATCTCGGCCGTGTCGCACT 
4501   TCACCCTGGGCGCGGTGCTGGAGCAGCAGGAGCACACCGCCGCCCTGACCGACCGCCCGG 
4561   CAGCCCCGGACGAGAACCTGCCGCCGCTGCTGCGGGAGGCCCTGCAAATCATGGACTCGG 
4621   ACGACGGCGAGCAGGCGTTCCTGCACGGCCTGGAGTCGCTGATCCGCGGCTTCGAGGTGC 
4681   AACTGACCGCCCTGCTGCAAATCGTGTGAGGGCCCGAGCGAGGAGCCCGGTCCCTTTGTG        
 
 
           XbaI 
4741   GGGCCGGGCTCCTCTGGTTGGTACTCTAGATTAATTAATCCAGCTTTTGTTCCCTCTAGA 
4801   GGATCCTGTGCGTTCGCACGCACAGGCCCGGTGTGAGAAGGGTCTCTGCAGAGCGGGAGA 
4861   ACCACTCTATCATTGATAGAGTTTGTCCACTCTATCATTGATAGAGTAGGCTCTGGGAGT        
 
                        EcoRI 
4921   ACCCGTGTGTACGACCCGAATTCTGACACTTGAGGAGGAGAGCAAAATTCTCATGGGTTA 
4981   CGCCGGGCCCATCTCGCCCATCGAGACCGTGCCGGTGAAGCTGAAGCCGGGCATGGACGG 
5041   CCCGAAGGTCAAGCAGTGGCCGCTGACCGAGGTCAAGATCAAGGCCCTGACCGCCATCTG 
5101   CGAGGAGATGGAGAAGGAGGGCAAGATCACCAAGATCGGCCCGGAGAACCCGTACAACAC 
5161   CCCGATCTTCGCCATCAAGAAAGAGGACTCGACCAAATGGCGCAAGCTGGTCGATTTCCG 
5221   CGAGCTGAACAAGCGCACCCAGGACTTCTGGGAAGTCCAGTTGGGCATCCCGCACCCGGC 
5281   CGGCCTGAAGAAGAAGAAGTCGGTCACGGTCCTGGACGTCGGCGACGCCTACTTCTCGGT 
5341   GCCGCTGGACGAGGGCTTCCGCAAGTACACCGCCTTCACCATCCCGTCGATCAACAACGA 
5401   GACCCCGGGCATCCGCTACCAGTACAACGTGCTGCCGCAGGGCTGGAAGGGCTCGCCGGC 
5461   CATCTTCCAGGCGTCGATGACCAAGATCCTGGAGCCGTTCCGCGCCAAGAACCCGGAGAT 
5521   CGTCATCTACCAGTACATGGCCGCCCTGTACGTGGGCTCGGACCTGGAGATCGGCCAGCA 
5581   CCGCGCCAAGATCGAGGAGCTGCGCGAGCACCTGCTGAAGTGGGGCTTCACCACCCCGGA 
5641   CAAGAAGCACCAGAAGGAGCCGCCGTTCCTCTGGATGGGCTACGAGCTGCACCCGGACAA 
5701   GTGGACCGTCCAGCCGATCCAACTGCCGGAGAAGGACTCCTGGACCGTCAACGACATCCA 
5761   GAAGCTGGTCGGCAAGCTGAACTGGACGTCCCAGATCTACCCGGGCATCAAGGTGCGCCA 
5821   ACTCTGCAAGCTGCTGCGCGGCACCAAGGCGCTGACCGACATCGTCCCGCTGACCGAGGA        
5881   GGCCGAGCTGGAGCTGGCCGAGAACCGCGAGATCCTGAAGGAGCCGGTGCACGGCGTCTA 
5941   CTACGACCCGTCGAAGGACCTGATCGCCGAGATCCAGAAGCAGGGCGACGACCAATGGAC 
6001   GTACCAAATCTATCAGGAGCCGTTCAAGAACCTGAAAACCGGCAAGTACGCCAAGCGCCG 
6061   CACCACCCACACCAACGACGTGAAGCAACTGACCGAGGCCGTCCAGAAGATCTCGCTGGA 
6121   GAGCATCGTCACCTGGGGCAAGACCCCGAAGTTCCGCCTGCCGATCCAGAAAGAGACCTG 
6181   GGAGATCTGGTGGACCGACTACTGGCAGGCCACCTGGATTCCGGAGTGGGAGTTCGTCAA 
6241   CACCCCGCCGCTGGTGAAGCTGTGGTATCAACTGGAGAAGGAGCCCATCGCCGGCGCGGA 
6301   AACGGCCCGCCTGCGCGGCCCCGGCCGCGCCTTCGTGACCATCACCTTCAAGCAGATCCC       
 
                                   HpaI 
6361   GAACCCCCTGCTGGGCCTGGACCAGGGTTAACTAGCGTACGATCGACTGCCAGGCATCAA 
6421   ATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCCGGC 
6481   CATCATGGCCGCGGTGATCA 
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APPENDIX E: PLASMID MAPS 
 
 
1.11111111 1.1. 1.  
 
 
 
22. 
 
3. 3. 
 
44. 
 
45. 
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